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CHAPTER I 
 
INTRODUCTION 
 
This chapter is a modified version of a published review article (1).  The journal, Developmental 
Biology, grants permission for reproduction within doctoral candidate theses. 
 
Enteric Nervous System  
The enteric nervous system (ENS) is a complex network of ganglia intrinsic to the intestinal 
wall that is necessary for normal motility and homeostasis of the gastrointestinal (GI) tract.  The 
ENS originates from vagal, rostral truncal, and sacral neural crest (NC) populations that migrate 
to the fetal gut in the developing embryo (2).  In the mouse, vagal and rostral trunk neural crest 
cells (NCC) emigrate from the neural tube to the foregut and migrate caudally to populate the 
entire gut.  Sacral NCC delaminate later from the neural tube, enter the hindgut, and migrate 
rostrally, opposite the vagal NCC, to co-populate the post-umbilical portion of the gut.  As these 
populations migrate from the neural tube and along the gut, cell-autonomous signaling as well as 
cues from the environment play a role in their lineage divergence (2).  NCC contributing to the 
ENS, appropriately called enteric neural progenitors (ENPs), differentiate from a stem cell-like 
state to give rise to glia and numerous neuronal types (3-5).  For successful ENS development, 
correct timing and dosage of gene expression affecting ENP survival, proliferation, and 
differentiation is essential.  The necessity of balancing these processes is clearly seen in the 
human functional bowel disorder, Hirschsprung disease (HSCR), which is clinically recognized by 
the absence of ganglia in a variable portion of the distal intestine.   
Research in ENS development has previously focused on HSCR in part because of the 
dramatic megacolon phenotype that results from aganglionosis of the distal bowel.  This spotlight 
has remained trained on HSCR as a GI disorder due to success in identifying susceptibility genes 
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in patients and the recapitulation of aganglionosis in rodent models bearing mutations in 
homologous genes (6). Concurrent advances in treating HSCR patients through surgical removal 
of distal aganglionic bowel followed by reattachment of ganglionated proximal intestine to the 
anus has led to increased survival (7).  Yet long term clinical follow-up of HSCR patients has 
found that surgical intervention does not completely “cure” intestinal symptoms in these 
individuals who continue to suffer from intestinal disorders, such as enterocolitis and chronic 
constipation, despite successful surgical removal of the aganglionic gut segment (7-10). The 
occurrence of such chronic bowel dysfunction across a variety of surgical procedures (10) and 
evidence from developmental studies of HSCR mouse models (11-13) hint that defects in ENS 
development in the proximal, ganglionated portions of the intestine may be causative.  In 
particular, mechanistic analyses of HSCR mouse models indicate that defects in ENP 
developmental potential, the ability of NCC to differentiate into a variety of cell types, contribute 
to HSCR.  Moreover, the concept that imbalance of NC-derived cell types within the ENS could 
lead to GI dysfunction is gaining strength, fueled by evidence from gene-specific mouse mutants 
that lack aganglionosis yet show deficits in ENS lineages, GI motility, and immune response 
(Table 1.1).  This chapter collates multiple studies whose evidence adds weight to this concept 
and raises future questions for the field to address.  
 
Enteric NCC deficits in Hirschsprung mouse models 
Early studies in HSCR mouse models focused on determining the genetic causes of 
aganglionosis in spontaneously occurring mutants as a means to identify genes that contribute to 
development of the ENS.  Initially, little thought was given to the possibility that ENS defects in 
ganglionated regions of the bowel might contribute to intestinal dysfunction.  However, more 
recently, abnormalities in proximal ganglionated regions of the intestine have been recognized 
(12, 14, 15).  This discovery led investigators to hypothesize that long term complications in HSCR 
patients could result from deficiencies in ganglia that had been formed in the proximal intestine  
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(12, 15). As the field has learned more about the developmental processes that contribute to 
aganglionosis in mouse models, evidence for effects of individual HSCR genes on NCC lineage 
divergence in the fetal intestine has emerged. 
 
Sox10   
Sox10 is a SRY-related High Mobility Group-box transcription factor putatively expressed 
in all neural crest cells.  Mice with a loss-of-function Sox10+/- (Sox10Lacz or Sox10tm1Weg) (11, 13) 
or a dominant-negative allele of Sox10 (Sox10Dom/+) (16, 17) both recapitulate the HSCR 
phenotype of distal bowel aganglionosis.  Specifically, Sox10Dom is a dominant-negative 
mutation wherein an insertion mutation leads to an intact DNA binding domain, but a novel tail in 
the transcription activating domain (16, 18). The first clue that perturbations in normal Sox10 
levels could produce alterations in development potential came from in vitro studies conducted 
on neural crest-derived progenitors isolated from dorsal root ganglia of Sox10-/-, Sox10+/-, and 
Sox10+/+ mice (11).  These isolated cells were allowed to grow and then differentiate in culture.  
The developmental potential of isolated progenitors was scored by the differentiated cell types 
these cultured cells produced.  Sox10 deficient NCC showed altered developmental potential and 
were deficient in gliogenesis at both high and low plating densities.  While this study focused on 
neural crest-derived cells collected from dorsal root ganglia, a subsequent effort by the same 
group determined that the temporal appearance of early and late neuronal differentiation markers 
within the fetal foregut and midgut of Sox10+/- mutants in vivo was also disrupted (13). Careful 
analysis revealed that neural progenitor cells expressing early neuronal markers like PGP9.5 
were increased in frequency among Sox10+/- mutants, while more mature neurons marked by 
expression of neurofilament 160 were reduced.  Interestingly, although the NC progenitor pool 
was decreased in Sox10+/- mutants, total neuronal numbers were not, suggesting that reduction 
of Sox10 promotes a neural fate, but may not contribute to later neural differentiation processes. 
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Whether these fetal irregularities persist in the postnatal intestine of Sox10+/- mutants remains in 
question. 
An independent study assessed developmental potential of ENPs for the dominant-
negative allele of Sox10, Sox10Dom/+, while concurrently investigating the effects of genetic strain 
background on ENS development (12).  This analysis found that ENPs from Sox10Dom/+ mutants 
also had altered developmental potential in vivo and documented ENS irregularities in fetal and 
postnatal intestine of heterozygous Sox10Dom/+ mice.  Moreover, the authors reported atypical 
myofibroblast-like cells with cytoplasmic Phox2b expression in and around myenteric ganglia.  
While similar cells were also observed in wild type littermates, the overall number of these unusual 
cells was increased in Sox10Dom/+ mutants.  Taken together the studies by Paratore et al., (2001, 
2002), and Walters et al., (2010), suggest that altered developmental potential of NCC, including 
enteric cell types, occurs in HSCR individuals carrying Sox10 mutations.  However, whether this 
altered developmental potential ultimately disrupts the balance of cell types in the postnatal 
enteric ganglia in vivo and how such alterations would affect intestinal function has not previously 
been explored.  To this end, I explicitly analyzed neuron, glia, and specific neuronal subtype 
populations as well as motility and inflammation in the Sox10Dom/+ mouse model (Chapter 2).  
 
Ednrb/Edn3 
Endothelin receptor B (Ednrb) is expressed in migrating NCC while its preferred ligand, 
Endothelin 3 (Edn3) is expressed in the gut wall.  Several spontaneously occurring and genetically 
modified rodent models with altered Ednrb or Edn3 expression exist (19-23). One study has 
documented alterations in proximal ENS density and patterning among Ednrbs-l/s-l homozygous 
mutants (14) and a more recent study has shown that Ednrb-/- have fewer cholinergic neurons in 
the colon, but more colonic VIP neurons compared to Ednrb+/- littermates (24). In regard to 
functional outcomes, Ednrb mutants do exhibit enterocolitis that leads to early death.  Fujimoto 
et. al., (25) first described the presence of enterocolitis in the piebald lethal (Ednrbs-l/s-l) mouse.  
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Ednrbs-l/s-l mice have an increase in enterocolitis compared to wild-type littermates and a subset 
of Ednrbs-l/s-l mice die presumably due to acute infectious processes as they have no gross 
megacolon, but exhibit acute splenitis and an increase in intestinal Ig-A secreting plasma cells at 
time of death (26).  Similarly, a subset of Ednrb-null (EdnrbTm1Ywa/Tm1Ywa, hereafter referred to as 
Ednrb-/-) mice die prematurely with signs of widespread bacteremia (27).  Interestingly, these 
inflammatory processes appear mediated, at least in part, by ganglionated portions of the intestine 
as ~40% of Ednrb-/- mice that undergo corrective pull-through surgery to remove aganglionic 
bowel still go on to develop enterocolitis (28).  Mice with mutations in Edn3 (Et-3) have not been 
assessed for enterocolitis, but have been evaluated for altered GI motility and proportions of 
enteric neurons.  ET-3 -/- (Edn3tm1Ywa/tm1Ywa) lack colonic migrating motor complexes in the 
ganglionated portions of their bowel.  Additionally, despite having a lower density of neurons in 
the myenteric plexus, they have twice as many NOS expressing neurons compared to their wild-
type littermates (22).  
 
Ret Signaling Pathway 
Gene deficits among members of the Ret signaling pathway have been the most 
extensively studied models for HSCR phenotypes.  Ret is a receptor tyrosine kinase expressed 
on ENPs that has documented roles in proliferation, migration, and survival of these cells. 
Although several Ret ligands and co-receptors exist, Ret signaling in the development of the ENS 
primarily occurs in conjunction with its Gfra1 co-receptor and its preferred ligand, Gdnf (29). 
In humans, a single functional mutation in RET is sufficient to cause HSCR.  In mice, gene 
targeting of Ret (Rettm1Cos/tm1Cos , commonly referred to as Ret-/-) results in complete loss of the 
ENS in the small and large intestines (30, 31).  However, mice with heterozygous loss (Ret+/-) 
appear normal and healthy, with no aganglionosis or loss of neuron numbers in either myenteric 
or submucosal ganglia (29). Whether the proportions of various neuron subtypes in Ret+/+ and 
Ret+/- are equivalent remains unknown.  Interestingly, Ret+/- mice do show a reduction in neuron 
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size and cholinergic neuronal fiber count in certain regions of the bowel and also exhibit deficits 
of intestinal contractility (29).  The cellular basis of the motility deficits observed in heterozygous 
Ret+/- mutants is of interest not only from a mechanistic standpoint, but also because 
heterozygous deficiencies are more prevalent in patient populations. 
Intermediate phenotypes in Ret mutant mice that exhibit the distal aganglionosis present 
in human HSCR patients have been generated.  These include the RetDN/+ (Rettm3.1Jmi/+) mouse 
that harbors a dominant-negative mutation (15) and the RetC620R/+ (Rettm1Cti/+) mouse that carries 
a gain-of-function point mutation (32). NC lineage segregation has not been evaluated in either 
of these two models.  However, the ENS in the proximal bowel of the RetDN/+ mouse contains 
fewer neurons and exhibits decreased neuronal fiber density.  These heterozygous models 
provide an ideal opportunity to investigate roles for Ret in NC lineage segregation.  
Gfra1 (Gdnf receptor alpha-1) is a GPI-linked co-receptor that preferentially binds Gdnf 
(glial derived neurotrophic factor) with Ret (33, 34).  Deficits in ENS development in Gfra1 mutants 
tend to recapitulate those found in Ret mutants.  This evidence supports the theory that Ret 
signaling through Gfra1 and Gdnf, not other co-receptor:ligand pairs, is largely acting in early ENS 
development.  Similar to complete loss of Ret, ablation of Gfra1 (Gfratm3Jmi/tm3Jmi, commonly called 
Gfra-/-) leads to a nearly complete absence of neurons in the small intestine and colon (35, 36).  
And, as is seen for Ret heterozygous mutants, animals lacking a single copy of Gfra1 possess 
normal numbers of neurons in both myenteric and submucosal plexi, but significant reductions in 
neuron cell size are evident in some regions of the intestine and contractility of the intestine is 
abnormal in these animals (29).   
Studies from mouse models with altered Gdnf expression, particularly those that disrupt 
levels or timing of Gdnf production, provide the best evidence to date that Ret signaling influences 
ENP lineage divergence.  Similar to Ret and Gfra1 knockouts, Gdnf null mice (Gdnftm1Rosl/tm1Rosl 
knockout mutants, commonly called Gdnf-/-) do not develop enteric ganglia caudal to the stomach 
and exhibit early lethality.  However Gdnf+/- mice, in contrast to Ret+/- and Gfra-1+/- mutants, do 
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exhibit hypoganglionosis throughout the intestine (37).  To investigate the effect of Gdnf 
expression levels on ENS development, Wang and colleagues (38) over-expressed Gdnf in the 
fetal intestine.  Overexpression starting at embryonic day 17 was accomplished using transgene 
constructs that conferred expression in enteric glia or the muscle cells, while postnatal, global 
Gdnf expression was accomplished through daily peritoneal injections starting at birth.   Both 
modes of Gdnf overexpression resulted in increased neuronal proliferation in submucosal 
neurons of the small intestine as well as neurons of both plexi in the colon.  While myenteric 
neurons in the small intestine showed no significant increases in proliferation, the timing of GDNF 
overexpression affected submucosal neuronal subtypes.  Early born neuron subtypes that were 
established before the onset of GDNF overexpression, such as serotonergic neurons, and ChAT 
expressing neurons, were not significantly affected.  However, neurons that appear early but also 
continue to be born in the postnatal period, such as NOS+ neurons, were significantly increased 
in number in both Gdnf overexpression models.  In addition, gross intestinal contractility changes 
were found in mice with Gfap-driven Gdnf overexpression.  While the altered contractility may 
indirectly correlate with increased numbers of NOS neurons, the mechanistic basis remains to be 
determined as electrical properties of specific neuronal subtypes were not evaluated and multiple 
neuronal subtypes were not examined.  It will be interesting to determine if overexpression of 
Gdnf before embryonic day 17 alters ratios and functionality of earlier born neuronal subtypes or 
if postnatal reduction of Gdnf levels cause reductions in late born neuron types.   
It is worth noting that while Ret signaling through the Gfra1:Gdnf (co-receptor:ligand)  
combination plays an early and major role in ENS development, signaling through interactions 
with Gfra2:Nrtn plays a later role.  This is especially relevant for the maintenance and proliferation 
of neurons in the submucosal plexus of the small intestine and both plexi of the colon (29).  The 
possibility that Gfra2:Nrtn are able to compensate for a loss of Gdnf in late stages of development 
expression or whether this axis selectively affects NC subtypes is yet to be determined.  While 
heterozygous Ret+/-, Gfra-1+/-, and Gdnf +/- mouse mutants do not exhibit absence of enteric 
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ganglia in the distal intestine that is characteristic of HSCR, all of these models share loss of 
intestinal contractility and exhibit reduced release of neurotransmitters in vitro (29).  
Understanding the causes of altered GI motility is crucial for developing strategies to treat patients 
with functional GI deficits that comprise a substantial proportion of the population.  The realization 
that heterozygous deficiency of Ret, Gfra1, and Gdnf alter the composition and functionality of 
the ENS likely would not have come about without studies to better understand the rare disorder 
HSCR.  These results nicely illustrate how studies of rare disorders can inform common problems.   
 
Enteric NCC deficits in non-Hirschsprung Mouse Models 
 Although mouse mutants have been used to model the obvious aganglionosis that occurs 
in human HSCR, studies in non-HSCR mouse models provide the most substantial evidence that 
disruption of NC-derived lineages can occur in the ENS and that these imbalances can alter GI 
function.  Understanding the etiology of GI dysmotility is relevant to a large fraction of the 
population as millions of people suffer from intestinal motility disorders.   Surprisingly, the 
etiologies of chronic constipation, pseudo-obstruction, Crohn's disease, ulcerative colitis, and 
other GI disorders that appear to have genetic components remain relatively obscure (39-42). 
Given the evidence detailed below, it is likely that ENS defects, including abnormal NC lineage 
segregation, contribute significantly to many GI disorders.  Discoveries in non-HSCR mouse 
models should aid in teasing apart the etiologies of these disorders. 
 
Ascl1 (formerly Mash-1) 
 Ascl1 (Mash-1) is a basic helix-loop-helix transcription factor most extensively studied for 
its role in neurogenesis in the central and sympathetic nervous systems (43).  However, Ascl1 
also largely influences development in a subpopulation of ENPs.  Blaugrund et al., (1996) 
determined that Ascl1-dependent enteric progenitors give rise to a subset of transiently 
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catecholaminergic cells which differentiate into serotonergic neurons.  Transiently 
catecholaminergic cells initially express catecholaminergic gene products, such as tyrosine 
hydroxylase, but lose catecholominergic gene expression upon differentiation.  Ascl1 null 
embryos (Ascl1tm1And/tm1And, commonly referred to as Ascl1-/-) have severely reduced neuronal 
serotonin (5-HT) expression and exhibit gross ENS deficits, such as a reduction in overall 
neuronal number and more widely spaced and erratically arranged ganglia.  This study only 
evaluated one other neuronal subtype, the late born CGRP (calcitonin gene related peptide) 
expressing neurons, which appeared unaffected in Ascl1 null mutants.  Recent studies described 
below have found that perturbations in neuronal serotonin expression alter neuronal subtype 
proportions and development; thus, it would be interesting to evaluate other neuronal subtypes in 
the Ascl1-/- mutants.  
 
Serotonin (5-HT)  
 Although serotonergic neurons only comprise 1-2% of the myenteric plexus in rodents 
(44), they are one of the earliest types of neurons that exit the cell cycle in the developing ENS 
(3) and they also affect the development of later born neurons, GI motility (45), and GI epithelial 
growth (46).  The exact role 5-HT plays in GI development and function has been somewhat 
obscured by the fact that two 5-HT expressing cell types exist in the gut — enterochromaffin cells 
within the gut epithelium and neurons within the myenteric and submucosal plexi.  The recent, 
fortuitous discovery that 5-HT expressing epithelial cells rely on the enzyme Tph1 (tryptophan 
hydroxylase 1) for 5-HT synthesis while enteric neurons rely on the enzyme Tph2 (tryptophan 
hydroxylase 2) (47, 48) has permitted a more thorough investigation of 5-HT in ENS development.  
Li et al., (2011) conducted a study utilizing Tph1, Tph2, and Tph1/2 knockout (KO) mice to 
determine the effects of 5-HT depletion (epithelial vs neuronal vs total gut respectively) on enteric 
development and GI motility.  These studies identified perturbations of both ENS development 
and GI motility in the Tph2 KO (neuronal 5-HT depleted) mice.   In contrast such perturbations 
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were not seen in Tph1 single knockout or exacerbated in the Tph1/2 double knockouts.  In 
comparison to wild-type ENS development, Tph2 KO mice had a significantly lower neuronal 
density in the ileum and a significant decrease in the late born dopaminergic neurons.  
Complementary gain-of-function experiments using ENPs isolated from Slc6a-/- (serotonin 
transporter) mutants, as well as treatment of ENP cultures with 5-HT both confirmed and extended 
the finding that 5-HT impacts development of dopaminergic neurons in the fetal intestine.  
Functional deficits due to loss of neuronal 5-HT were also documented in Tph2 KO mice including 
significantly faster gastric emptying but overall slower total GI transit and colonic emptying. How 
disruption of one enteric neuronal population, like 5-HT+ neurons, might impact cell types within 
the ganglia is diagrammed in Figure 1.1.  Experiments to investigate the effect of neuronal 5-HT 
overexpression on ENS development and GI motility have yet to be conducted.  
 
Dopamine Receptor 2 (Drd2) 
 Do alterations of ENS dopaminergic signaling significantly alter GI function?  Li et al, (49) 
conducted a study in which dopaminergic signaling was disrupted through dopamine receptor 2 
(Drd2) knockouts.  Five dopaminergic receptors (Drd1a-5) are expressed in the gut, but Drd2 is 
restricted to enteric neurons. Drd2-/- (allele name Drd2tm1Schm/tm1Schm) knockout mice had faster 
total GI transit times as well as faster colonic motility when compared to wild type littermates.  
Absorption of food was affected as Drd2
-/- mice were runted although they ate more food and 
drank more water than wild type siblings.  Other neurons and other cell types receiving signals 
from dopaminergic neurons in the bowel may be able to compensate for changes in dopaminergic 
neuron number or function by altering dopamine (DA) receptor expression.  However, this 
possibility remains to be investigated in detail. 
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Hand2 
 Hand2 (heart- and neural crest derivatives-expressed protein 2) is a basic helix-loop-helix 
DNA binding protein that plays a role in neurogenesis and proliferation (50).  Several studies in 
recent years have implicated Hand2 in lineage divergence among ENS progenitors (45, 51-53). 
Collectively, these efforts demonstrate how loss of a single gene can alter proportions of specific 
neuronal classes in the ENS with a significant impact on intestinal motility.   
Initially, Hendershot et al (2007) ablated Hand2 expression in NC derivatives through 
crosses of a conditional floxed allele (Hand2tm1.1MajH:Wnt1-Cre) with a Wnt1 promoter driven-Cre 
transgene (54).  This strategic approach removed Hand2 from all NCC with the result that 
organization and connectivity of enteric ganglia was disturbed accompanied by an overall 
reduction in neuron numbers.  Complete absence of VIP expressing neurons from the fetal 
intestines of these mutants, while ChAT+ neurons were maintained, was the first indication that 
loss of Hand2 could have a specific effect on a discrete neuron lineage.   In subsequent analyses, 
Lei et al (2011) depleted Hand2 from a specific subset of progenitors during ENS development 
using a Nestin-Cre driver (allele Hand2tm1.1MajH:Nestin-Cre).  Through this refined ablation of Hand2, a 
Nestin-independent population of ENPs that accounted for approximately 15% of total enteric 
neural precursors was revealed.  In Hand2 depleted mutants, this population was able to 
proliferate and compensate for a decrease in nestin-dependent neurons.  However, this 
compensatory effect was unique to specific subsets of neurons in Hand2 mutants.  For example, 
Nestin-independent precursors were able to proliferate and compensate for the loss in nestin-
dependent ChAT neurons, but could not compensate for the loss of NOS or calretinin expressing 
neurons.  Additionally, Nestin-independent precursors appeared skewed towards a neuronal fate.   
In wild type animals and Nestin-driven Hand2 depleted mice, greater than 90% of glia were 
Nestin-dependent. Glia were reduced overall in Nestin-driven Hand2 depleted animals and nestin-
independent precursors did not compensate for this loss of glia.  In addition to skewed ratios of 
NC derivatives, Nestin-driven Hand2 depleted mice had an overall disorganized plexus and 
14 
 
typically died by postnatal day 20.  While the cause of death was uncertain, these animals 
exhibited massive distension of the entire GI tract, and it is certainly plausible that GI dysfunction 
contributed to their premature death.    
 D'Autreaux et al., (2007) also observed that NC-specific depletion of Hand2 disrupted 
terminal differentiation of enteric neurons.  Moreover, this group later demonstrated that Hand2 
depletion in the ENS impacted not only GI motility, but inflammation as well (45).  Similar to the 
Lei et al., (2011), they observed disruption of enteric plexus organization as well as a significant 
decrease in NOS expressing neurons in Hand2 deficient mice (Hand2+/- and Hand2flox/-). However, 
they also found that neuronal subtype specification is Hand2 dosage specific by analyzing ratios 
of NOS+ neurons in various combinations of Hand2 targeted alleles.  In contrast to the Lei et al., 
(2011) study, D'Autreaux et al., (2011), found glia numbers were not significantly reduced in the 
myenteric plexus of Hand2 haplo-insufficient mutants.  This finding could either reflect the 
capacity of enteric glia to differentiate despite low levels of Hand2, temporal effects of Hand2, 
and/or the effect of differential Hand2 expression levels in distinct NCC subpopulations.  Effects 
of transcription factor levels and timing have previously been shown to play a role in cell lineage 
segregation in the pancreas (55-58).  And, differential expression of transcription factor levels 
may be functional in the ENS as well since this phenomenon has been documented in ENPs at 
stages concurrent with lineage segregation (59).  Regardless of the underlying mechanism, the 
D’Autreaux and Lei studies also differ since Nestin-Hand2 depleted mutants die near weaning 
with gross bowel distention, but Hand2+/- mice are fertile and have a normal lifespan. However, 
despite a normal lifespan, Hand2+/- heterozygotes do not have normal intestinal function, as 
D'Autreaux et al., (2011) documented these mutants have a significant increase in total GI transit 
time and markedly slower colonic motility compared to wild type littermates.  Surprisingly, despite 
a reduction in overall neuronal density and decrease in GI motility, Hand2+/- mice are protected 
against TNBS induced inflammation when compared to wild type littermates (60).  This finding 
was unexpected as increased gut motility is thought to protect against microbial overgrowth and 
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infection (61).  Margolis et al., (2011) concluded that an overall decrease in neuronal density is 
protective against GI inflammation despite the decrease in motility seen in these mutants.  Indeed, 
neurons have been implicated in GI inflammation (62).  For example, T cell activation in the 
intestine leads to an altered electrical response from the ENS and post-ganglionic sympathetic 
innervation is known to regulate mast cell actions (reviewed in Sharkey & Mawe, 2002). However, 
the specific mechanisms and theneuron subtypes contributing to inflammatory processes remain 
largely unknown.  Future studies elucidating roles for distinct neuronal subtypes and enteric glia 
in initiating and propagating inflammation will be essential to understanding how the ENS 
mediates enterocolitis.  
 
Bone Morphogenic Proteins (BMPs)  
BMPs orchestrate several developmental programs in a dosage and time specific manner 
during the course of development including neurogenesis in the developing gut.  ENPs encounter 
BMP signaling throughout development as the notochord and somites mature (63).  In addition, it 
is known that BMP 2, 4, and 7 are expressed in the developing fetal intestine (64, 65).  
 The influence of BMPs agonists and antagonists on ENP lineage segregation has been 
studied in vitro and in vivo for multiple enteric lineages.  In vitro, isolated rat ENPs treated with 
BMP2 and BMP4 levels above those normally encountered in vivo appear to specify TrkC 
expressing neurons prematurely and cause an overall increase the number of TrkC expressing 
neurons (64).  Mouse models with neuronal BMP4 overexpression show no changes in ENS 
neuronal density in vivo; however, neuronal subtype proportions are skewed with significant 
increases in dopaminergic neurons, serotonergic neurons, and TrkC expressing neurons in 
specific gut regions (65).  Additionally, BMP4 overexpression causes glial numbers to increase 
markedly at the expense of neurons (66).   
Antagonsim of BMP signaling in neurons through neuron specific enolase (NSE)-driven 
noggin overexpression corroborated findings in regard to the role of BMPs in ENS development. 
16 
 
Noggin overexpression in neurons increases overall ENS neuronal density which is consistent 
with BMPs’ opposing role in promoting neural differentiation at the expense of proliferation (67). 
Noggin overexpression increased the proportion of serotonergic neurons (65), but led to 
decreases in TrkC and GABA and CGRP expressing neurons (64) (65) as well as the glia to 
neuron ratio (66).  Importantly, these mice also exhibited irregular bowel transit (65) as well as 
increased sensitivity to chemically induced inflammation (60). It is clear that decreased BMP 
signaling tips the balance to favor more neurons and glia as well as certain neuronal subtypes; 
however, we can only speculate now as to how these imbalances are exactly influencing GI 
function.  Also, it is imperative to mention that these studies (64-66) and others (67) note the 
dosage and timing of BMP expression affects the timing and differentiation capacity of cell types.  
 
Norepinephrine Transporter (NET) 
 Although the ENS is not known to house any intrinsic norepinephrine producing neurons, 
developing transiently catecholaminergic neural precursors express norepinephrine transporter 
(NET).  Transiently catecholaminergic subtypes include, but are not limited to, 5-HT expressing 
neurons and some (but not all) Calretinin and NOS expressing subtypes (68, 69). To determine if 
NET is essential for the specification of these transiently catecholaminergic neuronal subtypes, Li 
et. al., (69) evaluated transiently catecholaminergic subtypes in the myenteric plexus of NET null 
mice (Slc6a2tm1Mca, common name NET-/-).  NET-/- mice have an overall decrease in myenteric 
neuron numbers, with 5-HT and Calretinin+ subsets significantly reduced in number.  In NET-/- 
mutants, NOS+ neurons were observed to be slightly reduced in number, but the reduction was 
not significant.  These results indicate that NET is essential for certain transiently 
catecholaminergic subtypes.  However, it is unknown whether both the transiently 
catecholaminergic NOS and non-transiently catecholaminergic NOS populations of neurons were 
largely unaffected by the NET deficiency or if one of these populations was able to proliferate and 
compensate for an undocumented loss in the other population.   
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Fgf2 and Sprouty2 
 Mutations in Sprouty2, an FGF2 antagonist, have been associated with intestinal neuronal 
dysplasia (IND) in humans (70) and Fgf-2-/- (Fgf2tm1Zllr/tm1Zllr) mice similarly exhibit abnormally large 
ganglia that contain fewer, but larger, neurons than wild-type mice (71). Hagl and colleagues (72) 
classified enteric neurons in Fgf-2-/- mice based on morphology measures (73) and found a 
significant decrease in calbindin expressing Dogiel Type 2 neurons .  Neurons may be classified 
by their shape, function, neurotransmitters, electrical properties, and/or gene expression patterns.  
Most of the studies mentioned previously used gene expression detected by 
immunohistochemistry to classify neurons. Because the studies by Hagl et al (2012) assessed 
morphology and calbindin expression as characteristic features, the authors hypothesized that 
the neuronal population lost was sensory in nature.  Additionally, Fgf-2-/- mice exhibit alterations 
in chloride secretion and translocation of bacteria across the mucosal barrier.  How the ENS 
modulates permeability to bacterial penetration has not been determined (71). 
 
Transgenic Models 
 Recent development of fluorescent transgenic mouse models (59, 74, 75) has permitted 
refined analyses of ENS development that were not previously possible by immunohistochemical 
studies of mutant strains.  In particular, it has long been accepted that ENPs either enter the 
foregut mesenchyme proximally and migrate down its length in a rostral to caudal fashion (vagal 
ENPs) or they enter the gut at the distal end and migrate caudal to rostral (sacral ENPs).  These 
processes left unexplained how subsets of HSCR patients exhibit 'skip segment' aganglionosis 
where small region(s) of the colon contain ganglia (O'Donnell & Puri, 2010) instead of continuous 
aganglionosis that is typically seen in the distal colon.  How skip segment aganglionosis might 
arise given known mechanisms remained a quandary although several groups suggested that 
extramural ENPs could account for the ganglionated 'skip segments' seen in some HSCR cases 
(76, 77).  Synthesis of information from multiple transgenic models now suggests these skip 
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regions occur because normal migration of ENPs across the mesentery between the small 
intestine and the colon occurs, but subsequent filling of the proximal colon by ENPs that migrate 
from the cecum fails.  Mesenteric ENPs were initially reported by Drukenbrod & Epstein (75).  
However, only recently has mechanistic data emerged that can explain the role of these 
mesenteric ENPs in skip segment aganglionosis.  Recent analysis by Nishiyama et al., (78) using 
elegant live cell imaging, has unequivocally shown that ENPs migrate across gut mesentery to 
populate the majority of the colon before cells migrating down the length of the gut tube arrive. 
The integration of these analyses is just one more example of how studying fundamental 
processes in normal development can serve to elaborate the etiology of disease. 
 
Summary 
Post-surgery, chronic constipation and/or enterocolitis afflicts many HSCR patients, and 
some Ednrb mouse models suffer from enterocolitis as well despite surgical removal of the 
aganglionic segment (28).  Because the distal aganglionic region has been removed in these 
patients and mouse models, the effect of and role played by ganglionated proximal intestine in 
long-term GI function has to be considered.  To date, evidence suggests the balance of cell types 
within enteric ganglia that derive from NC during lineage segregation can significantly alter the 
ENS.  Studies from mouse models that mimic the diagnostic feature of HSCR, aganglionosis, are 
in their infancy, but recent studies and additional data presented within subsequent chapters are 
consistent with the possibility of disrupted lineage segregation in at least some HSCR mutants.  
Specifically, Chapter 2 herein is an in depth study in regard to enteric neural crest-derived lineage 
imbalance and alterations in gastric emptying and small intestine transit in the Sox10Dom/+ HSCR 
mouse model. In the same vein, Chapter 4 details aberrant pyloric sphincter function in the 
Sox10Dom/+ HSCR mouse. 
Likewise, analysis of enteric development in mouse mutants that do not exhibit overt 
aganglionosis (non-HSCR) also indicates that any one of several gene deficits can disrupt the 
19 
 
normal processes of ENS ontogeny and skew the resulting profile of neurons and glia away from 
normal composites.  It should be emphasized that while several non-HSCR mouse mutants 
exhibit alterations in enteric neural crest lineages, how these imbalances directly or indirectly 
cause GI dysfunction remains to be determined.  Many studies evaluating ENS architecture and 
composition do not assess GI function and those preliminary studies that do focus on gross 
assessments, such as overall changes in GI transit time or colonic motility.  A need for further 
histological, physiological, and electrophysiological studies to determine exactly how certain 
populations and imbalances in these populations affect GI function would be valuable for better 
understanding the etiology of intestinal dysmotility.   
As the ENS field moves forward, we must consider several factors.  How much does one 
need to tilt the balance of neural crest derivatives for GI dysmotility to occur?  The answer to this 
question is paramount.  Some variability in neural crest derivative portions is expected since 
different inbred mouse strains may have slight differences in neuronal subtypes proportions but 
still have normal bowel function (48). It may be that only certain environmental stressors, such as 
infection, cause certain imbalances to manifest as disease.  Reduced penetrance seen in some 
human diseases could be due to a slight tip of the balance by genetic modifiers, causing the 
balance to wax and wane between disease and unaffected amongst family members. Other 
functional bowel disorders in humans appear to have a genetic component, but the genetic 
etiologies and risk factors remain unknown.   Small perturbations that do not lead to overt 
aganglionosis, but cause imbalances of cell types or alterations in ENS signaling, could explain 
disorders such as chronic constipation despite the presence of detectable enteric ganglia 
throughout the intestine.  This possibility is likely given a recent case study documenting chronic 
constipation in a patient with a RET mutation, but no detectable HSCR disease (79).  In Chapter 
3, I present data further corroborating this possibility as I observed increased total gut transit times 
in Ret deficient male mice compared to wild type littermates.   
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Additionally, recent studies have unearthed previously unrecognized ENP subpopulations 
that appear to be distinct in their developmental capacity.  It was formerly believed that ENPs 
were homogenous with regard to expression of Nestin, but Lei et al (2011) identified a previously 
unknown ENP nestin-independent population.  A study by Mundell and colleagues (80) revealed 
a distinct ENP population that does not express Ednrb and appears to have substantial capacity 
to compensate for loss of other enteric progenitors during ENS development.  The ability to fate-
map, isolate, and manipulate these and other subpopulations as the ENS forms will be important 
and is explored in Chapter 6.  In the future, such efforts will provide insight into how and when 
subpopulations are specified, how distinct subpopulations influence lineage diversification, and 
define the ability of distinct subpopulations to compensate for disturbances in other enteric cell 
types that might otherwise derail GI motility and immune response. 
Of ultimate importance in patient care is determining how study findings in HSCR and non-
HSCR mouse models relate to human disease.  Most histological studies in human tissues utilize 
cross sections. This type of section limits the ability to analyze the patterning, cell connectives, 
and density of the ENS.  Few studies have attempted laminar visualization and analysis of cell 
types in the ENS in human tissues (81, 82).   Thus, true proportions of specific ENS cell types are 
unknown in humans in non-disease and disease states and can only be estimated from cross 
section studies and studies in other animals.  In Chapter 8, experimental techniques are described 
where such laminar analysis of the ENS in human tissue (HSCR and non-HSCR) is attempted.    
Currently, HSCR patients are not genetically screened and standard histology for disease 
diagnosis and determining surgical boundaries only calls for assessing for presence or absence 
of ganglia.  However, the type of genetic mutation, histological findings (such as eosinophilia), 
and other clinical information could inform clinicians as to what patients are most likely to suffer 
from adverse outcomes post-surgery.  To begin to address these questions and issues, I define 
and describe a HSCR cohort in Chapter 5.   Ultimately, efforts to elucidate the developmental 
processes affected in HSCR disease will call for future studies to be conducted in both animal 
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models as well as patient populations and such potential future studies are detailed within Chapter 
7.  A clearer understanding of such processes should lead to better outcomes for HSCR patients 
as well as non-HSCR patients who suffer from inflammation and aberrant GI motility. 
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CHAPTER II 
 
DEFECITS IN THE GANGLIONATED REGIONS OF THE SOX10DOM/+ MOUSE INTESTINE 
  
This chapter is a modified version of an article in press (1). 
 
Introduction 
The ENS regulates multiple gastrointestinal (GI) functions including motility, secretion, and 
inflammatory processes (2). The ENS originates from neural crest-derived progenitors (NCPs) 
that migrate from the neural tube to colonize the entire intestine (2).  Normal function of the ENS 
relies upon complete colonization of the bowel as well as appropriate lineage segregation of NCPs 
to generate a balanced repertoire of distinct neuron classes and glial cell proportions. 
 In Hirschsprung disease (HSCR), migrating NCPs fail to populate the distal intestine 
leading to a variable length of aganglionic bowel (3).  Mutations in RET, EDNRB, EDN3, or SOX10 
cause HSCR in patients, although other genetic variants influence disease penetrance and extent 
of aganglionosis (3-7). Despite surgical resection of the aganglionic  segment, many HSCR 
patients suffer from residual chronic constipation (5-33% of patients) and decreased bowel 
function (8). In addition, a substantial number of patients suffer from Hirschsprung associated-
enterocolitis (HAEC) (9). Differences in surgical procedures and recovery explain some adverse 
outcomes.  Yet, many patients suffer from residual symptoms where no iatrogenic cause is found. 
An understanding of the processes that contribute to residual symptoms in HSCR patients would 
serve to better predict which patients will suffer from HSCR-related sequelae and guide treatment 
options. 
Prior evidence from mouse models with mutations that affect the ENS, yet exhibit no overt 
aganglionosis, suggests that deficits in enteric NCP lineage segregation contribute to GI 
dysmotility (10). Chronic GI dysfunction in HSCR patients after surgery suggests that HSCR 
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susceptibility genes (e.g., SOX10) not only contribute to aganglionosis, but may also affect 
ganglionated regions of the bowel. It has been suggested that Sox10 affects multipotency of NC-
derived cells and neuronal and glial specification. However, these implications are derived from 
in vitro experiments or from other NC-derived structures, such as dorsal root ganglia (11-13), 
While Sox10 is essential for enteric NCP migration and colonization of the bowel, studies to 
elucidate the role of Sox10 in NCP fate specification in the ENS in vivo have not been undertaken.  
Given established roles for Sox10 outside the ENS and the presence of residual symptoms in 
HSCR patients, we hypothesized that perturbations in Sox10 disrupt NCP lineage segregation 
and alter the function of ganglionated bowel in the Sox10Dom/+ HSCR mouse model. To test this 
hypothesis, we fate-mapped NCPs using a Cre-LoxP system. Fate-mapping and 
immunohistochemical labeling of cell types in the myenteric plexus revealed that the normal 
complement of NC-derived lineages is disrupted in the enteric ganglia of Sox10Dom/+ mutants.  
These changes are region specific and disturbances in specific cell types in the colon correlate 
with extent of aganglionosis.  Alterations seen in neuronal subtype proportions in Sox10Dom/+ 
animals suggest a novel role for Sox10 in neuronal class specification.  Since changes in neuron 
ratios within enteric ganglia can alter GI motility, we investigated the potential for aberrant 
intestinal transit in the proximal small intestine of this HSCR model.  GI motility assays exposed 
alterations in gastric emptying and small intestine transit that were age- and sex-dependent.  Our 
results show that the Sox10Dom HSCR mutation alters NC lineage segregation and GI motility 
despite the presence and normal density of ENS ganglia in the proximal small intestine.  Such 
changes could partially explain adverse outcomes in surgically treated HSCR patients and help 
clinicians better identify and treat patients at high risk for experiencing post-surgical GI 
dysfunction. 
 
Methods 
Animals  
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Sox10Dom/+ and homozygous B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato/Hze/J), hereafter 
R26RtdTom, were maintained on a C57BL/6J background. Wnt1tm1Amc, hereafter Wnt1-Cre, mice 
were maintained on a Crl:CD1(ICR) background.  The Sox10-Cre BAC construct was generated 
by linking nuclear localized Cre joined to a human growth hormone mRNA stabilization sequence 
(14, 15)  to the regulatory elements of Sox10 within a well-characterized Sox10 BAC (Figure 2.1). 
The resulting Tg(Sox10-CrehGH)1Sout  line, hereafter Sox10-Cre, was made congenic on the C3HeB/FeJ 
background.  Transgene driven reporter expression mirrors known Sox10 expression in NC-
derived lineages. (Corpening Rosebrock J et al., 2014. In preparation). Experimental animals for 
NC-derived lineage quantification were from crosses between Sox10Dom/+; Sox10-Cre or 
Sox10Dom/+; Sox10-Cre/Cre mice to R26RtdTom mice.  Sox10Dom/+ mice were identified by the 
presence of white feet and belly spotting as well as discernable hypoaganglionosis and/or 
aganglionosis revealed by the absence of tdTomato fluorescent ganglia in the distal intestine. The 
Sox10Dom/+ recapitulates HSCR in humans with animals exhibiting varying lengths of 
aganglionosis within the bowel despite harboring the same HSCR causing mutation. Sox10-Cre 
transgene presence was verified by PCR genotyping (Table 2.1).  The Institutional Animal Care 
and Use Committee at Vanderbilt University approved all experimental protocols.   Wnt1-Cre 
genotyping information and detailed methods and materials in regard to this chapter can be found 
within Chapter 7 Extended Methods.  
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Immunohistochemistry 
Regions of the duodenum, ileum, and mid-colon were collected from postnatal (P) 15-19 
day Sox10Dom/+ and Sox10+/+ littermates.  Laminar muscle preparations containing myenteric 
plexus were isolated and subjected to immunohistochemistry (IHC)(16) (Tables 2.2 & 2.3).  Z-
stack images of samples were captured on a Zeiss LSM 510 confocal microscope (20X objective 
with 1.5X software zoom) to quantify NC derivatives within the ganglia and primary connectives 
of the myenteric plexus. Image brightness and contrast were adjusted in Adobe Photoshop to aid 
in cell quantification.  We quantified n=5-6 samples per genotype for all duodenum and ileum NC 
lineage analyses and n=5-6 Sox10+/+ and n=10-11 for Sox10Dom/+ samples for colon NC lineage 
analyses.   
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Gastrointestinal transit assays 
To determine gastric emptying and small intestine transit rates, 4-week (27-30 days) or 6-
week (42-48 days) mice were gavaged with a rhodamine dextran fluorescence containing meal 
following established procedures (17, 18). Fifteen minutes post-gavage, the stomach and 10 
equal segments of small intestine were collected and homogenized separately.  Fluorescence 
signal from the stomach and each intestinal segment was read on a Molecular Devices/LJL 
Analyst HT (Molecular Devices, Union City, CA, USA). Gastric emptying percent was determined 
by calculating the proportion of fluorescence that had left the stomach to total recovered 
fluorescence.  A small intestine transit score was assigned by determining the geometric mean of 
fluorescence within the 10 equal small intestine segments. Miller and Burk originally described 
this method in rats (18). Full details for this procedure in mice can be found in recent studies (19, 
20). To depict small intestine transit rates, the average percent contribution of each individual 
intestine segment to the motility score was calculated.  A heat map was generated using MATLAB 
(Mathworks, Natick, MA, USA), where intestine segment numbers contributing the most to the 
small intestine transit score are shown in darker red and those contributing little or none to the 
score in lighter red.  Color intensity in between segment number hashes was interpolated to create 
each heat map. n=6-8 mice per genotype, sex, and age.   
 
Inflammation  
Transverse sections (~5 µM) of entire colon from 6 week or older Sox10Dom/+ and Sox10+/+ 
littermates were stained with hematoxylin and eosin.  An expert pathologist blinded to genotype 
scored sample inflammation based on a previously developed scoring system utilizing 
Hirschsprung mouse models (21).  Specifically, a final score of 0-7 was assigned by assessing 
severity of inflammation (0-3 with 0 = no inflammation or rare neutrophils; 1 =mild inflammatory 
infiltrates, no necrosis; 2 = moderate to marked inflammatory infiltrates and mucosal necrosis and 
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3 = transmural necrosis) and depth of inflammation (0-4 with 0 = none, 1 = mucosa, 2 = 
submucosa, 3 = muscularis propia; 4 = subserosa/serosa). n=6-9 mice per genotype and per sex.  
 
Statistics 
 For NC lineage quantification, 5 duodenal, 3 ileal, and 2 colonic images were manually 
counted for each animal.  For Sox10Dom/+ mice with hypoganglionosis in the mid-colon, additional 
images were quantified so a comparable number of neurons were counted between Sox10+/+ and 
Sox10Dom/+ mice. We tested for differences in cell type proportions, gastric emptying rates, small 
intestine transit rates, and inflammation scores using a Student’s t-test assuming unequal 
variance (Welch’s t-test).  ANOVA (F-test) was used to test for significance of slope and to 
determine coefficients of determination (r2).  Statistical analysis was performed using JMP 
(version 10) software.  Variance is reported as ±SEM. 
 
Results 
Validation of the Sox10-Cre BAC transgene system 
Studies to assess alterations in enteric cell types in vivo have largely focused on 
comparing total numbers of neurons and glia, although a few studies have assessed neuronal 
subtypes (20, 22).  While informative, IHC alone may not comprehensively identify all NC 
derivatives in the ENS and may miss alterations in patterning and distribution of enteric ganglia 
depending on the marker used. The Wnt1-Cre transgene has been the gold standard for labeling 
NC derivatives since its introduction in 1997 (23). However, Wnt1-Cre transgenic animals suffer 
neurological developmental defects (24) and both heterozygotes and homozygotes are 
susceptible to early death due to seizures (personal communications, Elise Pfaltzgraff).  
Additionally, Cre expression through the Wnt1-Cre transgene is driven by a single Wnt1 enhancer; 
thus, important regulatory regions that could drive Wnt1 expression in specific cell types may be 
excluded within the Wnt1-Cre transgene (23).  To avoid potential confounders that accompany 
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use of the Wnt1-Cre transgene line, other members of the Southard-Smith lab generated a Sox10-
Cre BAC transgenic line to label NC derivatives (Figure 2.1). Because Sox10 is ubiquitously 
expressed in NC cells emerging from the neural tube, the use of Sox10 regulatory regions linked 
to a Cre driver enables extensive labeling of NC derivatives. (Corpening Rosebrock et al., 2014 
in preparation)(25, 26). (Further details in regard to generation of the Sox10-Cre transgene can 
be found in the “Methods” section of this chapter as well as in Figure 2.1).    
 
Because the Wnt1-Cre transgene has been the standard for labeling NC derivatives, we 
compared the labeling of NC derivatives in the ENS in the duodenum, ileum, and colon in Wnt1-
Cre or Sox10-Cre lines crossed to a R26RtdTom line.  In these crosses, we compared R26RtdTom 
expression with IHC labeling of NC derivatives by an antibody to Phox2b.  All NC derivatives 
express Phox2b although enteric neurons express Phox2b at high levels and enteric glia express 
Phox2b at relatively low levels (27) (Figure 2.2). Both transgenes were expressed in the vast 
majority of enteric Phox2b+ cells (>97%) in all regions of the intestine examined.  However, the 
Sox10-Cre transgene performed significantly better in the ileum (*P<0.05) and the colon (*P<0.02) 
(Table 2.4).  
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Sox10-Cre presence does not lead to adverse phenotypes 
After validation of transgene expression in enteric NC derivatives, we attempted to 
generate mice homozygous for the Sox10-Cre transgene. Transgenic homozygote breeders are 
desirable in a study where many mice are needed, but where litter sizes (such as those on a 
C57/BL6 background) are small.  A limitation of the Wnt1-Cre transgene is that attempts to 
generate Wnt1-Cre homozygotes have been difficult.  Wnt1-Cre homozygotes typically succumb 
to seizure induced death before they are able to breed (personal communications, Elise 
Pfaltzgraff). We successfully crossed Sox10Dom/+; Sox10-Cre males to Sox10-Cre females to 
generate mice homozygous for the Sox10-Cre transgene.  Mice were first screened for 
homozygosity of the transgene through semi-quantitative PCR.  (See Extended Methods.)  
Homozygosity was validated by crossing a Sox10Dom/+; Sox10-Cre/Cre male to a homozygous 
R26RtdTom female.  We observed tdTomato fluorescence in NC derivates in all progeny of the two 
litters produced from this cross.  Sox10-Cre transgene presence in progeny was also verified by 
PCR genotyping. 
Sox protein family members are known to regulate each other and to self-regulate 
(reviewed in (28)).  Thus, the Sox10Dom mutation could potentially affect Sox10-Cre transgene 
expression.  In order to study NC derivatives in Sox10Dom/+; Sox10-Cre animals, we first needed 
to verify that the Sox10-Cre transgene and the Sox10Dom mutation do not interact and affect 
reporter expression in our study.  In our crosses, we observed expression of R26RtdTom in the ENS 
in all mice carrying the Sox10Dom mutation and Sox10-Cre transgene and reporter expression 
appeared equivalent between wildtype and mutant animals, suggesting no or little interaction of 
the transgene and mutated Sox10. 
Additionally, random integration of transgenes during generation of transgenic lines can 
alter or ablate expression of other genes depending on integration location. And because the 
Sox10-Cre transgene requires the same transcriptional machinery as the endogenous Sox10 loci, 
transgene presence in a cell could potentially hijack transcriptional machinery needed for Sox10 
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expression or expression of other genes.  This hijacking could lead to a more severe phenotype 
and thus higher death rates in Sox10Dom/+ mice.  To rule out potential effects of the Sox10-Cre 
transgene on our study, we monitored Sox10-Cre mouse viability and fertility.  We noticed no 
viability or growth defects nor any other additional phenotypes in the Sox10-Cre line (line F) used 
in this study.  To test if the Sox10-Cre transgene affected the Sox10Dom/+ phenotype, we monitored 
the number of Sox10Dom/+; Sox10-Cre+ and Sox10Dom/+; Sox10-Cre- pups that reached 
experimental age (P15-19). If Sox10-Cre were to increase the severity of the Sox10Dom/+ 
phenotype, we would expect fewer pups harboring the Sox10Dom/+ mutation and transgene to 
reach experimental age than pups with the mutation but not the transgene.  When we compared 
our expected progeny ratios to observed, we found no statistical difference (P=0.2413; X2 
goodness of fit) (Table 2.5). 
 
 
 
Fate-mapping enteric NC derivatives in Sox10+/+ and Sox10Dom/+ mice  
  Once we validated the Sox10-Cre transgene as an effective means to label enteric NC 
derivatives, we combined a Sox10-Cre BAC transgene with a Cre-dependent R26RtdTom reporter 
in crosses with Sox10Dom/+ mice to evaluate NC derivatives within enteric ganglia between 
Sox10+/+ and Sox10Dom/+ mice. Analysis of Sox10Dom/+ mutants, on a mixed background in these 
crosses, is advantageous since this model recapitulates the variable penetrance and severity of 
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aganglionosis seen in human HSCR patients (5, 29). In the resulting progeny, the cytoplasmic 
reporter, tdTomato, which is concentrated in the cell soma and labels cellular processes, reveals 
ganglia structure, density and connectives of cells in which Cre is expressed. We collected 
laminar gut muscle preparations in postnatal pups between postnatal days (P)15-19 before the 
majority of these animals develop and perish due to megacolon at weaning.  We observed similar 
myenteric ganglia density, spacing between ganglia, and overall architecture of ganglia in the 
duodenum, ileum, and ganglionated regions of the colon in both Sox10+/+ and Sox10Dom/+ pups 
(Figure 2.3).  While comparable ganglia patterning and density were seen, the possibility 
remained that total numbers of myenteric NCPs might differ between Sox10+/+ and Sox10Dom/+ 
animals and could lead to altered GI function. We compared total numbers of enteric NC-derived 
cells between Sox10+/+ and Sox10Dom/+ pups. This analysis revealed similar total numbers of NC-
derived cells between Sox10+/+ and Sox10Dom/+ mice in both duodenum and ileum (Table 2.6).  
 
Correlation between disease severity and neuron or glia proportions  
In vitro and in peripheral nervous structures outside the ENS, timing and levels of Sox10 
expression affect neuronal and glial fate acquisition from NC progenitors (11-13, 30, 31). 
However, the role of Sox10 in neuronal and glial fate acquisition in the ENS in vivo has not been 
determined. Feasibly, disruption of Sox10 could alter the ratios of these cell types and contribute 
to GI dysfunction by impacting motility or by contributing to inflammation secondary to perturbing 
enteric glia (32). To examine the possibility that ratios of enteric neurons and glia are abnormal in 
Sox10Dom/+ pups, we quantified the proportions of neurons and glia out of total NC derivatives 
within the myenteric plexus at P15-17.  Because different regions of the bowel have distinct 
functions and it is unknown how proximal to regions of aganglionosis aberrancies in lineage 
segregation might occur, we assessed neuron and glia proportions in the duodenum, ileum, and 
mid-colon.  Enteric neurons (Hu+) (20) and glia (FoxD3+) (33) (Figure 2.4) were IHC labeled, 
counted, and their proportions out of total NC derivatives calculated (Figure 2.5A).  Proportions  
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of neurons and glia were found to be comparable within the duodenum (neurons P=0.28; glia 
P=0.36) and the ileum (neuron P=0.78; glia P=0.50) between Sox10Dom/+ and Sox10+/+ animals 
(Figure 2.5B & C).   
While neuronal and glial proportions in the mid-colon revealed no statistical difference 
between Sox10Dom/+ and Sox10+/+ animals (neurons P=0.06; glia P=0.37), we noted an overall 
decrease in neuron proportions and an overall increase in glia proportions in Sox10Dom/+ mice 
(Figure 2.5B & C).  Given the variable length of aganglionosis present in HSCR Sox10Dom/+ mice, 
which models that seen in HSCR patients, we compared colonic neuronal and glial proportions 
against the length of colonic aganglionosis for each Sox10Dom/+ mouse. This analysis detected a 
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strong inverse correlation between neuron proportions and length of colonic aganglionosis 
(*P<0.003; r2=0.70) (Figure 2.5D).  Conversely, a strong direct relationship is present between 
glia proportions and extent of colonic aganglionosis (*P<0.005; r2=0.66) (Figure 2.5D).  Thus, 
while neuron and glia proportions in the Sox10Dom/+ small intestine are not altered and do not 
correlate with aganglionosis, in the colon, neuronal numbers decrease in concert with an increase 
in glial numbers as the area of the bowel affected by aganglionosis increases.  Correlation scores 
for cell type proportions and extent of aganglionosis for each region of the bowel examined are 
summarized in Table 2.7.   
 
Rare, enteric NC derived cell types in Sox10+/+ and Sox10Dom/+ mice.   
Given the presence of multiple lineages, including myofibroblasts, in colonies grown from 
cultured enteric NCPs in vitro,(12, 13, 34, 35) we anticipated the possibility of identifying cells 
within the ENS that express neither neuronal nor glial markers.   Use of the Sox10-Cre transgene 
system revealed enteric NC derivatives that were not labeled by neuronal (Hu+) or glial (FoxD3+) 
immunoreagents.  However, these cells were extremely rare within myenteric ganglia and primary 
connectives with an average incidence of 1.5 cells in 1000 NC derivatives in the duodenum, 0.6 
cells in 1000 in the ileum, and 6 cells in 1000 in the colon. The presence of this cell type did not 
significantly differ between Sox10+/+ and Sox10Dom/+ in any region of the intestine tested 
(duodenum P=0.41; ileum P=0.90; colon P=0.23) (Figure 2.6A).  Furthermore, proportions of this 
cell type did not correlate with length of aganglionosis (Table 2.7).   
Concurrently, while evaluating neuron and glia proportions, we documented a relatively 
infrequent population of enteric NC-derived cells that expressed both neuronal (Hu+) and glial 
(FoxD3+) markers.  These cells were typically found in small clusters —mainly as couplets, triplets 
or quadruplets—but on occasion were found singularly (Figure 2.6B).  This cell type was very rare 
in both Sox10+/+ and Sox10Dom/+ mice and its rate of appearance did not differ between Sox10+/+ 
and Sox10Dom/+ mice in the duodenum (P=0.71) or ileum (P=0.12).  While still rare, Sox10Dom/+  
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mice had more of these double positive cells within the colon (*P<0.005). On average, Sox10Dom/+ 
colon samples contained 40 Hu+FoxD3+ cells per 1000 NC derivatives while Sox10+/+ colons only 
contained 25 Hu+FoxD3+ cells per 1000 NC derivatives.  Unlike neurons and glia, the proportion 
of this cell type did not correlate with disease severity in the colon of Sox10Dom/+ mice (P=0.80; 
r2<0.01).  Additionally, no correlations were seen for this cell type in regions of the small intestine 
(Table 2.7). 
 
Regional alterations among enteric neuronal subtypes in Sox10Dom/+ mice  
Because clinicians have identified chronic constipation and incontinence as problematic 
long term outcomes in Hirschsprung patients (8), we examined the relative proportions of two 
neuronal subtypes in Sox10Dom/+ mutants with well-known roles in GI motility.  Calretinin is 
expressed in cholinergic neurons and its presence identifies excitatory muscle motor neurons 
within the myenteric plexus as well as some interneurons and intrinsic primary afferent neurons 
(2, 36).  Therefore, alterations in Calretinin expressing (Calretinin+) neuron numbers could affect 
intestinal contraction dynamics and overall motility.  Proportions of Calretinin+ neurons out of total 
neurons (Hu+) in the myenteric plexus were quantified through IHC (Figure 2.7A). The proportion 
of Calretinin+ neurons in Sox10Dom/+ mice duodenum was significantly greater compared to  
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Sox10+/+ littermates (*P<0.05) (Figure 2.7B).  Calretinin+ neurons were also present in 
higher proportions in the ileum of Sox10Dom/+ mice (*P<0.03) (Figure 2.7C).  In sharp contrast to 
findings in the small intestine, an overall decrease in the proportion of Calretinin+ neurons was 
evident in the colon. (*P<0.03) (Figure 2.7D).  Concurrently, greater variance in colonic Calretinin+ 
neuronal subtype proportions was present in Sox10Dom/+ mutants compared to Sox10+/+ samples, 
similar to the effect seen for colonic neuronal and glial proportions.  We also tested the relationship 
between Calretinin+ neuron proportions and length of aganglionosis.  This analysis revealed that 
Calretinin+ neuron proportions decrease dramatically as the length of aganglionosis increases 
(*P<0.0001. r2=0.84) (Figure 2.7E). This effect was limited to the colon as Calretinin+ neuron 
proportions did not correlate with length of aganglionosis in the duodenum nor ileum (Table 2.7). 
To further define alterations in other motor neuron types, we evaluated nNOS expressing 
neurons in Sox10Dom/+ mutants (Figure 2.8A).  Nitrergic (nNOS+) neurons in the myenteric plexus  
are primarily inhibitory motor neurons responsible for the relaxation of intestinal smooth muscle 
and also include some interneurons (2). Interestingly, although Calretinin+ neuron proportions 
were altered in the duodenum in Sox10Dom/+ mice, nNOS+ neuron proportions were comparable 
between Sox10+/+ and Sox10Dom/+ animals (P=0.68) (Figure 2.8B). Similarly, nNOS+ proportions 
were nearly identical in the ileum between the two genotypes (P=0.51) (Figure 2.8C). However, 
there was a trending increase in nNOS+ neuron proportions in the colon of Sox10Dom/+ mice 
compared to Sox10+/+ controls (P=0.099) (Figure 2.8D).  While Calretinin+ neuron proportions in 
the colon decreased as length of aganglionosis increased, the opposite was true for nNOS+ 
neurons.  Animals with greater extents of aganglionosis also exhibited greater proportions of 
colonic nNOS+ neurons (*P=0.0014; r2=0.74) (Figure 2.8E).   Like the majority of cell types we 
evaluated, correlations for nNOS+ neurons were only detected in the colon and not the duodenum 
and ileum (Table 2.7). 
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Gastric emptying and small intestinal transit in Sox10Dom/+ mice   
Substantial numbers of HSCR patients suffer GI dysfunction even after surgical resection 
of aganglionic regions.  Given the skewing of neuron proportions observed in Sox10Dom/+ animals 
resulting from increased Calretinin+ neurons in the duodenum and ileum, we examined GI motility 
dynamics proximal to the colon in Sox10Dom/+ mice.   To evaluate gastric emptying and small 
intestine transit rates, fasted mice were gavaged with a non-absorbable fluorescent meal.  Gastric 
emptying was determined by calculating the proportion of fluorescent signal that had left the 
stomach to the total recovered fluorescence, and small intestine transit rates were determined by 
calculating the geometric mean of fluorescence within the small intestine (18-20).  Because distal 
intestinal obstruction can affect GI transit more proximally and pups with severe aganglionosis 
often succumb to megacolon around weaning, we chose to limit our analysis to more mature 
Sox10Dom/+ mice that survived past weaning to 4-weeks or 6-weeks of age. Sox10Dom/+ animals 
that survive to adulthood typically have short lengths of aganglionosis, reach full adult size, and 
feed and breed normally. 
Initially, gastric emptying and small intestine transit rates were compared in 4-week old 
Sox10Dom/+ and Sox10+/+ animals.  Because HSCR shows a sex bias in humans with three in four 
HSCR patients males (3), we chose to evaluate GI motility in both Sox10Dom/+ male and female 
mice.  In 4-week old animals, Sox10Dom/+ males had significantly slower small intestinal transit 
rates than Sox10+/+ males (*P<0.04) (Figure 2.9A). Nearly identical results were obtained for 
females, with 4-week old Sox10Dom/+ females also showing significantly reduced small intestinal 
transit rates (*P<0.006) (Figure 2.9B).  Gastric emptying rates were comparable between 
Sox10Dom/+ and Sox10+/+ for both sexes at this age (males: P=0.96; females: P=0.68) (Figure 2.9A 
& B).   
These findings are not surprising given the skew of neuronal subtypes we observed in the 
small intestine of Sox10Dom/+ and known outcomes among HSCR patients.  However, because 
neurally mediated traits are susceptible to change upon increased exposure to sex hormones (37, 
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38), gastric emptying and small intestine transit rates were also evaluated in older, sexually 
mature (6-week+) animals.  For older male mice, we observed statistically comparable small 
intestine transit rates between Sox10Dom/+ males and their wild type Sox10+/+ counterparts 
(P=0.57).  But, in contrast to the phenotype of 4-week old males, we observed a marked increase 
in gastric emptying rates of 6-week old Sox10Dom/+ males that was not observed in 6-week old 
normal Sox10+/+ littermates (*P<0.005) (Figure 2.9C).   Small intestine transit rates were 
comparable between 6-week old Sox10Dom/+ and Sox10+/+ females (P=0.31) (Figure 2.9D).  And, 
unlike 6-week old males, gastric emptying rates were comparable in female 6-week old Sox10Dom/+ 
and Sox10+/+ mice (P=0.58) (Figure 2.9D).  To summarize, at an early age, both female and male 
Sox10Dom/+ have significant small intestine transit deficits; however, in older Sox10Dom/+ animals, 
only males exhibit any type of motility defect. (See Table 2.8 for a numerical summary of GI transit 
results.) 
 
Sox10Dom/+ mice exhibit negligible colonic inflammation 
Many Hirschsprung patients suffer from severe bouts of enterocolitis and previous studies 
reported that some animals with an Ednrb HSCR mutation suffer from enterocolitis that can 
ultimately lead to bowel perforation, sepsis and death (21, 39). Additionally, inflammatory 
processes within the bowel could potentially affect GI motility, making it difficult to determine if GI 
motility deficits in Sox10Dom/+ mice result from changes in electrical properties due to ENS deficits 
and/or influences of inflammatory processes on the bowel.  To determine if enterocolitis could be 
affecting GI motility in adult Sox10Dom/+ mice, we harvested entire colons from Sox10Dom/+ and 
Sox10+/+ 6 week+ old littermates.  Colons were hematoxylin and eosin stained and scored for 
inflammation by a pathologist blinded to genotype. We adopted a grading rubric for inflammation 
based on previous studies in HSCR mouse mutants (21). Briefly, each mouse was assigned an 
inflammation score (0-7) based on the severity (0-3) and depth (0-4) of inflammation.  
Interestingly, Sox10Dom/+ mice had no or very little inflammation, comparable to their WT 
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littermates (P=0.99) (Figure 2.10B).  Since males and females may differ in the levels of 
inflammation, we also compared inflammation scores by sex.  Even when separated by sex, we 
observed similar levels of inflammation in Sox10Dom/+ and Sox10+/+ mice (Figure 2.10C & D).  Other 
hallmark features of Hirschsprung disease as reported in HSCR patients, such as regions of 
hypoganglionosis proximal to aganglionosis and thickened muscularis propria were evident 
(Figure 2.10A). Given the intestinal transit alterations in Sox10Dom/+ and the lack of inflammation 
in this HSCR model, our results suggest the motility deficits in this HSCR model are neurally 
mediated.   
 
Discussion  
We utilized the Sox10-Cre transgene to evaluate enteric NC derivatives in Sox10Dom/+ and 
Sox10+/+ pups. Both the Wnt1-Cre and Sox10-Cre transgene label the vast majority of NC 
derivatives within the ENS.  However, we found that the Sox10-Cre transgene driven expression 
of the R26RtdTom led to significantly more NC derivative labeling in the ileum and colon than 
crosses with Wnt1-Cre mice (Table 2.4). These findings, along with known neurological 
developmental defects in the Wnt1-Cre line (24), justified our use of the Sox10-Cre transgene in  
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this study.  However, the biological factors driving the differences we observed between Wnt1-
Cre and Sox10-Cre lines are unknown.  It is believed that the neurons and glia of the duodenum 
derive solely from the vagal NC population, whereas vagal and sacral NC populations contribute 
to the neurons and glia in the ileum and colon (40). Therefore, differential expression of Wnt1-Cre 
or activation of the Wnt1-Cre enhancer in specific sacral NC cells could explain our findings.  
Alternatively, but possibly related, Wnt1 expression in sacral NC population is temporally brief 
(41) compared to Sox10 expression.  Therefore, action of transcription machinery on the Wnt1-
Cre transgene may be too brief to drive Cre-recombinase expression to levels needed for Cre-
LoxP action within R26RtdTom.  Whatever the reason, this finding highlights the importance of 
integrating key regulatory regions of a “gene of interest” into a transgene to ensure proper 
expression of transgene components as well as appropriate transgene choice in studies. 
The Sox10Dom/+ HSCR mutant is one of several HSCR models frequently studied to better 
understand the NC deficits that give rise to aganglionosis (3, 10, 31, 42). The Sox10Dom allele 
disrupts migration of NCPs as they populate the fetal intestine and contribute to extensive colonic 
aganglionosis (43, 44). Additionally, isolated Sox10Dom/+ enteric NPCs do not produce a normal 
profile of cell lineages when cultured in vitro (13).  Despite the insights gained from studying fetal 
effects of Sox10 mutations on NCP migration and consequent aganglionosis, no prior efforts have 
investigated postnatal consequences of Sox10 mutations on ganglionated regions. In this study, 
we undertook a comprehensive assessment of NC derivatives in the proximal, ganglionated 
intestine of Sox10Dom/+ mice to test the hypothesis that the Sox10Dom mutation leads to imbalances 
in enteric NC derived lineages and deficits in bowel function. Our analysis revealed effects of the 
Sox10 mutation on neuronal-glial lineage segregation in the colon, but not the small intestine.  
Interestingly, this study identified significant imbalances in proportions of excitatory and inhibitory 
enteric neurons accompanied by deficits in intestinal transit and gastric emptying.  Calretinin+ 
neurons with roles in muscle contraction were significantly increased in the duodenum and ileum 
while nNOS+ neurons with roles in muscle relaxation were unchanged in these regions. 
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 Sox10 effects on glial cell specification and NCP multipotency are well established in other 
aspects of the peripheral nervous system, like dorsal root ganglia (11, 30, 31, 45). Surprisingly, 
our analysis indicated no effect of the Sox10Dom mutation on neuronal-glial balance in the 
duodenum and ileum although there was a significant correlation between proportions of neurons 
and glia in the Sox10Dom colon with overall extent of aganglionosis.  It is possible that Sox10Dom/+ 
neurons and glia are born in equal proportions in the colon, with more neurons subsequently 
succumbing to apoptosis while glia persist.  However, increased apoptosis has not been observed 
in several ENS mutants to date (13, 46, 47). Moreover, cell death cannot adequately account for 
observed increases in colonic nNOS+ neuron proportions to levels well above the wild type 
average in Sox10Dom/+ mice with severe aganglionosis.  Our study suggests that timing of NCP 
lineage choice is likely a key factor in determining not only the length of aganglionosis, but 
ultimately the proportions of enteric glia, neurons, and neuronal subtypes.  It has been postulated 
that premature neuronal differentiation contributes to HSCR disease by depleting the enteric NCP 
pool. Premature NCP differentiation would not only exhaust the NCP pool, but may cause certain 
cell types to be born more or less often based on when (temporally) and where (local environment) 
lineage choice occurs. This phenomenon could account for the region specific imbalance of 
different NC-derived cell types we observed in Sox10Dom/+ mice.  Such a possibility is corroborated 
by recent findings in the developing telencephalon, where oscillating or sustained expression of 
specific transcription factors controls whether neural progenitor cells go on to differentiate into 
specific cell types or continue to proliferate and give rise to daughter neural progenitor cells (48). 
 A possibility, not mutually exclusive from our hypothesis above, is that changes in neuron, 
glia, and neuronal subtype proportions in Sox10Dom/+ animals in the colon are driven by birth dates 
of NC derivatives.  Birth date  for a neuron in the ENS can be defined as the point a cell has 
undergone its last mitotic division and taken on characteristics of a terminally differentiated neuron 
such as expression of a specific neurotransmitter (49). For example, serotonergic neurons are 
some of the first neuron subtypes to be born, with birthdates as early as E8 (49).  Conversely, 
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some VIP neurons are extremely late-born with birthdates recorded as late as P5 (49).   Therefore, 
it could be in hypoganglionic regions of the colon in HSCR mouse models, we would see early 
born neuronal subtypes to be in greater proportions than those born at later stages because the 
progenitor pool is depleted before it can give rise to these late-born neuron types.  If this were the 
case, then neuron subtype proportions in hypoganglionic regions should correlate directly with 
the ganglion size (ie extremely hypoganglionic areas with very few cells per ganglia would have 
more early born neurons while less hypoganglionoic areas with larger ganglia would have a near 
normal complement of neuron subtypes with only a few late-born neuron subtypes missing.)  The 
birth dates of glia are still unknown in the ENS, but this hypothesis is testable by comparing the 
proportions of a neuron subtype to the relative ganglia size (NC derivatives within an image.)  We 
performed this analysis for nNOS neuron proportions in the colon and found no correlation 
between nNOS neuron proportions and relative ganglia size (P=0.1031; r2=0.08) (Figure 2.11).  
Although this finding rules out the possibility that birthdates of neuronal subtypes exclusively 
drives our phenotype, this does not mean that birth dating does not play a role.  In fact, it is known 
that early born neuron subtypes affect the fate of later born neuron subtypes.  For example, 
ablation of enteric serotonergic neurons (early born) in embryonic development leads to 
decreases in dopaminergic neurons and increases in CGRP neuron types (50). Rather, this 
finding suggests, as above, that multiple factors including timing and environment (intra- and 
extracellular) are influencing fate choice.   
Given the diversity of cell types that can arise from cultured NC progenitors in vitro (51), 
we were not surprised to identify NC-derived cells in the intestine that did not label with neuronal 
or glial immunoreagents.  These cells are infrequent and might represent a novel cell type or 
possibly cell turnover within ganglia.  Because proportions of these NC-derived cells were 
equivalent between Sox10Dom/+ and Sox10+/+ animals and because they were so rare, we did not 
attempt to characterize this lineage further.  Interestingly, in both Sox10Dom/+ and Sox10+/+ mice, 
we observed cells that double-labeled with neuronal (Hu+) and glial (FoxD3+) markers.  This cell  
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type may represent either a novel lineage or a progenitor(s) undergoing differentiation.  Given 
their morphology and tendency to be found in clusters, these cells could also represent neural 
progenitors with adjacent daughter progenitors or daughter cells not fully committed to a specific 
cell type.  The latter is certainly feasible given that Foxd3 is expressed in enteric NCPs as well as 
enteric glia (33, 52). Enteric neural progenitors certainly exist in the adult intestine, and their exact 
location and nature are being actively investigated (17, 25, 34). However, no markers have been 
found that exclusively label neural stem cells in the intestine, convoluting efforts to characterize 
this cell type.  If truly an enteric neural stem cell, the increase in this cell type in the Sox10Dom/+ 
colon might represent a futile attempt by the remaining neural stem cells to populate the 
hypoganglionic or aganglionic areas of the distal intestine.   
 Because HSCR is an oligogenic disorder, whereby an independent variant in any one of 
several genes can produce aganglionosis, our findings are potentially of broad relevance to other 
HSCR models.  To our knowledge, this is the first study to examine NC derivative imbalance and 
GI function in the proximal intestine of a HSCR model. Previous studies in Gdnf, Edn3, and Ednrb 
HSCR mouse models have noted distal intestinal changes in neuron types, neurotransmitter 
expression, and/or colonic migratory complexes (22, 53-55). These initial studies were important 
and our findings corroborate their results.  Sandgren and colleagues (53) noted changes in neuron 
types within a HSCR mouse model, specifically mice with the Edn3 lethal spotted mutation.  
Specifically, Sandgren et al., found that homozygous lethal spotted mice had higher proportions 
of nNOS+ neurons in the ileum and distal colon compared to heterozygous lethal spotted mice. 
In EdnrB deficient mice, Zaitoun et al., (22) identified a decrease in colonic ChAT expressing 
(cholinergic) neurons somewhat analogous to the decreased proportions of Calretinin 
(cholinergic) neurons we documented in colon of Sox10Dom/+ mice.  Increased numbers of colonic 
nNOS+ neurons were also observed.  Although these studies are informative, our study is the 
first to examine the relationship between NC derivative proportions in the colon and aganglionosis 
length. Our analysis benefited from the varying levels of aganglionosis present with the Sox10Dom/+ 
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mutation on a mixed background and may not have been possible in other HSCR mouse models 
where extent of aganglionosis does not differ markedly between littermates.  
Recent studies show that prenatal obstruction (atresia) affects NC derivatives in rats (56) 
and extent of aganglionosis in our HSCR mouse model could be viewed as varying lengths of 
obstruction.  Although we realize obstruction cannot be excluded as a factor that impacts NC 
derivative choice in the colon, Sox10Dom/+ are born in Mendelian ratios to their WT littermates, 
suggesting obstruction does not play a large role prenatally. We also chose P15-19 pups for NC 
derivative studies to ensure that the ENS was fully developed and to try to avoid influences of 
obstruction on the ENS. (The majority of Sox10Dom/+ mice suffer from obstruction and expire due 
to megacolon near or at weaning when they transition to solid food.) Future studies will be needed 
to elucidate how different types of obstruction, such as constipation or atresia, affect ENS 
constituents.  Additionally, whether all changes in NC derivatives, gastric emptying, small intestine 
transit, and colonic motility are comparable among HSCR mutant alleles remains to be seen. 
Although we are the first to characterize gastric emptying and small intestine transit defects in a 
HSCR mouse model, previous groups have shown colonic motility defects in HSCR models such 
as those with Ednrb mutations.  Ro et al., demonstrated that both heterozygous and homozygous 
mice with the Ednrb piebald lethal mutation exhibit aganglionosis and have severely reduced or 
completely absent colonic migrating motor complexes (CMMCs) (55). Similarly, Roberts and 
colleagues demonstrated abnormal or absent CMMCs in Gdnf+/- and Edn3-/- HSCR model mice 
respectively (54). Similarities and disparities in outcomes between HSCR mutant models should 
help elucidate exactly when and where HSCR genes act within HSCR gene pathways. 
Mice with deficits in ENS patterning or NCP lineage segregation but no overt 
aganglionosis can exhibit altered GI motility (10, 20). And, as previously stated, HSCR models 
have not previously been evaluated for motility deficits within ganglionated regions of the small 
intestine. While many studies limit their analysis to male mice, we chose to examine both males 
and females given the difference in incidence of HSCR and other neurodevelopmental disorders 
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between males and females.  In the Sox10Dom/+ model, we documented slower small intestine 
transit rates in 4-week old males and females.  Because Sox10Dom/+ mice show increases in 
excitatory motor neurons (Calretinin+) in the small intestine, but no changes in inhibitory motor 
neurons (nNOS+), we hypothesize that imbalances in motor neuron cell types cause changes in 
peristalsis coordination and/or neuron signaling. Because other neuronal subtypes also affect 
motility, we cannot at this time directly attribute these changes in GI motility to our findings in 
Calretinin+ and nNOS+ neurons.  However, given that Calretinin+ and nNOS+ neurons comprise 
the majority of motor neurons in the myenteric plexus, our hypothesis provides a plausible and 
attractive explanation.  Future analyses are required to determine the exact electrophysiological 
changes within the ENS in Sox10Dom/+ mice and ascertain if other cell types that contribute to 
motor activity (such as serotonergic neurons or Interstitial Cells of Cajal) are perturbed.  In 
contrast to our results in young animals, mature Sox10Dom/+ and Sox10+/+ mice showed 
comparable small intestine transit rates.  It could be that the Sox10Dom/+ intestine adapts or 
compensates for deficits as the ENS matures or that we have selected for more mildly affected 
mice at this age since many severely affected mice succumb to HSCR near weaning.  However, 
we also observed increased gastric emptying in older Sox10Dom/+ males that we did not see in 
females, a result that was unexpected. Increased gastric emptying in HSCR mouse models has 
not previously been reported and the underlying physiological basis for this effect in males is not 
clear.  For many neurodevelopmental diseases, females are postulated to be protected or 
differentially affected due to circulating sex hormones while males are more susceptible (37, 38).  
This tendency for males to be more severely affected by neurodevelopmental disorders may 
explain why males are afflicted more often with HSCR than females (3:1) and could explain why 
6-week old Sox10Dom/+ males have increased gastric emptying rates, but not females.  
Furthermore, increased gastric emptying rates may confound small intestine transit rates because 
gastric contents are more rapidly entering the small intestine.  Therefore, it is possible that our 
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Sox10Dom/+ males still have a decreased small intestine transit rate compared to their wild type 
counterparts, but this phenotype is being masked by increased gastric emptying.  
 Despite the fact that infection and inflammatory processes are known to affect GI transit 
speed, we saw no difference in colonic inflammation between Sox10Dom/+ and Sox10+/+ adult mice.  
This finding suggests that differences in gastric emptying and small intestine transit are at least 
partially driven by neural mechanisms.  It remains to be seen whether Sox10Dom/+ mice are more 
or less susceptible to inflammation when challenged by surgery, infection, or chemical treatment.  
Some HSCR patients and mouse models have susceptibility to enterocolitis, but the mechanisms 
driving this susceptibility are still not well understood (8, 21, 39). Future studies should elucidate 
the etiology of enterocolitis susceptibility and the role the ENS may play in these inflammatory 
processes. 
Collectively, this study demonstrates for the first time skewed enteric NC derivative 
proportions in the small intestine and altered GI motility in a HSCR mouse model.  These findings 
demonstrate a role for Sox10 in NC lineage specification in vivo in the ENS.  Moreover, our results 
suggest a novel role for Sox10 in neuronal subtype choice and indicate that perturbations in Sox10 
can affect GI transit in ganglionated regions of the intestine. Distinct regions of the Sox10Dom/+  
intestine were found to have different abnormalities and GI transit assays revealed sex and age 
dependent effects, suggesting that timing and environment play a key role in not only NC lineage 
segregation, but ultimately functional outcomes.   
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CHAPTER III 
 
GASTROINTESTINAL TRANSIT IN EDNRBTM1YWA/+ AND RETTM1COS/+ ADULT MICE 
 
Introduction 
 Hirschsprung disease (HSCR) is a complex disease with several factors influencing 
disease penetrance and phenotype expressivity (1, 2). HSCR can segregate through multiple 
generations in families, but most of the cases appear spontaneously (2).  To date, the occurrence 
of HSCR has been attributed to mutations in eleven different genes (1) (Table 3.1).  However, 
several genetic modifiers exist and presence or absence of a known, characterized mutation does 
not always guarantee HSCR disease manifestation. 
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 RET is arguably one of the most well studied HSCR genes.  The RET (REarranged during 
Transfection) proto-oncogene encodes a receptor tyrosine kinase found on the surface of NCC 
and other cell types (3-6). The first mapping studies within a HSCR family identified an area of 
Chromosome 10 as a susceptibility locus (7, 8) and later studies identified a mutation in RET in 
this region that accounted for HSCR disease (9, 10).  Subsequent studies have gone on to identify 
over 100 mutations in the RET gene in HSCR cases and a well described SNP in an enhancer 
region of RET appears to increase risk of HSCR in at least some ethnicities (reviewed in (1))(11).  
Not surprisingly, in HSCR cases where patients are genetically screened and mutations are 
identifed, RET mutations account for roughly 50% of familial cases and 15-20% of sporadic cases 
(1, 11). Ret has also been studied extensively in HSCR mouse models.  Several HSCR mouse 
models with targeted Ret mutations exist (3, 12, 13) and studies in these mice have aided in 
understanding the role of the Ret signaling pathway in ENS development and other organ 
systems.   
 Another well studied HSCR gene is EDNRB.  The EDNRB gene encodes a G-coupled 
protein receptor and a mutation in EDNRB was linked to HSCR in an Old Order Mennonite 
community (14).  The discovery of EDNRB as a HSCR gene was aided by the spontaneously 
occurring piebald-lethal mouse line where mice homozygous for the piebald-lethal locus 
succumbed early in life to megacolon due to aganglionosis.  Mapping studies in this mouse model 
identified a syntenic region identical to the locus mapped in the Old Order Mennonite community, 
helping researchers hone in on EDNRB as a candidate HSCR gene (15). Subsequent studies in 
mouse models with Ednrb deficiency have further solidified this gene as a large player in HSCR 
occurrence and HSCR associated sequelae (15-21).  
Despite enormous efforts to understand HSCR through HSCR cases and mouse models, 
much remains to be determined in regard to gene function and disease occurrence.   In humans, 
it appears RET haploinsufficiency drives the HSCR phenotype.  But not all patients with a RET 
mutation will go on to have HSCR.  Furthermore, supposed activating mutations in RET can lead 
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to MEN2A (Multiple Endocrine Neoplasia Type 2A) and HSCR in the same patients (22-24).  
EDNRB mutations also show incomplete penetrance and many patients with EDNRB mutations 
also show deficits in pigmentation and sensorineural deafness (1, 2).  This triad of HSCR disease, 
lack of pigmentation, and sensorineural deafness is better known as Waardenburg-Shah 
Syndrome Type 4 (WS4).   
Additionally, recent genetic studies have focused on defining what genetic modifiers and 
environmental influences may ultimately lead to HSCR occurrence and affect severity of the 
disease (18, 25-32). For the most part, these studies operate within a strict definition of HSCR 
disease.  Patients either have HSCR disease or no disease—aganglionosis occurs with variable 
lengths of the intestine affected or the ENS is assumed totally unaffected.   However, such thinking 
does not lend itself to the complex nature of HSCR and the multiple genes involved.  Subtle 
disease or phenotypes could exist in the ENS of patients with deficiencies in HSCR genes, but 
with no aganglionosis.  To add credence to this possibility, one case study exists where a patient 
with MEN2B and chronic constipation had no aganglionosis, but harbored a RET mutation and 
deficiencies of Substance P within ENS neuronal axons (33).  Furthermore, constipation has been 
shown to cluster within families (34, 35), suggesting a heritable factor.  However, the etiology of 
familial constipation has yet to be determined. 
 Given the complex nature of HSCR disease and HSCR gene pathways as well as the 
occurrence of heritable constipation with unknown etiology, I hypothesized that ENS driven 
motility deficits could exist in the presence of altered HSCR gene expression where no detectable 
aganglionosis was present.  To test this hypothesis, I tested GI transit in Rettm1Cos/+ and 
Ednrbtm1Ywa/+ mice.  Both of these mouse models have a deficiency in a HSCR gene, but do not 
exhibit aganglionosis.  I found that neither male nor female Ednrbtm1Ywa/+ and Rettm1Cos/+ adults had 
any gastric emptying or small intestine motility deficits by my test methods.  However, Rettm1Cos/+ 
males had significantly slower total intestinal transit time, suggesting slow transit constipation in 
these mice.   
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Methods 
Methods for GI motility tests are presented here in brief.  However, in depth methods in regard to 
these experiments can be found in Chapter 7. 
 
Animals 
Ednrbtm1Ywa/+ and Rettm1Cos/+ mice were propagated on a 129S6/SvEvTac background.  
Ednrbtm1Ywa/+ were generated by Hosoda et al (15) by substituting exon 3 of the EdnrbB gene with 
a Neo cassette, effectively ablating gene function.  Rettm1Cos/+ were generated by Schuchardt and 
colleagues (3). A 0.8 kb portion of the Ret gene was replaced by a Neo cassette; the deleted 
portion of the gene includes sequence for a lysine residue required for Ret kinase activity.  I 
genotyped both mouse models by assessing for the presence or absence of the Neo cassette via 
PCR.  Primers to detect part of the Neo cassette (366 bp) are as follows: Forward = 
CCTGCCGAGAAAGTATCCATC; Reverse = TTCAGCAATATCACGGGTAGC.  PCR to detect 
the Rapsn gene (592 bp) was also included in genotyping as a positive control: Forward =   
AGGACTGGGTGGCTTCCAACTCCCAGACAC and Reverse = 
AGCTTCTCATTGGTGCGCGCCAGGTTCAGG .    Thermocycler conditions were as follows: 
94°C for 5 min, [(94°C for 30 seconds, 55°C or 58°C for 30 sec, ramp to 72°C at 0.5°C per second, 
72°C for 30 seconds, ramp to 94°C at 0.5°C per second) x 25-35 times], 72°C for 10 minutes, 4°C 
indefinitely. The Institutional Animal Care and Use Committee at Vanderbilt University approved 
all experimental protocols.    
 
Small intestine transit 
This method was described previously in Chapter 2.  A more detailed explanation of this 
test can be found within Chapter 7. 
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Total intestinal transit 
Briefly, Adult mice were gavaged with a meal of 6% carmine in a 0.5% 
methylcellulose/0.09% NaCl solution.  Start time of transit was recorded as time of gavage.  Mice 
were given free access to water and food during the course of the experiment.  Mice were 
monitored for presence of carmine (bright red) in fecal pellets.  Once a red fecal pellet was noted, 
a stop time was recorded.  The difference between start and stop time was recorded as the “total 
transit time” for each mouse.  Detailed methods in regard to this assay can be found in Chapter 
7. 
 
Statistics 
I tested for differences in gastric emptying rates, small intestine transit rates, and total 
intestine transit times using a Student’s t-test assuming unequal variance (Welch’s t-test). JMP 
(v10 or v11) software was used for statistical testing.   
 
 
Results 
To determine if alterations in HSCR genes could cause alterations in GI motility, but not 
overt aganglionosis, I evaluated gastric emptying, small intestine transit rates, and total intestinal 
transit times in Ednrbtm1Ywa/+ and Rettm1Cos/+ adult mice.  Because the aganglionosis that defines 
HSCR disease shows a sex specific prevalence (4:1 males to female), I tested both males and 
females to determine if any GI motility alterations caused by HSCR gene alterations showed 
similar sex ratios. 
 
Gastrointestinal transit times are comparable in Ednrbtm1Ywa/+ and Ednrb+/+ mice.  
I first evaluated gastric emptying and small intestine motility rates in adult Ednrbtm1Ywa/+ 
and Ednrb+/+ adult male littermates.  Male Ednrbtm1Ywa/+ mice had comparable gastric emptying 
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rates (P=0.41) and small intestine motility rates (P=0.44) to Ednrb+/+ littermates (Table 3.2).  
(Variance in small intestine motility scores tended to be large for both genotypes, hence the larger 
sample number tested for this group compared to females.) In regard to total intestinal transit 
times, which additionally accounts for colonic transit, I observed nearly equivalent mean lengths 
of time in Ednrbtm1Ywa/+ and Ednrb+/+ male mice (P=0.92) (Figure 3.1A; Table 3.2).   
 
Next, I evaluated gastric emptying and small intestine motility rates in adult Ednrbtm1Ywa/+ 
and Ednrb+/+ females.  Similar to my evaluation in males, I observed no significant difference 
between gastric emptying rates (P=0.76) and small intestine motility scores (P=0.38) between 
Ednrbtm1Ywa/+ and Ednrb+/+ females (Table 3.3). Total intestinal transit time was also comparable 
(P=0.67) (Figure 3.1B).  Interestingly, I did note three Ednrbtm1Ywa/+ mice (n=2 female; n=1 male) 
that had total gut transit times over 400 minutes which is well above all other recorded 
Ednrbtm1Ywa/+ and Ednrb+/+ mice (Figure 3.1A & B).  These mice represented roughly 18% (3 of 17) 
of all Ednrbtm1Ywa/+ mice tested. 
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Total intestinal transit time is slower in Rettm1Cos/+ males but not Rettm1Cos/+ females. 
Next, I evaluated gastric emptying and small intestine motility rates in Rettm1Cos/+ and Ret+/+ 
adult mice.  I observed Rettm1Cos/+ males had extremely similar gastric emptying rates (P=0.94) 
and small intestine motility rates (P=0.98) when compared to their Ret+/+ littermates (Table 3.4).  
Interestingly, comparisons of total intestinal transit times revealed a large increase in total 
intestinal transit times in Rettm1Cos/+ males (P=0.0062) (Figure 3.2A; Table 3.4).   
Similar to males, I observed comparable gastric emptying rates (P=0.40) and small 
intestine motility rates (P=0.67) between female Rettm1Cos/+ and Ret+/+ adult mice (Table 3.5). In 
stark contrast to findings in males, total intestinal transit time between the two female genotypes 
did not differ significantly (P=0.57) (Figure 3.2B; Table 3.5).  
 
Discussion 
 I tested gastric emptying, small intestine transit, and total intestinal transit in male and 
female Ednrbtm1Ywa/+ and Rettm1Cos/+ mice.  Both of these mouse models have targeted genetic 
ablation of one copy of a known HSCR gene.  However, they have no overt aganglionosis, making 
them ideal for studying how alterations in Ednrb or Ret may affect ENS development and function 
outside of gross neural crest migration and proliferation defects. Interestingly, I found no statistical  
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differences in GI motility parameters in male or female Ednrbtm1Ywa/+ compared to wild type 
littermates although increased total intestinal transit was observed in a few Ednrbtm1Ywa/+ mice.  GI 
motility in Rettm1Cos/+ mice also appeared largely unaffected, except for significant increases in 
total intestinal transit times in Rettm1Cos/+ males, implicating a sex specific GI transit defect. 
I was somewhat surprised that I observed no significant differences between Ednrbtm1Ywa/+ 
and Ednrb+/+ adult littermates in any of the physiological factors measured (gastric emptying rates, 
small intestine motility rates, total intestinal transit times).  It could be that no differences exist in 
GI function between Ednrbtm1Ywa/+ and Ednrb+/+ of either sex.  The Ednrbtm1Ywa gene contains a Neo 
cassette insertion, replacing exon 3 (15). This deletion of exon 3 presumably results in 
haploinsufficiency of the Ednrb gene.  It might be that increased transcription, translation, reduced 
breakdown, or other cellular mechanisms involving the wild type Ednrb gene are able to 
compensate for lack of Edrnb expression from the Ednrb-tm1Ywa locus.  Alternatively, expression 
from one Ednrb gene locus might also be sufficient for normal development and function of the 
enteric nervous system.  Genetic studies in humans support this hypothesis.  In humans, EDNRB 
mutations are estimated to be the primary causative gene in only 6-8% of HSCR cases (2).  And 
for most human HSCR cases that involve EDNRB, the disease appears only in an autosomal 
recessive fashion, with two mutations in the EDNRB needed for HSCR manifestation (1, 2).  
Furthermore, even in the earliest gene mapping study that led to EDNRB being discovered as a 
HSCR gene, not all family members with both copies of the mutated form of EDNRB had HSCR, 
demonstrating incomplete penetrance of the disease (14). Thus, it appears that ENS development 
is not as sensitive to perturbations in EDNRB expression and more sensitive to perturbations in 
other genes, such as SOX10 and RET.  This explanation seems plausible given our knowledge 
of SOX10 and RET.  SOX10 is temporally upstream of EDNRB and, as a transcription factor, 
would putatively disturb more downstream targets than a mutation in EDNRB.  And, autosomal 
dominant mutations in SOX10 or RET mutations can cause HSCR disease (1, 2). Additionally, 
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although not tested, it is possible that expression of other related genes, such as EDNRA, could 
have compensatory affects when EDNRB expression is reduced.   
Another competing hypothesis is that physiological differences in gastric motility measures 
exist between Ednrbtm1Ywa/+ and Ednrb+/+ but are more subtle and not detectable by my test 
methods, and/or would only be detectable under certain conditions.  It is important to note that I 
did not incorporate additional challenges or stressors within my experimental design.  Had I 
challenged the Ednrbtm1Ywa/+ and Ednrb+/+ mice, such as with a high fat diet, differences in gastric 
motility measures may have been observed.  In humans, many GI deficits do not manifest until 
specific infectious or environmental challenges present.  For example, gastroparesis (slowing of 
gastric emptying) tends to occur with a female prevalence in the context of poorly controlled 
diabetes (36).  Future studies with such stressors or with different test methods will have to be 
conducted to determine if more subtle changes in GI motility exist in Ednrbtm1Ywa/+ mice. 
Although I saw no statistical difference in intestinal transit between Ednrbtm1Ywa/+ and 
Ednrb+/+ mice, three Ednrbtm1Ywa/+ mutants did have substantially higher total intestinal transit time 
than the other mutant and wildtype animals (Figure 3.1A & B).  These animals could represent 
outliers due to variations in testing conditions, but this scenario is unlikely as we did not see any 
wildtype outliers within Ednrb+/+ tested animals nor in Ret+/+ which are on the same strain 
background.  Additionally, these three Ednrbtm1Ywa/+ mice were tested on different days, further 
suggesting against daily variations in test conditions.  As mentioned previously, HSCR disease is 
an oligogenic disorder—one or more mutations can cause predisposition or occurrence of the 
disease and other genetic variants push the predisposition to disease manifestation and/or modify 
the severity of the disease.  Although Ednrbtm1Ywa/+ mice do not suffer from aganglionosis, the 
increase in total intestinal transit time for the three Ednrbtm1Ywa/+, but not other Ednrbtm1Ywa/+ mice, 
could be viewed as incomplete penetrance of slow transit constipation.  This hypothesis is 
supported by studies in Ednrb+/+and Ednrbtm1Ywa/tm1Ywa mice where Hirschsprung associated-
enterocolitis phenotypes appear incompletely penetrant (19, 20).  In brief,   Zhao and colleagues 
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(19) performed corrective colonic resection surgery on Ednrb+/+ (control) and Ednrbtm1Ywa/tm1Ywa 
(short-segment aganglionosis) adult mice.  Following post-surgical recovery, mice were sacrificed 
and small intestine and colon samples were collected and scored histologically for severity and 
depth of inflammation.  Not surprisingly, Ednrbtm1Ywa/tm1Ywa mice were more susceptible to 
enterocolitis post-surgery than Ednrb+/+ wild type littermates.  However, this phenotype showed 
variable expressivity and incomplete penetrance with ~40% of Ednrbtm1Ywa/tm1Ywa suffering from 
enterocolitis.  Even in a study where Ednrbtm1Ywa/tm1Ywa mice did not have corrective surgery (and 
thus were purportedly more susceptible to severe infection due to presence of aganglionosis), 
only 65% succumbed to gut-derived bacteremia (20). Importantly, in my study, I tested 
Ednrbtm1Ywa/+ mice, not Ednrbtm1Ywa/tm1Ywa, as the goal was to determine if these mice may have GI 
deficits within the context of a fully ganglionated GI tract.  Roughly 18% of Ednrbtm1Ywa/+ mice 
tested in my total intestine gut transit study had severely slowed total intestinal transit.  Thus, the 
hypothesis that incomplete penetrance and genetic modifiers influencing total intestinal transit 
time in Ednrbtm1Ywa/+ mice is compatible with my results and with previous studies. 
 Similar to my findings in Ednrbtm1Ywa/+ mutants, Rettm1Cos/+ male and female mice did not 
differ from their wild type Ret+/+ littermates in regard to gastric emptying and small intestine transit 
scores.  However, Rettm1Cos/+ males showed significantly slower total intestinal transit time and this 
phenotype was not detected in Rettm1Cos/+ females.  This finding is not surprising given the one in 
four occurrence of HSCR disease in males (1, 2), the tendency for males to be affected more 
often by neurodevelopmental disorders in general (37, 38), and sex differences in motility 
detected in Sox10Dom/+ mutants (see Chapter 2).  However, in adult male Sox10Dom/+ mutants, I 
observed increased gastric emptying, a phenotype not observed in Rettm1Cos/+ males. Echoed from 
previous discussion above, deficits in gastric emptying or small intestine motility in these mice 
might not manifest unless mice are stressed or challenged.  Additionally, the gut has many modes 
of communication and feedback mechanisms, with activity or obstruction in the distal bowel 
affecting activity and motility in proximal regions (39).  This could explain the differences I observe 
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in Ret and Sox10 mutants as the colons of these mice are fully ganglionic or aganglionic 
(obstructive) respectively. 
The long total intestinal transit times in Rettm1Cos/+ males appears to be mediated primarily 
by slowed colonic motility since gastric emptying rates and small intestine motility rates are 
comparable between Rettm1Cos/+ and Ret+/+ male mice.  This hypothesis is corroborated by the 
consistency of Rettm1Cos/+ feces I saw during my studies.  In general, Rettm1Cos/+ male feces 
appeared dryer—or had less water content—upon collection compared to Ret+/+ male mice.  Since 
the colon is largely responsible for water reabsorption, longer transit times of feces in the colon 
could lead to dryer feces (i.e. constipation). Previous studies have successfully measured water 
content of feces in mice (40), and future studies could be directed at measuring water content in 
Rettm1Cos/+ feces to validate if slow transit constipation is occurring in. 
Although I saw no statistical differences in Ednrbtm1Ywa/+ motility measures, increased total 
intestine transit time in a few Ednrbtm1Ywa/+ mutants as well as significantly increased total transit 
in Rettm1Cos/+ male mice suggests that perturbations in  Ret and Ednrb  expression can affect ENS 
development and function even when aganglionosis is not present.  These findings could explain 
clustering of constipation in families where HSCR is not present.   Interestingly, at least in respect 
to alterations in Ret, only male mice showed signs of slow transit constipation. This finding mirrors 
sex-specific findings in Sox10Dom/+ mice (Chapter 2) and is expected in light of the higher 
prevalence of HSCR disease in males. Neurodevelopmental disorders are known to show sex 
discrepancies, but the sex-specific factors driving differences in HSCR disease prevalence and 
phenotypes in HSCR mouse models have not been studied.  Future studies to define these factors 
will not only aid in understanding HSCR outcomes, but also understanding other 
neurodevelopmental disorders. 
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CHAPTER IV 
 
DEFICITS IN SOX10DOM/+ PYLORIC SPHINCTER DYNAMICS 
 
Introduction 
The pyloric sphincter acts as a gatekeeper to the small intestine, opening and closing to 
allow stomach contents into the duodenum. Neural, musculature, and hormonal factors control 
pyloric sphincter dynamics (1).  Developmental anomalies, disease, and trauma can affect any of 
these factors, leading to pyloric dysfunction such as that seen in pyloric stenosis, gastroparesis, 
and dumping syndrome. 
Dumping syndrome, characterized by rapid gastric emptying, can manifest as a host of 
symptoms, including abdominal discomfort, nausea, vomiting, diarrhea, rapid heart rate, 
sweating, and dizziness (2).  Dumping syndrome occurs commonly after major gastrointestinal 
surgical procedures, including Nissan duplications in the pediatric population (3) and gastric 
bypass surgeries used in the adult population for weight loss management (2, 4).  Because the 
pylorus and/or innervation are modified or removed in these procedures, it comes as no surprise 
that dumping syndrome occurs.   However, this syndrome can also be a part of other medical 
conditions, such as diabetes, Zollinger-Ellison, and Cyclic Vomiting syndrome (5, 6).  Patients 
may present with dumping syndrome where gastric surgery, related medical conditions, and 
medications have been ruled out as a possible cause.   Such cases suggest congenital defects 
and/or environmental causes.   
  We recently described increased gastric emptying in male mice with the Sox10Dom 
Hirschsprung disease mutation (Chapter 2).  Dumping syndrome is not commonly reported as 
occurring with HSCR. A literature review revealed only a handful of HSCR patients presenting 
with dumping syndrome (7) and most HSCR actually go on to develop gastroparesis (delayed 
emptying) (reviewed in (8)). Given that SOX10 is initially expressed in all neural crest cell 
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populations and expression persists in several glial populations after development, it could be 
SOX10 signaling has different or wider consequences on peripheral nervous system (PNS) 
function than other HSCR genes.   
Despite numerous studies detailing Sox10 function in the PNS, the exact affect SOX10 
mutations have on pyloric sphincter development and function have not been explored.  We 
previously identified imbalances in neuron subtypes in the duodenum of Sox10Dom/+ Hirschsprung 
mice which could be contributing to small intestinal transit slowing (Chapter 2).  Although we did 
not evaluate neuron subtypes within the pyloric sphincter muscle walls in our previous study, we 
hypothesized intrinsic neurally-mediated deficits could be driving changes in pyloric sphincter 
function given our findings in the duodenum.  
To test our hypothesis, we measured and compared pyloric sphincter opening pressures 
in Sox10Dom/+ and Sox10+/+ male mice.  Sox10Dom/+ pyloric sphincters opened at lower pressures 
than Sox10+/+ pyloric sphincters, explaining the increased gastric emptying found previously in 
Sox10Dom/+ mice (Chapter 2).  Importantly, we devised and conducted these tests in an ex vivo 
system in order to eliminate any effects on the pyloric sphincter from extrinsic nerve inputs.  
Additionally, evaluation of pyloric sphincter morphology revealed no gross changes in 
musculature, suggesting the alteration in pyloric sphincter function in Sox10Dom/+ mice is driven 
by intrinsic ENS deficits. 
 
Methods 
Pyloric Sphincter Dynamics 
Sox10Dom/+ and Sox10+/+ mice were maintained on a C57/BL6 background. Adult (6-week 
to 9-week old) mice were sacrificed via isoflurane inhalation followed by cervical dislocation.  The 
entire stomach and proximal portion of the duodenum were removed from the mouse and 
immediately placed in modified, deoxygenated Krebs buffer (95% N2, 5% CO2; 2.5 mM CaCl2, 
11.1 mM dextrose, 4.7 mM KCl, 1.0 mM KH2PO4109 mM NaCl, 34 mM NaHCO3, 0.9 MgSO4). 
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Within the Krebs buffer, extraneous mesentery, pancreas, and other tissue were removed from 
the sample with care not to puncture any part of the gut tube.  The stomach was then cut so that 
only the distal 0.3 to 0.5 remained.  The duodenum was trimmed so the most proximal ~1.5-2 cm 
remained.  Next, under a dissection scope, forceps were used to carefully remove as much 
contents as possible from the stomach and duodenum.  During this step, care was taken in order 
to not disrupt the pyloric sphincter.  (Any efforts to ‘flush’ the gut with liquid to remove contents 
will result in the pyloric sphincter shutting and are highly discouraged!)  However, the dissector 
must not be shy in regard to trying to remove food from the pyloric sphincter area.  Remaining 
gastric contents can clog cannulae and flow during the pyloric sphincter flow experiment, resulting 
in loss of the sample (usually do to bursting or extreme expansion) and demands necessary 
exclusion of that data from the study.  Although we did not fast mice, fasting mice O/N without 
bedding or with bedding they will not eat could aid in keeping the cannulae from clogging. 
After thorough cleaning, the gut sample was transferred to Krebs buffer within a custom 
designed sample bath (Figure 4.1).  The cannulae within our set up were first flushed with Krebs 
buffer to avoid introducing a sudden increase in pressure when the gut is connected to the flow 
system.  Strands from braided nylon sutures were used to secure the stomach and duodenum to 
two canula spanning the distance of the sample bath (Figure 4.1).   Once secured, the sample 
was transported to an inverted microscope platform and connected to a flow system. (9)  Gut 
pieces were given a minimum of 5 minutes to equilibrate within warm Krebs buffer.  We started 
the flow at 5 mm/Hg and increased the pressure by ~5 mm/Hg at a minimum of every 2 minutes.  
Flow, back pressure, and forward pressure were measured throughout the study.  Pyloric 
sphincter opening pressure was recorded as the pressure when flow reached ≥1000 ul/min. n=3 
Sox10+/+ and n=4 Sox10Dom/+.  (Initially, we had n=4 Sox10+/+ mice.  However, one Sox10+/+ mouse 
was excluded from the statistical analysis because it was an outlier.  Importantly, our notes 
indicate over-stretching of tissue from this mouse during our experimental set up, probably 
explaining outcomes inconsistent with other Sox10+/+ mice.) 
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Muscle measurements 
Stomach with intact proximal duodenum were collected from adult mice (6-week – 9-week) 
immediately following euthanasia. The stomach was cut in half and the remaining sample (distal 
stomach and duodenum) were flushed with 1XPBS to remove all gut contents.  Gut samples were 
then placed on their sides in histology cassettes (Fisher, white, Cat. No. 15-182-702A) 
immediately submerged in 10% PFA, and fixed at least overnight at 4°C.  Following fix, tissues 
were delivered to the Vanderbilt Pathology Core for processing, embedding, sectioning, and H&E 
staining.  
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To determine if gastrointestinal musculature near and within the pyloric sphincter differed 
between Sox10Dom/+ and Sox10+/+ mice, we measured the shortest distance within the antral 
opening (Figure 4.3).  To ensure the same area of each animal was sampled for measuring, care 
was taken to only measure sections with visibly continuous lumen through the stomach, pyloric 
sphincter, and duodenum.  
We did consider using the same gut samples for the pyloric sphincter dynamic studies and 
the muscle measurements.  However, given the long hours post-sacrifice and exposure to flow 
pressures, we were concerned about how the pyloric sphincter flow studies could alter the muscle 
tissue prior to fixation.  Thus, we chose to use experimentally naïve tissue for this portion of the 
study. 
 
Statistics 
Average pyloric sphincter pressures were statistically compared and visualized with 
PRISM software.  Muscle measurements were statistically compared using a student’s t-test 
assuming unequal variance (Welch’s t-test) utilizing JMP v11 statistical software.   
 
Results 
Sox10Dom/+ pyloric sphincters open at lower pressures  
 To determine if the Sox10Dom/+ mutation affects pyloric sphincter opening conditions, we 
evaluated pyloric sphincter opening pressures in Sox10Dom/+ and Sox10+/+ adult male mice.  To 
eliminate the effects of gastric hormones (such as CCK) and extrinsic neural signaling (vagal 
inputs), we tested pyloric opening pressures in an ex vivo system.  Briefly, gut tissue samples that 
included the lower portion of the stomach, the pyloric sphincter, and the proximal duodenum were 
suspended between cannulae in a tissue medium bath (Figure 4.1).   Modified Krebs buffer was 
allowed to flow into and through the gut samples—entering from the stomach and exiting through 
the duodenum.  Flow through the sample was measured as we increased flow pressure in 
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~5mmHg increments.  Under normal physiological fasting conditions, the pyloric sphincter is 
tightly closed.  Many factors influence pyloric sphincter opening.  However, in general, as 
increasing amounts of food and/or liquid enters the stomach, pressure within the stomach 
increases.  Very high pressures eventually trigger the pyloric sphincter to open very wide, 
permitting gastric contents to flow into and through the small intestine.  To this end, in our assay, 
low levels of flow indicated a closed pyloric sphincter.  Abrupt, large increases in flow (>1000 
ul/min) indicated pyloric sphincter opening (Figure 4.2).   
 Using this system, we recorded and compared pyloric sphincter opening pressures in 
Sox10Dom/+ and Sox10+/+ adult male mice.  Sox10Dom/+ pyloric sphincters consistently opened at 
lower pressures (~10 mmHg) than Sox10+/+ pyloric sphincters (~15 mmHg) (Figure 4.2).  When 
compared statistically, the difference in average pressure opening between the two groups was 
significant (*P<0.05; Figure 4.2). 
 
Sox10Dom/+ and Sox10+/+ pyloric sphincter morphology is equivalent 
 Although we aimed to eliminate extrinsic neural inputs and gastric signaling in our pyloric 
sphincter tests, the possibility remained that differences in pyloric sphincter morphology and 
musculature could be driving the increased gastric emptying and aberrant sphincter opening in 
our Sox10Dom/+ males.  Alterations in innervation to smooth muscle can affect musculature 
morphology (10, 11).  In our own studies, we noticed variations in muscle thickness and texture 
in aganglionic regions of Sox10Dom/+ colons.  And in HSCR patients, aganglionic regions can 
contain thickened muscle (12).  We have not noticed differences in muscle thickness in 
ganglionated regions of Sox10Dom/+ intestine, but to rule out the possibility of aberrant muscle 
development in the pyloric sphincter region of Sox10Dom/+ we collected and evaluated pyloric 
sphincter morphology from Sox10Dom/+ and Sox10+/+ adult male mice.  We observed no gross 
morphological differences between the two genotypes (data not shown).  Additionally,  
  
98 
 
  
99 
 
measurements of antral opening length revealed no differences between Sox10Dom/+ and Sox10+/+ 
mice (P=0.86) (Figure 4.3).  
 
Discussion 
A previous study in our lab identified increased gastric emptying in adult Sox10Dom/+ male 
mice compared to wildtype Sox10+/+ mice (Chapter 2).  Given neuronal subtype imbalances also 
identified in the small intestine of Sox10Dom/+ mice (Chapter 2), we hypothesized that intrinsic, 
neurally mediated processes could lead to premature pyloric sphincter opening in Sox10Dom/+ male 
mice.  To test this hypothesis, we developed a novel ex vivo technique for applying pressure and 
measuring flow through the pyloric sphincter in isolated gut tissue samples (Figure 4.1).  Our 
findings indicate that the Sox10Dom/+ pyloric sphincter opens at lower pressures when compared 
to Sox10+/+ mice.  This premature opening appears to be neurally mediated as pyloric morphology 
and antral opening measurements are comparable between Sox10Dom/+ and Sox10+/+ male mice. 
 Our findings in the pyloric sphincter for Sox10Dom/+ male mice indicate that pyloric sphincter 
opening is induced at lower pressures than in wildtype mice; however, we do not know if this 
phenomenon occurs in HSCR patients.  If affecting HSCR patients, this premature opening of the 
pyloric sphincter could feasibly present as dumping syndrome.  A few HSCR cases of dumping 
syndrome have been reported (7), but this raises the question as to why this phenomenon would 
occur only in male Sox10Dom/+ mice (and not females) and only some patients.  Importantly, 
neurodevelopmental disorders tend to affect males more severely than females and estrogen has 
been suggested to have a neuroprotective effect (reviewed in (13)).  This sex-specific driving of 
phenotypes is expounded upon in detail in Chapters 2, 3 and 8 and could easily explain our 
findings in regard to pyloric sphincter function in Sox10Dom/+  male mice. This sex-specific finding 
though could only partially explain the lack of HSCR patient cases with dumping syndrome in the 
literature.  It is plausible that more HSCR patients have dumping syndrome and the lack of 
reporting is due to confusion of dumping syndrome symptoms, such as abdominal cramps and  
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diarrhea, with other HSCR related phenomenon.  Additionally, it could be that only specific 
mutations along with other genetic modifiers and/or environmental influences lead to altered 
pyloric sphincter dynamics.  This theory is compatible with what is known about Sox10 and other 
HSCR genes. Because Sox10 is a transcription factor and appears temporally before other HSCR 
related genes, it is possible that only Sox10 mutations have the ability to give rise to more severe 
GI phenotypes such as pyloric sphincter dysfunction.  Again in line with this hypothesis, it has 
been shown that some ENP populations are independent of specific HSCR genes or gene 
elements, such as Ret (14, 15) and Ednrb (16).  For example, in Ret-/- mice, a Ret independent 
population of NCC is still able to colonize the stomach (14, 15).  In mice with effectively null Sox10, 
NCC fail to reach the foregut at all, undergoing apoptosis before and during their migration from 
the neural tube (17, 18). Together, these findings suggest the possibility of Sox10 mutations more 
severely affecting other aspects of GI function compared to other HSCR genes; however, future 
testing of pyloric sphincter function in other HSCR mouse models and close monitoring of HSCR 
patients should clarify these possible disparities. 
Importantly, the premature pyloric sphincter opening in Sox10Dom/+ male mice is most likely 
mediated  intrinsically by the ENS given our ability to isolate gut tissue from extrinsic innervation 
and hormonal effects and also observed comparable pyloric sphincter morphology.  As a caveat, 
pyloric sphincter antral opening measurements were extremely variable, most likely due to 
variability in slicing of tissues and cross sections available to measure.  To strengthen this study, 
more pyloric sphincter samples from Sox10Dom/+ and Sox10+/+ male mice should be collected, 
processed, and evaluated.  Additional parameters that could be measured and compared are 
thickness of duodenal muscle wall and gastric muscle wall.  Also, H&E provides a gross overview 
of muscle morphology and permits some gross measurements, but more in depth evaluation of 
muscle fibers and structure, such as through IHC with α-actin, tubulin, or myosin-heavy chain  
antibodies and confocal imaging, could more strongly rule in or rule out any muscle abnormalities.  
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 Overall, we have identified a neurally-driven pyloric sphincter defect in the Sox10Dom/+ 
mouse model of HSCR; however, the exact neural mechanisms driving this phenotype are still 
unknown.  Alterations in Calretinin neuron proportions in the duodenum of these mice initially led 
us to pursuit this study (Chapter 2) and similar analysis of neuronal subtypes and ICC cells in 
pyloric sphincter tissue as well as gastric tissue could aid in identifying neuronal populations 
contributing to the pyloric sphincter phenotype.  Furthermore, our novel experimental set up could 
be utilized to help further define the neural networks affected—pharmacological reagents aimed 
at targeting specific neuronal groups could be introduced into the system and pyloric sphincter 
opening and flow could be measured and compared under several test conditions.  Finally, 
although preliminary, our results indicate that some HSCR patients could suffer from the effects 
of rapid gastric emptying.  Clinicians should bear such findings in mind when evaluating HSCR 
patients with GI distress post-surgery. 
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CHAPTER V 
 
CHARACTERIZATION AND OUTCOMES OF A HSCR PATIENT COHORT 
 
Introduction 
 Scientists first described Hirschsprung disease (HSCR) hundreds of years ago, but only 
within the last century was the cause of congenital megacolon—absence of ganglia in the distal 
intestine—recognized (1).  Once an almost always fatal disorder, the discovery of HSCR’s 
etiology promptly led to the development of live saving pull-through surgeries in the 1940’s 
through the 1960’s (2-4).  The vast majority of these surgeries entail removal of the aganglionic 
segment of the intestine followed by reanastomosis of ganglionated intestine to the anus.   
 Since the advent of pull-through surgeries, the survival of HSCR patients has uncovered 
many additional details about the disease.  Clustering of the disease in multiple families and 
communities showed heritability of the disease, led to the discovery of HSCR gene mutations, 
and demonstrated that the disease was oligogenic and incompletely penetrant.  The survival of 
HSCR patients also revealed a more insidious side of the disease.  Physicians initially viewed the 
removal of the aganglionic segment from HSCR patients as a curative procedure; however, 
subsequent follow up of HSCR patients revealed adverse outcomes post-surgery, such as fecal 
incontinence, chronic constipation or Hirschsprung-associated enterocolitis (HAEC).  Studies 
report chronic constipation in 7-16% of children (5, 6) and 5-30% of adults with HSCR (7-9).  And 
HAEC, in which symptoms can include fever, severe diarrhea, and rectal bleeding, afflicts 
anywhere between 2-28% of patients (9-11).  Not only do such outcomes burden caregivers and 
society in regard to healthcare resources, these outcomes can place emotional duress onto the 
patient and their caregivers (5, 12).  
Despite the now common knowledge of poor outcomes and suboptimal quality of life 
suffered by many HSCR patients post-surgery, physicians and researchers only partially 
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understand their etiology.  Recent studies in HSCR mouse models, including my study detailed 
in Chapter 2, have shown that the intact ENS above the area of aganglionosis is abnormal in 
these mice (13-16).  Specifically, the balance of ENS components, or correct proportions of glia 
and neuronal subtypes, is skewed (13)(Chapter 2).  If similar processes occur in HSCR patients, 
an abnormal intact ENS could partially explain changes in bowel motility as well as changes in 
neuromodulated inflammation.  Studies in our lab are currently being conducted to evaluate ENS 
neuronal subtype proportions in HSCR patients and compare our findings to patient outcomes. 
These studies are important; however, they require extensive amounts of time, expensive 
reagents, and new technique development. And, even if the etiology of these outcomes becomes 
clearly defined, years may elapse before researchers develop and test the appropriate tissue 
engineering technologies or pharmaceutical therapies to target specific ENS defects.  Also 
important, not all patients go on to develop HSCR related sequelae and some improve or worsen 
over time (9).  Such findings suggest that other genetic and environmental factors could influence 
patient outcomes.  Identifying such factors early in the course of the disease could help predict 
susceptibility of HSCR patients to such outcomes.  This ability to detect patients at higher risk of 
developing HAEC or motility defects could aid caregivers and health care professionals by 
providing a guide for prophylactic treatment measures or treatment guides when unfavorable 
outcomes do occur.   
 To this end, we hypothesized that clinical variables collected from HSCR patient records 
could potentially inform risk for unwanted outcomes post-surgery.  Some of these factors include 
sex, age at diagnosis, age of surgical resection, presence of other congenital anomalies, length 
of the aganglionic segment, family history, and pathology findings.  To test this hypothesis, I 
defined and collected clinical data on a HSCR patient population at Monroe Carell Jr. Children’s 
Hospital at Vanderbilt Medical Center.  I used this data to characterize the pediatric HSCR patient 
population at Vanderbilt between January 2004-2012 and will eventually use this data to test if 
specific clinical variables correlate with HSCR patient outcomes. 
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Methods 
Search Terms for Capturing HSCR Patient Population 
I initially chose the following search terms—pull-through, aganglionosis and 
Hirschsprung—within the electronic pathology record system at the Monroe Carell Jr. Children’s 
Hospital at Vanderbilt Medical Center to locate existing HSCR pathology specimens.  I limited the 
search between January 2004 and January 2012 (which encompasses the oldest electronic 
medical records that would also potentially have “on the shelf” corresponding histology/pathology 
specimens to analyze.) “Pull-through” was chosen as a search term because the vast majority of 
HSCR pediatric patients will undergo pull-through surgery to have the aganglionic portion of their 
bowel removed and/or ganglionated bowel attached to the anus. Pull-through surgeries are 
indicated in only a few other disorders which are rare, such as imperforate anus.  In the case of 
HSCR disease, pathologists collect interoperative biopsies during pull-through surgery to 
determine surgical boundaries (location of ganglionated versus aganglionated bowel.)  
Additionally, the surgically resected tissue undergoes full thickness biopsies post-surgery to 
validate surgical boundaries.  Thus, most of the records captured by the search term “pull-
through” were for HSCR patients with pathology specimens available for evaluation.  I chose 
“aganglionosis” as a search term as aganglionosis of the bowel defines HSCR.  However, I could 
not exclusively use the term aganglionosis as some pathologists use synonymous wording—such 
as “no ganglion cells present” or “absence of ganglia”—in their diagnosis of HSCR.  I initially 
chose “Hirschsprung” as a search term as this term would be the most inclusive search term for 
capturing HSCR cases.  However, while very sensitive to capturing HSCR cases, this search term 
was not specific.  In general, pediatric patients with any GI motility disorders (obstruction, 
meconium plug, inflammation, etc.) will have a biopsy to “rule out Hirschsprung’s.”  Thus, the term 
Hirschsprung appears in all pathology records with Hirschsprung as part of the differential 
diagnosis.  Additionally, most of these biopsies taken to rule in or rule out HSCR were not full 
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thickness (through all layers of the intestine), and I would not be able to utilize them in our study.  
Therefore, I dropped “Hirschprung” as a search term and I captured the initial patient population 
with the two search terms “pull-through” and “aganglionosis.”  This preliminary search led to n=90 
potential HSCR cases with n=40 originating from the search term “pull-through” and n=50 
originating from the search term “aganglionosis.”   
 
Filtering for HSCR cases  
All pathology records captured by the search terms “pull-through” and “aganglionosis” 
were manually combed and cases were further defined by meeting one or both of the following 
criteria: 
1) Pathologist, clinical, and/or operator(ion) noted diagnosis of Hirschsprung disease 
2) The terms or phrases “aganglionosis” or “no ganglion cells present” or “absence of ganglion 
cells” or synonymous wording within the pathologist note. 
Of the initial 40 records captured by the term “pull-through,” 30 HSCR cases were validated, 4 
cases were clearly not HSCR and excluded, and 6 cases were suggestive or inconclusive and 
warranted further investigation within the electronic medical record to verify a HSCR diagnosis.  
Of the initial 50 records for the term “aganglionosis,” 49 HSCR cases were validated, no cases 
were excluded, and 1 case was suggestive.  Next, pathology record numbers were compared 
within and between the two search term groups to identify any duplicates or overlap that may 
exist.  One duplicate record was found and 7 cases and 1 suggestive case overlapped between 
the two search term groups.  Accounting for these records, n=68 HSCR cases and n=6 suggestive 
HSCR cases were carried through to the next filtering step.  To determine if the n=6 suggestive 
HSCR cases were actual HSCR cases, corresponding electronic medical records (EMRs) were 
manually combed for these patients.  Review of StarPanel EMRs revealed that n=4 of these cases 
were definitively HSCR cases with aganglionosis.  One patient clearly had colonic 
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hypoganglionosis via biopsy and clinical signs and symptoms of HSCR, but no biopsy revealed 
overt aganglionosis.  Because this case could represent a mild form of HSCR, such as ultra-short 
segment, it was included in this study.  One suggestive case was not a HSCR case, but a pediatric 
patient who underwent pull-through surgery for severe ulcerative colitis.  This case was excluded 
from the study.  Given the confirmation of n=5 HSCR cases, the total number of HSCR cases 
carried to the next filtering step was n=73. 
By comparing pathology record numbers, I could identify and eliminate duplicate or 
overlapping HSCR cases within or between search terms when pathology record numbers were 
identical.  However, many HSCR patients will undergo multiple biopsies, especially if they 
undergo multiple surgeries to diagnose and/or treat HSCR.  A unique pathology record number 
is assigned to the biopsies corresponding with each pathology procedure.  Thus, one HSCR 
patient may have several pathology records.  However, every patient at Vanderbilt Medical Center 
has a unique EMR number.  Therefore, the next filtering step was to pull and compare EMR 
numbers within the identified HSCR cases.  Correction of one incorrectly recorded EMR number 
along with elimination of duplicates brought the HSCR case number to n=70.  This HSCR patient 
population was used for to determine cohort characteristics and demographics found in the results 
section. Figure 5.1 provides an overview of the filtering process used to define the HSCR cohort 
for this study. 
 
Cohort demographics, variables, clinical outcome recordings 
Study data were collected and managed using REDCap electronic data capture tools 
hosted at Vanderbilt University (citation).  REDCap (Research Electronic Data Capture) is a 
secure, web-based application designed to support data capture for research studies, providing 
1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and 
export procedures; 3) automated export procedures for seamless data download to common 
statistical packages; and 4) procedures for importing data from external sources.  A list of clinical  
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variables and outcomes collected from patient records using a custom designed data collection 
instrument in REDCap can be found in Table 5.1.  Table 5.1 is largely a reproduction of the HAEC 
criteria set forth by Pastor et al. (17) with some modifications upon consultation with physicians 
and knowledge of material I knew should or could easily be found in the medical record.   
 
Statistics 
 JMP (v10 & v11) statistical software was used for all statistical analyses.  X2 (goodness 
of fit) test was used to test for independence between different variables. 
 
Study goals 
 The goals and focus of this study have morphed significantly since the beginning of my 
training.  After difficulties with HSCR surgical resection staining and IHC (detailed in Chapter 7), 
we decided to shift the focus of this study. My main goal became running regression analysis with 
the collected independent clinical variables detailed above along with histological findings to 
determine which variables and histological findings could help predict HSCR patient long-term 
outcomes.  Currently, histology slides from HSCR patients are being evaluated by a collaborator 
and this information is not available at this time.  Thus, this chapter mainly serves to discuss the 
characteristics, known clinical variables, and outcomes of my HSCR patient cohort in anticipation 
of using this information for future analyses. 
 
Results 
HSCR cohort characteristics 
 After applying selection criteria, my HSCR cohort consisted of 70 HSCR cases with 
pathology and electronic medical records available.  Of these 70 cases, 49 (70.0%) were males 
and 21 (30.0%) were females.  Diagnosis of HSCR occurred in the vast majority of cases (n=49; 
70.0%) near birth (less than 2 months of age) with 21 patients (30.0%) diagnosed later in life (>2  
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months of age). Typically, patients underwent their first HSCR-related surgery at a young age and 
close to time of diagnosis.  As expected with current standard of care, almost all patients 
underwent a surgical pull-through procedure such as a one-stage pull-through procedure or a 
two-stage procedure with an initial colostomy and subsequent pull down at a later stage (n=64; 
91.4%).  Usually, the aganglionic segment was limited to the colon distal to the splenic flexure 
(n=54; 78.3%) Table 5.2 & Table 5.3 provide summaries and details in regard to these 
characteristics. 
 
Because HSCR disease segregates in families and positive family history could correlate 
with ultimate outcomes, I also recorded family history of HSCR when available.  Within our cohort, 
9 patients (12.9%) had a positive family history of HSCR.  The other 61 patients either had a note 
in their record that stated no family history of HSCR or the family history was unknown (Table 
5.3).  
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HSCR in the context of other congenital disease & disorders 
HSCR disease most often occurs as an isolated trait, but can occur as part of a syndromic 
disease.  Many of the syndromic diseases that can occur with HSCR are rare, such as Congenital 
Central Hypoventilation Disorder (CCHD), while others are more common, such as Down 
Syndrome (DS).  And interestingly, HSCR disease presents often in patients with Down Syndrome 
affecting 2.62% of all DS patients (18).  This phenomenon is in stark contrast to the general 
population, where roughly 1 in 5000, or 0.02%, are affected with HSCR (19).   In HSCR patient 
cohorts from other studies, the co-occurrence of DS and HSCR varies, but averages at 7.32% 
(18). In our study, DS patients accounted for 12.9%, or 9 out of 70 cases (Table 5.3).  Of these 
cases, 8 were male and 1 was female.  Interestingly, in our DS cases with HSCR disease, 7 of 9 
(77.8%) had additional congenital heart defects and 6 of 9 (66.7%) had congenital hypothyroidism 
diagnoses (Table 5.4; Figure 5.2).  These percentages are well above the average rates of 
congenital heart defects (44%)(20) and hypothyroidism (10-16%) (21, 22) reported in DS children, 
although a very recent study argues rates might be higher (23). Given the disparate rates of 
congenital heart defects and congenital hypothyroidism in our patient cohort compared to the DS  
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population as a whole, I tested the association of HSCR disease in DS patients with the 
occurrence of congenital heart defects or congenital hypothyroidism in DS patients.  I found that 
the occurrence of HSCR and congenital heart defects in DS patients was not independent. 
(*P<0.05)  Additionally, the occurrence of HSCR and congenital hypothyroidism was not mutually 
exclusive. (*P<0.0001). 
 Outside of DS, I found 12 (17.1%) HSCR patients diagnosed with other congenital or 
developmental diseases and disorders. Five of these cases involved congenital heart defects and 
two cases involved left renal agenesis.  Two of the cases had identified genetic anomalies, 
possibly explaining the occurrence of HSCR as well.  Table 5.5 summarizes these cases and 
other anomalies, such as Goldenhar syndrome and chordee that may or may not relate to HSCR 
occurrence. 
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HSCR cohort adverse outcomes 
 One difficulty in reporting HSCR patient outcomes revolves around defining an adverse 
event.  During the course of this study, I had difficulties calling chronic constipation and fecal 
soiling based on medical chart information alone.  Although I found numerous reports of 
constipation (brief and chronic) within the records, healthcare providers routinely recommended 
laxatives for use after surgery should any issues with constipation occur.  We should applaud 
awareness of this possible outcome and the preventative measures taken. But, for our purposes, 
the broad use of laxatives would presumably lead to a gross under estimation of the rates of 
patients who ever report to their physicians with constipation.  In this study, constipation or other 
motility issues were clearly noted within the medical note or communications for 28.6% of HSCR 
patients.  However, I did not attempt to test for association or correlations between constipation 
and other clinical variables due to the ambiguity and probable underestimation of motility deficit 
prevalence in my HSCR cohort. 
 Defining Hirschsprung-associated enterocolitis (HAEC) came with issues as well, 
highlighting typical issues encountered in a retrospective study.  One issue is that a definition for 
HAEC has not been agreed upon by the field.  Pastor et al (17) recently devised a classification 
system for defining presence or absence of HAEC occurrence in HSCR patients.  While reviewing 
medical charts, I collected the same variables proposed by Pastor and colleagues to aid in 
defining HAEC occurrence as well as pertinent data already known to influence HAEC risk (24, 
25) (Table 5.1).   I defined HSCR patients matching the criteria put forth by Pastor as HAEC 
cases.  However, the medical charts did not always contain all the variables presented in Pastor’s 
study. Thus, when I relied on these variables alone, I ran into a too conservative, unrealistic 
definition of HAEC which could under power future statistical modeling.  Furthermore, the goal of 
this study is to identify patients who may experience poor outcomes, including patients who may 
not meet the strict criteria proposed by Pastor (17).  Therefore, I adopted a more liberal definition 
of HAEC by also defining HAEC cases as any HSCR patient hospitalized with a diagnosis of 
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gastritis or enterocolitis or Hirschsrpung associated-enterocolitis.  Given this broader definition of 
enterocolitis, I found that 18 HSCR patients (25.7%) within our HSCR cohort met the definition of 
HAEC. An additional 14 patients (20.0%) probably had bouts of HAEC, but the lack of information 
in the record, presence of comorbidities, and young age precluded me from conclusively 
categorizing them as HAEC cases.  Also, several patients were lost to follow up or only followed 
shortly at Vanderbilt, leaving their HAEC status unknown. 
 
Discussion 
 HSCR is defined as absence of ganglia throughout a variable length of distal colon and 
removal of the aganglionic portion of the bowel is the gold standard for HSCR treatment.  Despite 
successful surgeries, many HSCR patients will suffer from short term or chronic fecal 
incontinence, constipation, and episodes of enterocolitis.  To determine what factors might affect 
post-surgical outcome risk, I defined a HSCR patient cohort at the Monroe Carell Jr. Children’s 
Hospital at Vanderbilt Medical Center.  Application of the search terms “pull-through” and 
“aganglionosis” as well as manual combing of electronic pathology and medical records led to 
successful identification of 70 HSCR cases between January 2004 and January 2012.  Clinical 
information and outcomes collected from patient records are poised for future regression analysis 
as we await histology evaluations.  Characterization of our HSCR cohort revealed similarities in 
regard to demographics and clinical features previously characterized in other HSCR cohorts (19, 
26) and also informed us of current medical practices and assumptions that healthcare providers 
may need to take into consideration. The following paragraphs provide discussion centering on 
this information. 
 
HSCR—All in the family? 
Within our HSCR cohort, nine patients (12.9%) reported a positive family history of HSCR.  
I struggled to find published percentages for isolated HSCR cases compared to familial HSCR 
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cases in the literature. This phenomenon can be partially explained by the relatively short time 
period since HSCR pull-through operations have existed. Additionally, from what I observed in 
the medical charts, any reporting of “isolated” occurrences called from medical records could be 
seriously flawed.  Most medical records I observed within the system did not record the pertinent 
negative—no family history of HSCR disease.  This finding could possibly indicate that health 
providers did not ask family members about HSCR family history.  This possibility is certainly 
plausible—given the rare nature of the disease, many medical personnel probably do not realize 
the genetic components or heritability of the disease.  Only within the last century did physicians 
discover the cause of HSCR and implement successful surgical procedures to save lives.  Before 
the option of surgical intervention, the incomplete penetrance of this disease permitted the 
transmission of HSCR mutations through families to go largely unnoticed. However, in the near 
past and present, survival and subsequent passing on of genes by HSCR patients may reveal 
that HSCR is in fact more familial than sporadic. 
This finding has key implications in regard to another finding in my study. In general, the 
clinical workup for the vast majority of HSCR cases in our study did not indicate genetic testing 
or counseling for the patients or their relatives.   Because our study was retrospective in nature 
and patients and family could not be interviewed, the number of cases that involved genetic testing 
or counseling could be underestimated.  However, this scenario is unlikely given that the majority 
of patients remained at Vanderbilt for follow-up care.  Furthermore, in recent history, genetic 
testing for HSCR disease has not been encouraged given that the mutation rarely changes the 
treatment plan (unless within RET which can carry an additional risk for MEN2A syndrome).  
Additional considerations discouraging genetic testing include costs of testing, the presence of 
mutations in several genes and regulatory regions that can drive the disease, and the fact that 
many genetic mutations and/or modifiers driving HSCR disease are probably still unknown. 
Despite current discouragement for genetic testing in HSCR disease, the high occurrence of 
congenital anomalies with HSCR, familial risk, and a better understanding of the genes and 
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pathways contributing to HSCR is apt to eventually force genetic testing into the picture.  If 
anything, HSCR patient families should undergo genetic counseling to understand familial risk 
and the likelihood of other congenital anomalies.  Additionally, any physician treating a HSCR 
patient should keep in mind comorbidities that can occur with HSCR.  Prato and colleagues (26) 
recently proposed a diagnostic work up for HSCR patients that takes into account the high 
occurrence of congenital anomalies that accompany HSCR disease (Figure 5.3).  The co-
occurrence of HSCR with other congenital anomalies is explored in more detail in the following 
paragraphs. 
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HSCR & Down Syndrome (DS) 
Some of the syndromic diseases that can occur with HSCR are quite rare, such as 
Congenital Central Hypoventilation Disorder (CCHD), while others are more common, such as 
Down Syndrome (DS).  Interestingly, HSCR disease occurs more often in patients with Down 
Syndrome (DS), affecting 2.62% of all DS patients (18).  This is in stark contrast to the general 
population, with an average incidence of 1 in 5000, or 0.02% (19).   Several studies have noted 
the co-occurrence of DS and HSCR and although studies differ, DS and HSCR appear together 
in HSCR patient cohorts on average 7.32% of the time (18).  Although the incidence of DS and 
HSCR in my study was slightly higher at 12.32%, this percent falls within published ranges (18).   
The high rate of HSCR in DS patients comes as no surprise given that DS affects many 
NC-derived structures.  For example, all DS patients have the characteristic craniofacial 
abnormalities, suggesting disturbance of cranial neural crest development and contribution to 
facial bones.  Other DS comorbidities that do not occur in all DS patients, such as congenital 
hypothyroidism and congenital heart defects, can be linked to disturbances in NC development 
as the NC contributes extensively to the thyroid as well as the septum and great vessels of the 
heart respectively.  Despite a small sample size, I found that HSCR, congenital heart defects and 
congenital hypothyroidism tend to present together in the context of DS.  From a developmental 
perspective, one could expect the presence of these three congenital anomalies to happen 
together more often than not.  The NCC that contribute to cardiac structures, the thyroid, and the 
ENS all originate from the vagal NC population.  More explicitly, the cardiac NCC, which contribute 
to cardiac structures and the thyroid, is a subset of the vagal NC population.  Thus, large 
perturbations to the vagal NC population could reasonably affect all structures the vagal NC 
contribute to. Although practicing clinicians are probably well versed in the risks of congenital 
heart defects and hypothyroidism in the DS population, our study suggests that clinicians should 
be hypervigilant when checking for congenital heart defects and congenital hypothyroidism when 
treating DS patients presenting with HSCR. 
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HSCR & other congenital disorders 
Corroborating previous studies (19, 26, 27), I found 17.1% of HSCR patients presenting 
with other congenital anomalies—including congenital heart defects, abnormal facies, strabismus 
and left renal agenesis (Table 5.5).  Interestingly, renal agenesis is typically associated with 
mutations in RET on chromosome 10 (28). One of our patients with left renal agenesis displayed 
a partial deletion of chromosome 4, but whether this deletion contributed to the HSCR or the left 
renal agenesis is unknown.  I did not locate any genetic studies in the clinical history of the other 
HSCR patient with left renal agenesis, but a positive family history of HSCR disease could indicate 
a RET mutation driven phenotype.  I found one HSCR patient with pervasive developmental 
disorder, but who had not undergone genetic testing.  Interestingly, two case reports have noted 
a 20p deletion in patients exhibiting HSCR and autism (29, 30).  In regard to other findings in 
Table 5.5, I did not find in the literature any connections of HSCR with chordee and only one 
unavailable case study from Poland suggests a patient with Goldenhar syndrome and HSCR.   
 
Adverse outcomes 
Although outcomes such as HAEC and constipation proved difficult to clearly define in our 
study, my findings for conclusive HAEC cases (25.7%) and constipation/motility issues (28.6%) 
falls within or near formerly published ranges of 5-30% (7-9) and 2-28% (9-11) respectively.  The 
lack of a standard outcome criteria in the field underlies the ambiguity in defining poor outcomes 
(17).  While many studies rely on questionnaires to HSCR patients or their family members to 
determine HSCR outcomes, a limitation of this study is the reliance of medical records to 
determine outcomes.  At the same time, medical record review strengthens this study by 
eliminating selection and response bias.  Regardless, a clear definition for HAEC is required 
before statistical modeling.  One option for including definite and suggestive HAEC in one’s model 
would be to assign differing likelihood or severity values to each case before running analysis.  
Although this type of analysis runs the risk of overfitting, this type of value assignment could help 
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add power to the study by permitting “suggestive” HAEC cases inclusion in the analysis and thus 
increasing sample size. 
Overall, this study presents a method for defining a HSCR patient cohort with 
accompanying medical and pathology records within the Vanderbilt Medical Center that other 
institutions could feasibly apply in their own patient populations.  Comparison of the demographic 
and clinical variables collected from this HSCR cohort to other previously published HSCR cohorts 
yielded comparable findings, suggesting satisfactory search criteria and data collection methods.  
In the future, the clinical data presented herein as well as additional histological findings in this 
HSCR cohort will serve as variables within a regression analysis study to determine what factors 
can readily predict patient outcome risks.  Findings from this analysis should guide healthcare 
provider clinical practices and thus provide better care for HSCR patients. 
124 
 
References 
 
1. Skaba, R. 2007. Historic milestones of Hirschsprung's disease (commemorating the 90th 
anniversary of Professor Harald Hirschsprung's death). J Pediatr Surg 42:249-251. 
2. Duhamel, B. 1960. [A new surgical procedure for the treatment of Hirschsprung's 
disease: the exclusion of the rectum with retrorectal and transanal lowering of the colon]. 
Langenbecks Arch Klin Chir Ver Dtsch Z Chir 296:384-388. 
3. Soave, F. 1964. A New Surgical Technique for Treatment of Hirschsprung's Disease. 
Surgery 56:1007-1014. 
4. Swenson, O., and Bill, A.H., Jr. 1948. Resection of rectum and rectosigmoid with 
preservation of the sphincter for benign spastic lesions producing megacolon; an 
experimental study. Surgery 24:212-220. 
5. Diseth, T.H., Bjornland, K., Novik, T.S., and Emblem, R. 1997. Bowel function, mental 
health, and psychosocial function in adolescents with Hirschsprung's disease. Arch Dis 
Child 76:100-106. 
6. Bai, Y., Chen, H., Hao, J., Huang, Y., and Wang, W. 2002. Long-term outcome and 
quality of life after the Swenson procedure for Hirschsprung's disease. J Pediatr Surg 
37:639-642. 
7. Jarvi, K., Laitakari, E.M., Koivusalo, A., Rintala, R.J., and Pakarinen, M.P. 2010. Bowel 
function and gastrointestinal quality of life among adults operated for Hirschsprung 
disease during childhood: a population-based study. Ann Surg 252:977-981. 
8. Ieiri, S., Nakatsuji, T., Akiyoshi, J., Higashi, M., Hashizume, M., Suita, S., and Taguchi, 
T. 2010. Long-term outcomes and the quality of life of Hirschsprung disease in 
adolescents who have reached 18 years or older--a 47-year single-institute experience. 
J Pediatr Surg 45:2398-2402. 
125 
 
9. Rintala, R.J., and Pakarinen, M.P. 2012. Long-term outcomes of Hirschsprung's disease. 
Semin Pediatr Surg 21:336-343. 
10. Teitelbaum, D.H., and Coran, A.G. 1998. Enterocolitis. Semin Pediatr Surg 7:162-169. 
11. El-Sawaf, M., Siddiqui, S., Mahmoud, M., Drongowski, R., and Teitelbaum, D.H. 2013. 
Probiotic prophylaxis after pullthrough for Hirschsprung disease to reduce incidence of 
enterocolitis: a prospective, randomized, double-blind, placebo-controlled, multicenter 
trial. J Pediatr Surg 48:111-117. 
12. Hartman, E.E., Oort, F.J., Aronson, D.C., Hanneman, M.J., van der Zee, D.C., Rieu, 
P.N., Madern, G.C., De Langen, Z.J., van Heurn, L.W., van Silfhout-Bezemer, M., et al. 
2004. Critical factors affecting quality of life of adult patients with anorectal 
malformations or Hirschsprung's disease. Am J Gastroenterol 99:907-913. 
13. Zaitoun, I., Erickson, C.S., Barlow, A.J., Klein, T.R., Heneghan, A.F., Pierre, J.F., 
Epstein, M.L., and Gosain, A. 2013. Altered neuronal density and neurotransmitter 
expression in the ganglionated region of Ednrb null mice: implications for Hirschsprung's 
disease. Neurogastroenterol Motil 25:e233-244. 
14. Roberts, R.R., Bornstein, J.C., Bergner, A.J., and Young, H.M. 2008. Disturbances of 
colonic motility in mouse models of Hirschsprung's disease. Am J Physiol Gastrointest 
Liver Physiol 294:G996-G1008. 
15. Ro, S., Hwang, S.J., Muto, M., Jewett, W.K., and Spencer, N.J. 2006. Anatomic 
modifications in the enteric nervous system of piebald mice and physiological 
consequences to colonic motor activity. Am J Physiol Gastrointest Liver Physiol 
290:G710-718. 
16. Sandgren, K., Larsson, L.T., and Ekblad, E. 2002. Widespread changes in 
neurotransmitter expression and number of enteric neurons and interstitial cells of Cajal 
in lethal spotted mice: an explanation for persisting dysmotility after operation for 
Hirschsprung's disease? Dig Dis Sci 47:1049-1064. 
126 
 
17. Pastor, A.C., Osman, F., Teitelbaum, D.H., Caty, M.G., and Langer, J.C. 2009. 
Development of a standardized definition for Hirschsprung's-associated enterocolitis: a 
Delphi analysis. J Pediatr Surg 44:251-256. 
18. Friedmacher, F., and Puri, P. 2013. Hirschsprung's disease associated with Down 
syndrome: a meta-analysis of incidence, functional outcomes and mortality. Pediatr Surg 
Int 29:937-946. 
19. Amiel, J., Sproat-Emison, E., Garcia-Barcelo, M., Lantieri, F., Burzynski, G., Borrego, S., 
Pelet, A., Arnold, S., Miao, X., Griseri, P., et al. 2008. Hirschsprung disease, associated 
syndromes and genetics: a review. J Med Genet 45:1-14. 
20. Freeman, S.B., Bean, L.H., Allen, E.G., Tinker, S.W., Locke, A.E., Druschel, C., Hobbs, 
C.A., Romitti, P.A., Royle, M.H., Torfs, C.P., et al. 2008. Ethnicity, sex, and the incidence 
of congenital heart defects: a report from the National Down Syndrome Project. Genet 
Med 10:173-180. 
21. Stirn Kranjc, B. 2012. Ocular abnormalities and systemic disease in Down syndrome. 
Strabismus 20:74-77. 
22. Jaruratanasirikul, S., Patarakijvanich, N., and Patanapisarnsak, C. 1998. The 
association of congenital hypothyroidism and congenital gastrointestinal anomalies in 
Down's syndrome infants. J Pediatr Endocrinol Metab 11:241-246. 
23. Purdy, I.B., Singh, N., Brown, W.L., Vangala, S., and Devaskar, U.P. 2014. Revisiting 
early hypothyroidism screening in infants with Down syndrome. J Perinatol. 
24. Laughlin, D.M., Friedmacher, F., and Puri, P. 2012. Total colonic aganglionosis: a 
systematic review and meta-analysis of long-term clinical outcome. Pediatr Surg Int 
28:773-779. 
25. Menezes, M., Pini Prato, A., Jasonni, V., and Puri, P. 2008. Long-term clinical outcome 
in patients with total colonic aganglionosis: a 31-year review. J Pediatr Surg 43:1696-
1699. 
127 
 
26. Pini Prato, A., Rossi, V., Mosconi, M., Holm, C., Lantieri, F., Griseri, P., Ceccherini, I., 
Mavilio, D., Jasonni, V., Tuo, G., et al. 2013. A prospective observational study of 
associated anomalies in Hirschsprung's disease. Orphanet J Rare Dis 8:184. 
27. Pini Prato, A., Gentilino, V., Giunta, C., Avanzini, S., Mattioli, G., Parodi, S., Martucciello, 
G., and Jasonni, V. 2008. Hirschsprung disease: do risk factors of poor surgical outcome 
exist? J Pediatr Surg 43:612-619. 
28. Jain, S. 2009. The many faces of RET dysfunction in kidney. Organogenesis 5:177-190. 
29. Michaelis, R.C., Skinner, S.A., Deason, R., Skinner, C., Moore, C.L., and Phelan, M.C. 
1997. Intersitial deletion of 20p: new candidate region for Hirschsprung disease and 
autism? Am J Med Genet 71:298-304. 
30. Garcia-Heras, J., Kilani, R.A., Martin, R.A., and Lamp, S. 2005. A deletion of proximal 
20p inherited from a normal mosaic carrier mother in a newborn with panhypopituitarism 
and craniofacial dysmorphism. Clin Dysmorphol 14:137-140. 
 
  
128 
 
CHAPTER VI 
 
DISCRETE POPULATIONS OF NEURAL CREST CELLS CONTRIBUTE TO THE ENS 
 
Introduction 
 Early studies assessing NC cell migration and contributions to the ENS led scientists to 
believe that the ENS is totally NC derived (1-4).  However, more recent studies have suggested 
that cells from the ventral region of the neural tube may also be contributing to peripheral nervous 
system components long believed to be only NC-derived. These cells, termed VENT cells by their 
discoverers, have been shown in avian species to contribute to numerous cranial nerves (5, 6), 
the otic vesicle (7), and the ENS (8).  However, if these cells exist in mammals and whether they 
contribute to the ENS is not known.       
 Stepping away from VENT cells, many questions surround NC subpopulations. It is known 
that certain regions of the NC (cranial, vagal, lumbar, etc.) innervate specific organs and give rise 
to certain cell types.  But defining subpopulations within these spatially defined groups is novel 
work.  Within vagal and sacral enteric NC-derived cell populations, an outstanding question 
exists—how “stem-like” or specified are NC-cells as they migrate from the neural tube to different 
regions of the gut? One extreme hypothesis is that all enteric neural progenitors (ENPs) are equal 
in their ability to give rise to different neuron types and glia until they reach the end of their 
migration in the intestine.  However, as the ENS field has progressed, studies have shown that 
the NC-derived cells that populate the gut may not show equal potency, or ability to differentiate 
into different cell types.  For example, it was long thought that all enteric bound ENPs express 
Nestin and Ednrb.  However, Lei and colleagues demonstrated that a Nestin independent 
population of ENPs exists and that this population can partially rescue ENS development when 
Hand2 expressing-Nestin dependent cells are genetically ablated (9).  Mundell et. al., determined 
that not all ENPs require a well known Ednrb enhancer region.  These Ednrb enhancer 
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independent ENPs are also able to partially compensate for deficits in the ENS when Ednrb 
enhancer dependent NC cells are genetically ablated (10).   
Early in my studies, I noticed regions of the ENS in P17-20 Sox10-Cre; R26RtdTom mice 
(with or without the Sox10Dom mutation) where reporter expression was not evident.  Indeed, 
certain areas of the intestine are known to contain no or very few neurons and only nerve fibers, 
such as Peyer’s patches (11, 12) (Figure 6.1).  However, in my studies, I noted consistent areas 
with particular patterning that had no or little reporter expression and that were not within Peyer’s 
patches (Figure 6.2).  IHC with a marker specific for neurons (Hu) revealed neurons in these 
areas (Figure 6.3).  Interestingly, these areas seemed to be expanded and more prevalent in older 
animals.  Given the recent studies detailed above as well as my own findings, we hypothesized 
that these areas could contain neural cell types deriving from VENT populations or a Sox10 
independent NC population. 
 To test this hypothesis, I evaluated for presence or absence of enteric neurons in mutant 
Foxd3flox/-; Wnt1-Cre mice, where NC specific ablation of Foxd3 leads to supposed loss of all NC-
derived ENS components (13). Absence of enteric neurons in the small and large intestine 
suggested that ENPs are entirely NC derived or that non-NC cell populations contributing to ENS 
rely on similar genetic signaling pathways as NCC.  However, presence of neurons in the stomach 
of some of mutants with NC specific Foxd3 ablation at early embryonic stages revealed a 
previously unrecognized NCC population that was not dependent upon Foxd3 for early migration, 
but ultimately required for survival. 
 
Methods 
Animals 
 Timed crosses were performed between Foxd3flox/flox; R26RYFP/YFP and Foxd3+/-; Wnt1-Cre 
mice to generate embryos with genetically ablated NC-derived ENPs. Crosses were performed  
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and pregnant females were kindly provided by the T. Labosky lab. For all mice, the morning of 
plug formation was designated as E 0.5. 
 
Dissections and IHC 
Pregnant females were sacrificed with isoflurane followed by cervical dislocation and 
embryos were collected and immediately placed in cold 1XPBS. Mutants were noted by 
craniofacial features (13).  Pups were then decapitated and tail/limb buds were collected for 
genotyping.  Since I obtained experimental mice from a lab that was closing their mouse colony, 
I was limited to a small sample size for each age tested.  Total number of embryos from pregnant 
dams received along with their embryonic age and genotype can be found in (Table 6.1).  
 
For each embryo, the abdominal cavity was fully opened.  To remove as much intact GI 
tract as possible, the esophagus was first gently, but firmly, tugged loose. Most of the time, this 
firm tugging resulted in the entire esophagus remaining intact, although sometimes the 
esophagus did tear.  Next, perianal tissue was cut loose from the rest of the embryo without 
disturbing the anus. Then, the whole GI tract was pulled gently away from the peritoneal cavity.  
This was best accomplished by using forceps to scoop behind the liver and using the liver and 
the kidneys as a barrier between the forceps and the GI tract as the entire peritoneal contents 
was pulled from the embryo.  Once the GI tract and other organs and tissue had been scooped 
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from the peritoneal cavity, forceps were used to gently remove extraneous organs and tissue from 
the GI tract.  The mesentery was cut to allow the GI tract to uncoil.  Following complete isolation 
of the GI tract for each pup, entire guts were fixed in sterile filtered 4% PFA for at least 4 hours at 
4°C.  After fixation, guts were rinsed in 1XPBS for at least 10 min at RT followed by two rinses in 
1XPBS/0.1% Triton X-100 for at least 10 min/rinse.  Next, samples were blocked for at least 1 hr 
at RT in NDS block (0.1 g BSA, 0.5 mL Normal Donkey Serum, 9.5 mL 1XPBS/0.1% Triton X-
100.)  Guts were then subjected to incubation in 1:800 Hu antibody dilution (gift of V. Lennon 
through M. Epstein) in NDS block O/N at 4°C.  The next day, guts were rinsed four times in 
1XPBS/0.1% Triton X-100 for at least 10 min/rinse followed by incubation in chick anti-GFP 
antibody (Abcam, Cat. No. AB13970) at 1:500 in NDS block.  Following primary antibody 
incubation, guts were rinsed four times in 1XPBS/0.1% Triton X-100 for at least 5 min/rinse and 
then incubated in secondary donkey anti-human TexasRed (Jackson Immuno, Cat. No. 709-075-
149) at 1:100 in NDS block for 1 hr at RT.  Following four additional rinses in 1XPBS/0.1% Triton 
X-100 for at least 5 min/rinse, guts were incubated in donkey anti-chick FITC (Jackson Immuno, 
Cat. No. 703-096-155) at 1:400 in NDS block for 1 hr at RT.  Finally, guts were rinsed for 15 min 
in 1XPBS/0.1% Triton X-100 followed by three 10 minutes rinses in 1XPBS. Guts were stored at 
4°C until imaging. For imaging, guts were laid on a slide, wetted with 1XPBS, and a cover slip 
was gently laid on top and fluorescent signaling was visualized on a BX41 Olympus fluorescent 
microscope.  After imaging, guts were placed back into 1XPBS and stored indefinitely at 4°C. 
During the IHC process, a Wnt-1Cre negative gut sample was subjected to secondary antibody 
incubations only to serve as a negative control.   
 
Results 
Genetic ablation of enteric NC-derived cells 
 By ablating enteric NC derivative populations, one may determine if other cell populations, 
such as VENT (VEntral Neural Tube) cells, are contributing neurons to the ENS.  The Foxd3 gene 
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is required for embryonic stem cell maintenance as well ENS precursor survival (13-15).  To 
effectively ablate NC-derived ENS cells while avoiding embryonic lethality, we used a previously 
established system of crosses in mouse mutants (13).  Briefly, Foxd3flox/flox; R26RYFP/YFP mice were 
crossed to Foxd3+/-; Wnt1-Cre mice.  In mutant Foxd3flox/-; Wnt1-Cre; R26RYFP (~25% of offspring), 
Cre-recombinase expression driven from the Wnt1-Cre transgene results in ablation of Foxd3 
expression within NC derivatives and subsequent death of NC-derived cells bound for the ENS.  
At the same time, Cre-recombinase acts on the floxed R26RYFP, resulting in YFP labeling of NC 
derivatives.  For controls, I used Foxd3flox/+; Wnt1-Cre; R26RYFP mice (~25% of offspring) which 
have intact NC-derived ENS cells as well as YFP labeling of NC derivatives.  In avian models, 
VENT cells migrate after NC populations have already migrated from the neural tube (reviewed 
in (16)).  Presumably, if VENT cells exist in the mouse, migration of VENT cells to peripheral 
nervous system (PNS) structures would take place after NC migration from the neural tube.  Vagal 
and rostral truncal NC cells that contribute to the ENS start migrating from the neural tube and 
reach the foregut between E8.5-9.5 (17) and sacral NC cells reach the hindgut by E14.5 (4).  
Thus, the time window for possibly observing VENT cells migration to and through the gut would 
be no earlier than E9.5. Additionally, although it is possible VENT cells proliferate and contribute 
to PNS near or after birth, the presence of Foxd3flox/-; Wnt1-Cre leads to perinatal lethality.  Thus, 
the time window I set for analyzing possible presence of VENT cells within the ENS of mice was 
E10.5 – E19.5.  Due to additional restrictions (mouse colony closing), I limited my analysis to 
embryos at E14.5, E16.5, and E17.5.   
 
Time dependent presence of neurons in the stomach, but not intestines, of Foxd3flox/-; 
Wnt1-Cre mice 
To test for the presence or absence of enteric neurons, I performed IHC to label neurons 
(Hu+ cells) in the intestines of mutant (Foxd3flox/-; Wnt1-Cre; R26RYFP) and control (Foxd3flox/+; 
Wnt1-Cre; R26RYFP) embryos at E14.5, E16.5, and E17.5.  In all mutants at all ages examined, I 
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observed no Hu+ cells nor YFP+ cells within most the length of the small intestine and large 
intestine (Figure 6.4)  Interestingly, all mutants examined at E14.5 had NC-derived neurons 
throughout their stomach with a few neurons reaching past the pyloric sphincter into the proximal 
duodenum (n=4).  At E16.5, mutants had reduced numbers of neurons within the ENS of their 
stomachs compared to control littermates (n=2) (Figure 6.4).  At E17.5, only 1 mutant had any 
gastric ENS neurons—which were extremely sparse—while all other mutants had no detectable 
gastric neurons (n=3).   
 
Discussion  
I undertook this study to determine if VENT cells or a Sox10 independent NC-derived 
population contributes to the ENS.  Although I observed no Foxd3 independent cell populations 
contributing to the ENS in the guts of Foxd3flox/-; Wnt1-Cre; R26RYFP mutants, the possibility 
remains that non-NC cells, such as VENT cells, exist and contribute to PNS structures.  For 
example, these cells could also rely on Foxd3 and Wnt1 expression.  Thus, genetic ablation of 
NC Foxd3+ cells would also ablate Foxd3+ non-NC cells contributing to the ENS.  Additionally, 
the VENT cells could rely on appropriate signaling from NC or other tissues for appropriate 
specification and successful migration.  NCC ablation or unsuccessful colonization of PNS 
structures could prevent VENT cells from migrating or properly differentiating.    
 An interesting, but unexpected, outcome of my Foxd3flox/-; Wnt1-Cre; R26RYFP analysis 
was the presence of neurons in the esophagus, stomach, and sometimes very proximal 
duodenum of all E14.5 mutants examined (n=4).  The sparser gastric neuron density in E16.5 
mutants followed by complete absence of neurons in mutants by E17.5 suggests that at least 
some NC-derivatives are migrating to the foregut and they or daughter cells differentiate into 
neurons, but succumb to early cell death.  I had initially expected to see no gastric neurons as a 
previous study noted complete absence of the entire ENS in Foxd3flox/-; Wnt1-Cre; R26Rlacz 
embryos (13).  However, this study limited analysis of the stomach to E17.5, effectively preventing  
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any chance that gastric neurons could be observed in these mutants.  Interestingly, this same 
study noted a reduction in cardiac NC-derivative numbers in these mutants, but these cells were 
eventually able to proliferate and nearly completely compensate for the initial reduction.  It could 
be that a unique population of NC-derivatives reaches the foregut in Foxd3flox/-; Wnt1-Cre mutants 
and that they are near or part of the same vagal, cardiac population that migrates to the heart.  In 
line with this hypothesis, previous studies have identified unique NC-derived cell populations in 
ENS mutants that only colonize the esophagus and stomach (17, 18). In Ret-/- mice, where Ret 
expression has been completely obliterated, E10.5 and E13.5 embryos as well as new born pups 
were reported to have total intestinal aganglionosis, but neurons were still detected in the stomach 
and esophagus (17, 18).  Interestingly, the Ret independent population of cells that colonized the 
foregut did not appear to derive from vagal neural crest cells, but rather proximal truncal neural 
crest cells (17) (Figure 6.5). 
Gdnf is a ligand for Ret and thus it comes as no surprise that reduction or ablation of Gdnf 
signaling leads to phenotypes that closely mimic those of Ret-/- mice. However, conflicting studies 
exist for Gdnf null, or Gdnf-/-, embryos in regard to ENS presence or absence in the stomach.  
Moore et al (1996) reported total intestinal aganglionosis in Gdnf-/- and sparse neurons were 
detected in the stomachs of Gdnf-/- mice from E12.5 – P0, although this data is not shown (19). 
Similarly, Sanchez et. al., (1996) reported total intestinal aganglionosis in Gdnf-/- embryos at all 
stages observed.  However, in line with my findings in Foxd3flox/-; Wnt1-Cre mutants, Sanchez 
and colleagues observed neurons in the esophagus and stomach of young Gdnf-/- embryos from 
E9.5 to E13.5, but detected no neurons in the lower esophagus or stomach of older, newly born 
Gdnf-/ -pups (20).  Deficiencies in Gfra, the primary co-receptor for Ret:Gdnf binding in ENS 
development, also leads to deficits similar to those seen in Ret-/- mice.  Gfra1-/- mice at E17 and 
at birth have total intestinal aganglionosis, but some neurons in the foregut (21, 22).  To 
summarize, mice with components of the Ret signaling pathway eliminated have what appears to 
be a Ret independent population of NCC that colonizes the foregut and gives rise to neurons;  
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however, while this population persists in Ret-/- and Gfra1-/- mice, this population 
disappears with time, presumably due to cell death, in Gdnf-/- mice.  Foxd3flox/-; Wnt1-Cre mutants 
closely mimic these mouse models, particularly Gdnf-/- mice as neurons are detected at early 
stages (E14.5 and E16.5) but not later stages (E17.5).  This close resemblance in phenotype 
could mean that the Ret independent NC population originating from truncal NC may also be a 
Foxd3 independent population.  Conversely, it is also possible that in Foxd3flox/-; Wnt1-Cre 
mutants, the Foxd3 independent population is part of a separate Ret dependent, vagal NC 
population (Figure 6.5). Future experiments could answer this question and are explored in 
Chapter 8. 
 Despite my findings in regard to foregut NC-derived populations in Foxd3flox/-; Wnt1-Cre; 
R26RYFP mutants, the question persisted as to the origin of ENS populations in Sox10-Cre; 
R26RtdTom animals that did not express the tdTomato fluorophore.  The possibility remained that 
these neurons that lack reporter expression derive from a Sox10 independent population of ENPs 
(Figure 6.5).  However, other explanations emerged later in my work that could more readily 
explain these strange areas.  One possible explanation is tissue integrity.  Neurons tend to be 
highly sensitive to osmotic changes during washes and fixations (personal communications, Mike 
Gershon and Kara Margolis.)  Large changes in osmolarity can cause neuron membranes to 
burst, expelling proteins into the environment.  It could be that my fixing conditions initially led 
neurons in certain areas (where tissue was thin or more prone to mechanical forces) to “leak” 
reporter if their membranes burst.  Similarly, another plausible explanation is that the fix time was 
inadequate to permeate through certain regions of the tissue and bind the fluorescent reporter 
within neurons (personal communications, Guoqiang Gu.) Importantly, I did see some reduction 
in these reporter absent areas in later experiments where an additional fix time (+12 hours at 4°C) 
after gut muscle strip subdissection was added.  (During my initial observations, gut muscle strips 
were only fixed on ice for 20-25 minutes.)  However, this reduction was small and these areas still 
persisted.  Given that these areas tended to occur more often in older animals (>P19) and were 
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present, but quite rare, in younger animals (P15-17), other biological explanations for these areas 
relate to transgene and reporter expression.  One explanation is the existence of Sox10 
independent NC-derived cell types that never express Cre-recombinase and proliferate later in 
life, primarily in the postnatal period.  However, this seems unlikely.  Even though ENS cell birth 
and turnover occurs throughout the life of the mouse, the number of new neurons is very small 
and could not account for such large areas that do not express Sox10. Alternatively, ROSA26 
expression is not ubiquitous in all cell types and R26R reporter expression could be 
downregulated or switched off over the course of development.  This would readily explain the 
appearance of areas without reporter expression and why older pups had increases in the number 
and size of these reporter absent areas. 
In summary, I set out in this study to determine whether VENT cells contribute the ENS of 
the mouse and to determine if a Sox10 independent population of cells contribute to the ENS.  
Unfortunately, these questions remain unanswered.  Serendipitously, this study did uncover a 
previously unrecognized population of NC-derived cells that do not require Foxd3 for NCC 
migration into the foregut but ultimately require Foxd3 for survival.  The biological underpinnings 
that allow a small group of NC cells to migrate to the foregut, but then disappear after supposed 
differentiation, remains to be determined.  As the field moves forward, future studies should aim 
to further define unique populations of NC cells and the factors that drive their potency, 
specification, and differentiation.  
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Chapter VII 
 
Summary and Future Directions 
 
HSCR is an example of a complex disease where aberrant ENP migration and 
differentiation leads not only to aganglionosis, but also anomalies in the ganglia that are present.  
Basic science studies in HSCR mouse models as well as clinical studies in HSCR patient cohorts 
have served to not only better define the disease, but also shed light on the mechanisms and 
processes that drive ENS development.  In this Chapter, I endeavor to provide brief synopses of 
my findings for particular topics along with their potential impact and ideas for future directions.   
 
NC lineage imbalance  
Previous studies have suggested that abnormal enteric NC differentiation occurs in HSCR 
and non-HSCR mouse models (reviewed in (1)).  In our lab, a previous study demonstrated that 
enteric ENPs isolated from Sox10Dom/+ and Sox10+/+ embryos differ in their in vitro developmental 
capacity, with fewer neurons and glia and more myofibroblasts being generated from Sox10Dom/+ 
ENPs compared to Sox10+/+ ENPs (2). Part of my study efforts were to extend these studies and 
determine if this difference in developmental potential manifested as ENS defects in vivo.  Fate-
mapping NC derivatives and utilizing IHC for specific ENS cell types in Sox10Dom/+ and Sox10+/+ 
pups revealed that indeed NC derivatives were affected in their ability to differentiate into correct 
cell types in the context of HSCR.  Imbalances in neural crest derivatives were regionally specific, 
and interestingly, imbalances encountered in the colon correlated with extent of aganglionosis.   
However, in regard to ENS cell type imbalance in Sox10Dom/+ and Sox10+/+ and other 
HSCR mouse models, much is left to be determined.  Initially, I sought to characterize numerous 
neuronal cell types within the ENS.  Several factors led me to limit my analysis to neurons, glia, 
and nNOS- and Calretinin-expressing neuronal subtypes.  First, I had difficulties in locating 
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appropriate antibodies and optimizing IHC.  Second, we had expected an obvious phenotype in 
regard to Sox10Dom/+ ENS patterning and skew in ganglia components.  However, I did not observe 
any obvious ENS patterning defects and only time-intensive counting of ganglia components in 
numerous animals revealed skewing of some ganglia cell types.  Despite these difficulties, future 
studies would benefit from knowing all the neuronal subtypes that are affected in HSCR.  Such 
knowledge would help determine how much the local environment and/or timing of differentiation 
affect resultant ganglia constituents.  To be specific, we know that early born neuron types, such 
as serotonergic neurons, affect the proportions of later born neuron types (3). The two neuronal 
subtypes I analyzed, Calretinin- and nNOS-expressing neurons, are at least born between E12-
P4 and E11-P0 respectively (4-6).  In regard to birth dates, these neuronal subtypes have a rather 
broad range when compared to other neuron subtypes such as Serotonergic neurons (born E8-
E14) or Neuropeptide Y neurons (born E10-18). Knowing which populations of neuronal subtypes 
are actually affected in HSCR will not only tell us more about the disorder, but also reveal more 
about discrete NC populations and how they interact. 
 Furthermore, even though much work has gone into characterizing neuronal subtypes and 
their birthdates in the ENS (4-7), relatively little is known about enteric glia.  It is known that glia 
modulate inflammatory processes as ablation of enteric glia leads to severe jejuno-ileitis (8, 9). 
And glia or glia-like cells generate new neurons after traumatic injury (10). However, birthdates of 
glia, their exact roles in modulating neuron signaling, and the specific genes they express are just 
now being examined.   My lab group is currently investigating the expression patterns of ENPs 
that express high and low levels of Phox2b, which are believed to correspond to future neurons 
and glia respectively. This work will be extremely important as arguably very few genes have been 
discovered or studied in these pathways in regard to ENS development, especially when 
compared to what is known about CNS development. While this Phox2b study will shed light on 
developmental processes, future studies could also serve to define characteristics of enteric glia 
in adult mice.  Similar to the Phox2b-centric study mentioned above, flow-sorting of enteric glia 
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from adult mice using a glia-specific marker followed by subsequent RNA seq or reverse-
transcriptase PCR for plausible glial genes should provide a basis for the genes that are 
expressed by some or all enteric glia.  (Surprisingly, only about a dozen known enteric glial 
markers have been documented. These markers include GFAP, SOX2, SOX10, BFABP, FOXD3, 
FABP7, BLBP, ERBB3, PHOX2B and S100A&B subtypes.) 
 Glia birthdates could be determined through simple experiments incorporating BrdU 
technology and IHC, similar to previous neuron-birthdating studies (4-6).  As a reminder, the 
birthdate of a specific cell type can be defined as the time period that a cell ceases to divide and 
starts to take on the characteristics of the cell type it is destined to become.  To this end, BrdU 
can be injected into pregnant dams at different developmental time points.  Postnatally, pups from 
injected dams are sacrificed and the ENS is subjected to IHC to detect glia and BrdU.  Should 
BrdU be detected in glia from a specific time period, such as E8, one can conclude that at least 
some ENP cells underwent final mitotic division and were differentiating into glia at E8.  By 
conducting this experiment at numerous time points during development, one can define the 
window of time a specific cell type is born.  Admittedly, if one uses a pan-glial marker, this 
experiment would first only define the time period all glia are born and the relative amounts of glia 
born at certain time periods.  Unfortunately, very few studies have identified glia subtypes by 
marker expression and those that have relied on more complicated means than strictly IHC, such 
as electrophysiological identification or changes in glia marker expression levels due to a 
biological stressor such as inflammation (11-14).  Some studies, including one published within 
the last month, have classified enteric glia based on location and morphology (15, 16). By 
identifying specific glia subtypes by location and morphology or by population-specific markers 
(once discovered), a similar type of experiment could be conducted to determine glia subtype 
birthdates. In total, these experiments will not only shed light on ENS developmental processes, 
but could also explain why glia proportions are only disturbed in the colon of Sox10Dom/+ mutants.  
Additionally, once glia subtypes are further defined, the exact processes that specific suptypes 
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contribute to, such as inflammation or modulation of neuron signaling, can be more readily 
explored. 
 
Defining NC populations 
 Along with characterizing individual cell types within enteric NC populations comes the 
task of characterizing discrete NC populations.  In Chapter 6, I described a NC population that 
did not require Foxd3 for migration into the foregut, but ultimately required Foxd3 expression for 
survival.  This population, along with the Ret-dependent and independent populations discussed 
in Chapter 6 (Figure 6.5), raises many interesting questions and possibilities for future directions 
in this work 
 First, the question remains as to whether the population of NC cells I observed in the 
stomachs of Foxd3flox/-; Wnt1-Cre embryos originates from the vagal or rostral truncal NC 
populations.  To test this hypothesis, one could use DiI injections to label neural crest in either 
the vagal or truncal populations in Foxd3flox/-; Wnt1-Cre and Foxd3flox/+; Wnt1-Cre embryos before 
NC migrate from the neural tube.  Mouse embryos can transiently develop and survive in culture 
for at least a couple days (up to E10.5), permitting DiI-labeled and unlabeled NC cells to migrate 
to the foregut. The presence of DiI-labeled cells from vagal and/or truncal regions in the foregut 
post-migration will reveal the origins of the NC cell population.  However, DiI-labeling can be non-
specific and dilutes over multiple cell divisions, and culturing whole embryos is difficult.  Other 
approaches to answering this questing include different labeling techniques, such as GFP-tagged 
adenovirus vectors (although speficity is also an issue here) and utilizing transgenic mouse lines 
that have reporter expression specific to the ventral neural tube.  The use of transgenic mouse 
lines would eliminate the need for ex vivo culturing of embryos; however, several transgenic lines 
may need to be tested as a pan-ventral neural tube marker is not currently known. 
 Furthermore, it is fascinating that NC cells within Foxd3flox/-; Wnt1-Cre go as far as 
differentiating into neurons within the stomach before they appear to undergo apoptosis.  
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Experimentally, the presence of apoptosis could be investigated through TUNEL assays within 
the stages that these NC cell populations seem to disappear (possibly E16-E17).  The more 
important question, as to why these cells do die, will be harder to establish.  It could be that lack 
of Foxd3 eventually leads to aberrant signaling between NC cells and the molecular signals in 
their environment (non-NC cells) which leads to cell death.  Or, aberrant signals between NC cells 
or signals needed from an absent NC population result in cell death.  These hypotheses could 
initially be explored through IHC staining of NC and non-NC cell populations in Foxd3flox/-; Wnt1-
Cre and Foxd3flox/+; Wnt1-Cre at different stages to determine if known regulatory receptors and 
their ligands (such as Ret:Gdnf or Ednrb:Edn3) are present at the correct time in the correct cell 
populations.  A more specific experiment would be to first define the NC cell population present 
in Foxd3flox/-; Wnt1-Cre through flow-sorting for these cells and then performing RNAseq analysis 
to determine grossly genes expressed at high levels in this cell population. This population can 
also be further defined by using IHC to determine if any glia or specific neuronal subtypes are 
present within this population.  This type of experiment could be important as it is known that a 
“transiently catecholaminergic” cell population gives rise to specific early born neuron types in the 
developing gut such as serotonergic neurons (17). Ablation of “transiently catecholaminergic” in 
Mash1-/- (or Ascl1-/-) mice results in the absence of serotonergic neurons, but presence, and 
importantly, survival of other neuron types such as CGRP expressing neurons (17). By comparing 
the types of neurons present in Foxd3flox/+; Wnt1-Cre before they succumb to cell death to those 
neuron types described in Mash1-/- mice would help to further define this NC cell population. 
Finally, elimination of Foxd3 expression at different time points, either through an inducible 
mutation or use of alternate Cre alleles with the Foxd3-flox allele, would help determine exactly 
when Foxd3 is directly or indirectly acting on specific NC processes such as migration and 
differentiation.  For example, previous members of my lab group generated an inducible Sox10-
Cre/ert2 transgene.  This transgene can be induced at specific developmental time points in 
Foxd3flox/+ or Foxd3flox/- embryos by tamoxifen gavage to the mother.  Inclusion of a Cre-loxP driven 
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ROSA26 reporter in this scheme would permit visualization of NCC location and number as well 
as provide evidence that induction of the Sox10-Cre/ert2 was successful.  
 
GI motility studies 
 In this study, we found that young, 4-week old Sox10Dom/+ mice had significantly slower 
small intestinal transit times when compared to Sox10+/+ mice.  However, older 6-week old 
females did not have any small intestinal transit slowing and, interestingly, I observed increased 
gastric emptying in 6-week old male Sox10Dom/+ mice.  Although a surprise, possible defects in 
pyloric sphincter function are compatible with Sox10’s biological roles and expression patterns 
and the neural lineage imbalance we identified in the nearby duodenum.  Differences in circulating 
sex hormones was put forward as a hypothesis to explain this discrepancy between findings in 
adult mice.  However, we never tested this hypothesis.  Because sex differences are seen so 
often in neurodevelopmental disorders and because the protective effects of female specific sex 
hormones are not well understood, this finding would be interesting and important to follow up.  
There are a couple of possible ways to rule in or rule out a role for sex hormones in pyloric 
sphincter and small intestinal transit changes in Sox10Dom/+ mice.  First, Sox10Dom/+ males could 
be subjected to hormone injections during periods of time that correspond to onset of circulating 
sex hormones in females.  Males subjected to hormone injections as well as untreated Sox10Dom/+ 
(and wildtype equivalents for each group) could be tested for changes in pyloric sphincter 
dynamics and small intestinal transit using tests previously described in Chapters 2, 3, and 7.  In 
this study, if sex hormones are playing a role, I would expect to observe similar gastric emptying, 
pyloric sphincter measures, and small intestinal transit assays in Sox10Dom/+ mice when compared 
to wildtype Sox10+/+ mice and female Sox10Dom/+ mice.  Conversely, Sox10Dom/+ female mice could 
undergo ovarectomies prior to puberty onset.  Loss of ovaries would lead to significant decreases 
in female sex hormones.  Thus, when testing for GI motility deficits, Sox10Dom/+ females should 
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mimic findings in untreated Sox10Dom/+ males should hormones be playing a role.  For this type of 
study, it will be important to monitor hormone levels in all untreated and treated mice involved to 
ensure physiological levels of hormones in treated mice coincide with levels in untreated mice.   
As a side note, if a group were to test varying levels of testosterone (such as through 
castration in males or injection to females) in these types of studies, they should proceed with 
caution.  Both females and males synthesize testosterone and testosterone is an intermediate in 
estradiol (estrogen) biosynthesis pathway. And estradiol has been implicated as the molecule 
responsible for the “neuroprotective effect” (reviewed in (18)). Thus, results from studies where 
testosterone is introduced may not be easy to interpret (i.e. Were changes due to testosterone? 
Or due to estradiol synthesis resulting from excess testosterone?)  Although determining how 
near complete absence of sex hormones affects neurodevelopment could be interesting, the 
global impact of such a loss would make findings difficult to interpret. Furthermore, because both 
females and males produce testosterone and the sheer amount of literature that suggests 
estradiol as the “neuroprotective” factor, the clinical relevance of testing decreased testosterone 
levels is lacking at this time. 
Revisiting the slow intestinal transit in 4-week Sox10Dom/+ old mice, we have yet to 
determine the exact cause of slower transit within the small intestine of these mice.  We put forth 
the hypothesis that imbalances in inhibitory (nNOS+) and excitatory (Calretinin+) neurons could 
be at least partially driving this alteration in motility.  However, other neuron types can affect GI 
motility and slower transit could result from different movement alterations, such as uncoordinated 
peristalsis or slower or less peristalsis.  Several lab groups have developed methods to trace 
rates of peristalsis, such as generating spatiotemporal maps of muscle constriction (19) or 
physically marking intestine pieces and tracing marker movements (20). We could use similar 
methods in our lab to look at peristalsis dynamics in Sox10Dom/+ mice.  I think a more important 
question for potential pharmaceutical targets in the ENS is to determine if the changes we 
observed in inhibitory (nNOS+) and excitatory (Calretinin+) neurons (and possibly other neuron 
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types) cause a physiological affect.  To get closer to answering this question, one could use a 
“force” assay where a piece of duodenum is hung between two hooks (within a tissue culture 
bath) and force generated by constriction of the muscle is measured after application of various 
pharmaceutical reagents.  For example, in Sox10Dom/+ mice, we observed an equal proportion of 
nNOS neurons in the duodenum when compared to Sox10+/+ littermates, but increased Calretinin 
neurons. Therefore, one could eliminate the contribution of nNOS neurons to gut movement by 
applying L-NAME (a readily available nNOS inhibitor) to duodenum pieces.  This loss of inhibitory 
neuron contribution would feasibly lead to the loss of relaxation by the intestinal muscle. The 
resultant constriction force, primarily due to Calretinin neurons, would then be measured.  Since 
Sox10Dom/+ mice have more Calretinin neurons than Sox10+/+, one would expect the constriction 
force in Sox10Dom/+ mice to be greater. 
 In regard to GI motility tests in other mouse models, I found no differences in small 
intestinal transit in Ednrbtm1Ywa/+ and Rettm1Cos/+ males and females compared to their wildtype 
littermates.  When testing for total intestinal transit time, Ednrbtm1Ywa/+ male and female mice were 
comparable to their wildtype littermates and the same was observed in Rettm1Cos/+ females and 
wildtype littermates.  Intriguingly, Rettm1Cos/+ males had significantly higher total transit times than 
their wildtype counterparts.  Given that Ednrbtm1Ywa/+ and Rettm1Cos/+ mice are reported to have no 
aganglionosis (21, 22), this finding in Rettm1Cos/+ males could help explain familial constipation and, 
similar to findings in Sox10Dom/+, suggests sex-specific severity of phenotypes in the ENS.  Finding 
the cause of constipation and defining the constipation type in Rettm1Cos/+ mice will be the initial 
steps in establishing this mouse as a model for studying familial constipation.  First, Rettm1Cos/+ 
mice have no aganglionosis, but their ENS neurons tend to be smaller on average compared to 
wildtypes (22). We can further characterize the ENS of Rettm1Cos/+ mice using IHC (similar to that 
carried out in Sox10Dom/+ mice) to identify skews in ganglia constituents that could drive 
constipation.  Additionally, if slowing of fecal contents is occurring in the colon, one would expect 
fecal material to be drier in Rettm1Cos/+ mice than in Ret+/+ mice. One may easily measure the water 
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contents of fecal material by collecting fresh feces and weighing it, eliminating water from the 
feces via desiccation, and then weighing dried feces (23).   
 
Inflammatory responses 
Interestingly, I observed no difference in inflammation in Sox10Dom/+ and Sox10+/+.  Some 
possible explanations for this finding are expounded upon in Chapter 2, and this finding 
emphasizes the importance of genetic and environmental interactions.  In my review of clinical 
charts for HSCR patients, I noticed a recurring event.  Many times, reports of HSCR patients 
hospitalized for gastritis and enterocolitis carried a note that other family members had just 
suffered from a bout of gastritis or other GI discomfort.  However, other family members did not 
require hospitalization for their symptoms.  While some of this can be attributed to vigilant 
caretakers realizing enterocolitis can be a life threatening event in HSCR, it also suggests that 
HSCR patients may have an increased or aberrant inflammatory response to infectious agents 
when compared to the general population.  It has become apparent in recent years that the ENS 
modulates inflammatory responses in the bowel (24, 25) and studies in mice and humans could 
help reveal how the ENS modulates inflammation in the context of HSCR. 
For example, the interaction between environment and inflammatory response could be 
tested in Sox10Dom/+ and Sox10+/+ mice in several ways. In many mouse studies, evaluation to 
determine differences in inflammatory responses is conducted by introducing a stressor that 
induces inflammation.  Examples of stressors include chemical insults such as introduction of 
DSS or TNBT or introduction of an infectious agent, such as C. difficile, that would normally elicit 
inflammatory processes in the bowel.  One could introduce similar stressors to Sox10Dom/+ and 
Sox10+/+ mice and then evaluate colonic inflammation.  Additionally, although I used H&E to grade 
inflammation, other tests are available that could also show if inflammatory processes are altered 
in these mice.  For example, differing levels in cytokine levels could be tested via RT-PCR or 
ELISA (26) or one could stain for myeloperoxidase (MPO) (27).  Furthermore, the microbiome of 
154 
 
Sox10Dom/+ and Sox10+/+ mice could differ, leaving the HSCR mouse mutant more susceptible to 
inflammation.  Several studies have used RNAseq to determine the relative quantities of specific 
strains and species of flora in different disease states (28-30) and a similar approach could be 
taken in HSCR mouse models.  Once differences in flora are determined, more specific studies 
could be carried out defining the interactions between specific microbiome organisms and the 
ENS. 
Ethical considerations preclude using environmental reagents to inflict unnecessary 
inflammation or pain (biopsy) to test possible inflammation triggers in HSCR patients.  However, 
simple additions to HAEC standard of care could reveal the infectious agents that most often lead 
to HAEC.  For example, stool samples from patients being admitted with HAEC could undergo 
laboratory testing to determine infectious agents present.  Infectious agents that appear most 
often in hospitalized patients could indicate that HSCR patients are more susceptible to 
inflammation when that particular agent is present.  Additionally, since the infectious agent will 
most likely be well characterized, such information could clue researchers into the biological 
pathways (neural and immune) that are affected and interacting in the context of HSCR.  
Furthermore, when HSCR patients present to the hospital or clinic with gastritis symptoms, 
implementing simple surveys that address environmental exposures (such as the presence of 
gastritis in other family members) as part of their care could clue physicians and caregivers into 
extra measures that may need to be taken in the home environment to help reduce the risk of 
HAEC in HSCR patients. 
 
Clinical considerations 
 In Chapter 5, I described clinical information from a HSCR cohort that could be helpful in 
determining comorbidities and what patients would go on to suffer from adverse outcomes, such 
as HAEC.  Although I focused my attention on clinical variables that could be collected from 
electronic medical records, more clinical and pathology data exists that could be collected and 
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tested for correlation with enterocolitis.  For example, the current focus while interpreting HSCR 
biopsies is to assess for presence or absence of ganglia.  However, many times, other 
pathological findings are noted within HSCR patient biopsies, such as eosinophilia, “foamy” cells 
within ganglia, and overt ganglionitis (personal communications, Hernan Correa.)  The reason for 
such findings is currently unknown and no study has evaluated their value in determining patient 
outcomes.  Interestingly, it is known that standing inflammation in the GI tract can lead to more 
severe inflammation after a stressor such as surgery or infection.  Thus, it is plausible such 
pathological findings have real value in predicting patient outcomes post-surgery. To this end, I 
am in an active collaboration with Dr. Hernan Correa (Pediatrics Pathology Director, Vanderbilt 
Medical Center), to grade surgical HSCR biopsies for pathological features and inflammation.  
The long term goal is to apply regression analysis to determine the independent variables 
(histology findings, sex, length of aganglionosis, etc.) that can predict or contribute to patient 
outcomes (enterocolitis).   
Also, early in my graduate school training, the initial focus of the HSCR population study 
was to define patterning and ENS deficits in HSCR patient resections.  However, difficulties with 
HSCR surgical resection staining and IHC, issues with power, and recent discoveries in HSCR 
mouse models (21) as well as my own findings in the Sox10Dom/+ HSCR model led us to rethink 
this project.  Specifically in regard to HSCR mouse models, Zaitoun et. al., (2013) observed a 
significant increase in colonic nNOS neurons within the Ednrb-/- HSCR mouse when compared to 
Ednrb+/- littermates.  I also observed an increase in colonic nNOS neuron proportions in the 
Sox10Dom/+ HSCR mouse mutant.  But more specifically than the Zaitoun study, I found that this 
increase correlated highly with the extent of colonic aganglionosis.  In other words, the longer the 
aganglionic segment, the higher the proportion of nNOS neurons.  Fortuitously, I have had 
success with NADPH-β staining on HSCR surgical resections (Chapter 7).  NADPH-β staining 
permits visualization of individual nNOS expressing neurons, and thus I can also determine if 
nNOS neuron numbers correlate with aganglioniosis extent in HSCR patients. Such information 
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could hold great clinical relevance as patients with longer lengths of aganglionosis could be 
experiencing a “double whammy’— greater lengths of aganglionosis not only means removal of 
more colon (and associated side effects), but more severe defects in the ENS of the colon that is 
remaining.   
Currently, I am grading nNOS expressing neuron density as part of a previous study.  (The 
lab just recently received IRB approval for connecting our findings to clinical outcomes.) There 
are a few caveats and modifications that one needs to consider while conducting this type of 
study. In my mouse studies, I was able to calculate the proportion of nNOS neurons to total 
neurons.  I do not currently have a stain to use in tandem with the NAPDH- β stain to detect and 
quantify all neurons.  Thus, nNOS neuron measurements will have to be made by comparing 
nNOS neuron numbers to total ENS area or ganglia area.  This feat is possible given that nNOS 
neuron connectives are plentiful and provide a clear outline of individual ganglia as well as other 
ENS components (Chapter 7, Figure 7.9).  Furthermore, in my mouse studies, I could calculate 
the percent of colon that was aganglionic because I could measure the total length of the colon. 
Of course, these types of measurement are not available for HSCR surgical resections.  However, 
information in regard to length of hypoganglionosis and aganglionosis (in cm) from the rectum 
can be teased from the surgical pathology records.   
 
The colon—the final frontier 
 Throughout my studies and discussion herein, I hugely ignored a population of NC cells 
that has only recently been recognized.  Midway through my graduate training, a paper was 
published detailing the presence of trans-mesenteric NC cells (31).  While for decades it has been 
assumed that NC exclusively travel caudally or rostrally along gut mesenchyme once they enter 
the gut, Nishiyama and colleagues discovered a population of NC cells that actually take a ‘short 
cut’ to the colon (31).  These NC cells enter the foregut, migrate to the gut mesentery along the 
duodenum, and then track across the gut mesentery into the colon, bypassing the jejunum and 
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ileum altogether.  (This path is possible as the duodenum and colon lay directly juxtaposed.)  The 
role of this NC population and how they might be affected in the context of HSCR has not been 
explored.  Nishiyama and our lab group have hypothesized that this NC population could explain 
“skip lesions” in HSCR, where areas of colon alternate between ganglionated and aganglionated 
(1, 31). Further characterizing this population of NC cells in wildtype animals as well as within 
HSCR is an open field for researchers.  Relatively little is known about why these NC cells migrate 
into the mesentery and others do not, the intrinsic and extrinsic cues that guide their migration, 
and the ENS cell types they eventually give rise to.  Do these cells fail to reach the colon in HSCR? 
Or do they reach the colon but succumb to cell death like the Foxd3 dependent cells in the 
stomach?  To begin to answer these questions, one may evaluate the migration patterns of NCC 
in the gut tube as well as within the mesentery at different developmental time points in HSCR 
mouse models.  Such a study could easily be completed with mouse crosses similar to ones I 
completed within Chapter 2, where nearly all ENPs and their daughter cells express the tdTomato 
reporter.  
  
Concluding Remarks 
Overall, this study has moved the ENS field forward by defining alterations in ENS 
subpopulations and functional parameters within the ganglionated regions of the Sox10Dom/+ 
mouse model.  Attempts to define and correlate HSCR patient variables with adverse outcomes 
were met with difficulties, but initial work here has laid the foundation for future studies.  
Furthermore, work within non-HSCR mouse models has provided a possible explanation and 
model for familial constipation and defined a new NC population that does not rely on Foxd3 for 
cell migration or differentiation, but ultimately relies on Foxd3 for viability.  Future efforts to further 
define effects of HSCR genes on ENS development should positively impact HSCR patient care 
and shed light on other GI disorders. 
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CHAPTER VIII 
 
EXTENDED METHODS & SHORT STUDIES 
 
Animals 
Genotyping 
Genomic DNA was collected from tail snips (postnatal mice) or limb buds (embryonic 
mice).  Tissues were placed in tail digest buffer (10 mM Tris pH 8.0, 10 mM EDTA, 0.5% SDS, 
100 nM NaCl) and incubated with Proteinase K (Fisher, BP1700 100; Gojira, PK 1001) at 55°C 
for a minimum of 2 hours.  Digestion of tissues was followed by phenol-chloroform extraction and 
EtOH precipitation of the DNA.  DNA was then resuspended in 250 µL TE buffer, pH 7.5.  
Conditions for PCR genotyping for specific transgenic and mutant lines are listed below.  All primer 
sets used for genotyping can be found in Table 8.1.  All PCR products were ran on a non-
denaturing acrylamide gel (10% gel in 1X TBE buffer) unless otherwise specified. 
Sox10-Cre 
For Sox10-Cre primer sets (Table 8.1), thermocycler PCR conditions were as follows: 
94°C for 5 min; [94°C for 30 sec, 55°C  for 30 sec, 0.5°C/sec ramp  up to 72°C, 72°C for 30 sec, 
0.5°C/sec ramp up to 94°C] repeated 34 times; 72°C for 10 min, 4°C indefinitely.  In cases where 
it was necessary to determine if mice were homozygous or heterozygous for the transgene, DNA 
quantity was measured post-extraction on a NanoDrop 2000 spectrophotometer (Thermo 
Scientific).  DNA quantity for PCR was equalized (150 ng/tube) and cycling repeats were reduced 
to 25.  Intensity of the resulting bands on acrylamide gel compared to control DNAs was used to 
determine homozygous or heterozygous state. In my attempts, Sp6 primers produced the clearest 
difference in band intensity in heterozygous versus homozygous mice.  This method for 
determining homozygosity was validated when I bred a putatively homozygous male and all his 
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offspring (2 litters) harbored the transgene.   
Sox10Dom 
Sox10Dom/+ genotypes were confirmed by PCR for pups used in analysis that had white 
paws and belly stripes or spots, but did not have obvious hypoganglionosis and/or aganglionosis 
when viewed under a dissection scope.  (The vast majority of pups in my studies with white paws 
and belly markings displayed overt hypoganglionosis and/or aganglionosis.  On very rare 
occasion, some pups with these markings did not display an overt ENS phenotype; however, 
these rare mice always tested positive for the Sox10Dom mutation via PCR genotypes.)   
Thermocycler PCR conditions for Sox10Dom genotyping were as follows: 92°C for 5 min; [92°C 
for 30 sec, 58°C  for 30 sec, 0.5°C/sec ramp up to 72°C, 72°C for 30 sec, 0.5°C/sec ramp up to 
94°C] repeated 27 times; 72°C for 10 min, 10°C indefinitely.   
Wnt1-Cre 
For Wnt1-Cre primer sets, thermocycler PCR conditions were as follows: 94°C for 3 min; 
[94°C for 30 sec, 55°C  for 1 min, 0.5°C/sec ramp  up to 72°C, 72°C for 1 min 30 sec, 0.5°C/sec 
ramp up to 94°C] repeated 35 times; 72°C for 5 min, 4°C indefinitely.   
EdnrbtmYwa1/+ & RettmCos1/+ 
For EdnrbtmYwa1/+ and RettmCos1/+ mice, primer sets, a portion of the Neo cassette sequence 
was amplified to identify knockout mice. Additionally, a portion of the Rapsn gene was amplified 
in parallel as a control. Thermocycler PCR conditions were as follows: 94°C for 5 min, [(94°C for 
30 seconds, *55°C for 30 sec, ramp to 72°C at 0.5°C per second, 72°C for 30 seconds, ramp to 
94°C at 0.5°C per second) x 25-35 times], 72°C for 10 minutes, 4°C indefinitely.  *This PCR 
protocol is notorious for producing non-specific bands.  Although the genotype of the mice can 
usually still be interpreted with these non-specific bands.  When I first joined the lab group, I ran 
this protocol with annealing temperatures at 55°C.  However, I eventually starting running this 
protocol with annealing temperatures at 58°C. The more stringent annealing temperature led to 
less non-specific amplification of other gene products. Also important, similarities within the 
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Neomycin cassette and Kanamycin cassette result in amplification of the Kanamycin cassette 
when this primer set is used.  This was discovered when I tried to genotyping pups from Sox10-
Cre x Ednrbtm1Ywa/+ crosses. The Ednrbtm1Ywa locus contains a Neomycin cassette (Chapter 3) from 
which our genotyping protocol in lab is based off of.  Unbeknownst to me, the Sox10-Cre 
transgene contains a Kanamycin cassette.  I noticed within crosses from these litters that many 
more pups than expected, (expected = 50%; observed =~70%), were genotyping “positive” for 
presence of the Neomycin cassette and that nearly 100% of mice that tested positive for the 
Sox10-Cre transgene also tested positive for presence of the Neomycin cassette.  Subsequent 
requests for information about the transgene sequence, which revealed that a Kanamycin 
cassette was within the transgene, led me to realize the overlap between genotyping products. 
Thus, any crosses between Sox10-Cre mice to mice that contain a Neo cassette must include 
more specific primer sets in order to differentiate mouse genotypes.   
Phox2bCFP & Sox10YFP 
For Phox2bCFP & Sox10YFP primer sets, thermocycler PCR conditions were as follows: 
94°C for 5 min; [94°C for 45 sec, 55°C  for 45 sec, 72°C for 45 sec,] repeated 35 times; 72°C for 
5 min, 10°C indefinitely.  More details in regard to these transgenic lines and genotyping can be 
found in the thesis of a previous Southard-Smith lab member (1).   
R26RtdTom 
 During my studies with R26RtdTom/tdTom mice, we had several issues in this line including 
increased occurrence of bifurcated vaginas in females leading to poor breeding or infertility and 
dystocia.  I also had issues with very small litter sizes, cannibalism, poor maternal care, and 
hydrocephalus.  We hypothesized that some of these issues may have occurred due to multiple 
generations of inbreeding in this mouse line.  (Small litter sizes are not uncommon on the C57/B6 
background.)  Efforts were made at one time to outbreed the line to C57/B6 stock without the 
R26RtdTom gene.  Unfortunately, the outbred line appeared to have the hydrocephalus 
phenotype carried through to the second outcross.  And, careful monitoring of females for 
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bifurcated vaginas as well as attempts to not breed brother-sister pairs improved some of our 
breeding issues in our lines that were not outbred.  Because of the issues in our outbred line as 
well as improvement in our inbred lines, we chose to discontinue our outbreeding efforts.  
However, if these issues resulting from inbreeding occur again, primer sequences for genotyping 
for outbreeding may be found in Table 8.1 and thermocycler conditions are as follows: HOT 
START; 94°C for 5 min, [(94°C for 30 seconds, 61°C for 30 sec, ramp to 72°C at 0.5°C per second, 
72°C for 30 seconds, ramp to 94°C at 0.5°C per second) x35 times], 72°C for 10 minutes, 10°C 
indefinitely.   
 
Crosses & mouse selection 
The progeny for my enteric NC-derived lineage analysis were derived from a series of 
crosses For NC-derivative studies, B6.Sox10Dom/+ males were first mated to C3Fe.Sox10-Cre (line 
F) females.  B6.Sox10Dom; C3.Sox10-Cre males produced from these crosses were then crossed 
to homozygous B6.Cg-Gt(ROSA)26Sortm9(CAG-tdTomato/Hze/J, hereafter B6.R26RtdTom/tdTom, 
females. Pups harboring the Sox10Dom or Sox10 wild types allele, Sox10-Cre transgene, and 
R26RtdTom were used in assessing enteric NC-derivative cell type proportions.  These crosses are 
detailed in Figure 8.1.  While the vast majority of test animals came from this type of cross, a 
couple litters were generated by mating a Sox10Dom/+ male that was homozygous for the Sox10-
Cre transgene to R26RtdTom/tdTom females.  
Early in my studies, I had to identify a reporter line that would appropriately and clearly 
label NC-derivatives within the ENS.  Initially, I attempted crosses with Wnt1-Cre or Sox10-Cre to 
B6.129-Gt(ROSA)26Sortm1Joe/J, hereafter R26RGNZ/GNZ.  We thought the R26RGNZ/GNZ line would 
work well as the GFP reporter included a nuclear localization signal, presumably leading to clear, 
nuclear labeling and easy quantification of cells.  Unfortunately, the signal from these crosses 
was weak.  Even in combination with IHC (primary antibody to GFP; secondary Cy2 antibody),  
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signal was not optimal for visualizing the ENS as a whole or individual ENS cells (Figure 8.2A).  
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In general, the reporter mainly appeared localized to parts of the nucleus instead of labeling the 
whole nucleus.  I also attempted Sox10-Cre crosses with B6.129-Gt(ROSA)26Sortm1(EYFP)Cos/J, 
hereafter R26RYFP/YFP mice. This reporter line worked much better in regard to labeling the ENS; 
however, additional IHC to the YFP reporter (primary antibody to GFP; secondary Cy2 antibody) 
was necessary for optimal signal visualization (Figure 8.2B). Also, use of an additional antibody 
to visualize the YFP reporter reduces the antibody choices to label NC-derived cell types.  I 
therefore turned to evaluating the R26RtdTom/tdTom line.  We were optimistic about this reporter line 
evidence from personal communications as well as the literature promised better reporter 
expression.  More specifically, the R26RtdTom contains an additional CAG sequence with the R26R 
reporter sequence has been reported to increase reporter expression above that when CAG and 
R26 are used on their own to drive expression (reviewed in (2)). Sox10-Cre and R26RtdTom/tdTom 
crosses produced progeny (~50%) with clearly labeled ENS (Figure 8.2C) without the need for 
additional IHC.  Unexpectedly, but fortuitously, the nuclei of many cells appeared to have 
differential reporter expression compared to their processes, making quantification of cell types 
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easier.  Additionally, glia tended to have brighter signals than neurons, also making cell types 
easier to differentiate during quantification.  Although unexpected, I hypothesize that glia have a 
brighter signal due to cell volume.  Glia have much smaller processes than neurons, whose axons 
and dendrites can extend for several centimeters.  Other possible explanations include differential 
expression of the reporter or differential turnover of the reporter driven by cell type specific 
mechanisms. 
 Once I had crosses with the appropriate mutation, it was important to determine if the 
Sox10-Cre transgene produced any additional adverse phenotypes or death within the Sox10Dom/+ 
mice.  (This possibility is explored and explained in depth in Chapter 2.) In my own personal 
observations of the mouse crosses, Sox10Dom/+ mice with the transgene did not appear physically 
different or more runted than their Sox10Dom/+ littermates without the transgene.  To test this 
statistically, when I first began these crosses, I recorded the number of Sox10Dom/+ mice with or 
without the transgene that survived to time of experiment (P15-P21).  If the Sox10-Cre transgene 
was causing lethal phenotypes or worst aganglionosis in Sox10Dom/+ animals, I would expect more 
Sox10Dom/+ mice with the transgene to succumb to death before time of experiment when 
compared to Sox10Dom/+ mice without the transgene.  I statistically tested this possibility (X2 
goodness of fit; JMP v11) and found no significant difference in the number of Sox10Dom/+ mice 
with or without the transgene (P=0.2413; n=25 Sox10Dom/+Cre+ and n=34 Sox10Dom/+Cre-).  Also 
see Table 2.5.    
 
Analysis of myenteric plexus NC-derived lineages 
Sample Collection 
P15-19 day mice were sacrificed with isoflurane and pieces of the duodenum, ileum, and 
the entire cecum and colon were immediately removed and placed into 1XPBS.  For the 
duodenum, 1.5-2.0 cm was taken starting ~0.5 cm distal to the pyloric sphincter.  For the ileum, 
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1.5-2.0 cm was taken starting ~1.5 cm proximal to the cecum and then heading more proximally.  
Before taking the mid-colon region in Sox10Dom mice, the entire cecum and colon was placed on 
a slide and viewed on a BX41 Olympus fluorescent microscope with a 5X objective.   A Sharpie™ 
marker or equivalent was used while viewing to mark the beginning of aganglionosis and/or 
hypoganglionosis in each sample if applicable.  The sample was then placed on a ruler to 
determine the entire length of the colon (end of cecum to anus), the length of aganglionosis, and 
the length of hypoganglionosis. Then, ~1.5 cm of mid-colon was taken.  In P15-16 mice, the mid-
colon was defined as starting 1.5 cm distal to the cecum.  In P17 and older mice, the mid-colon 
was defined as starting 2.0 cm distal to the cecum.  All regions of the gut were then flushed with 
1XPBS and immediately placed into NBF/0.5% Triton X-100 (NBF, Sigma, HT50112; Triton X-
100, MP Biomedical, 819620) on ice for a minimum of 20 minutes.  Gut pieces were then moved 
into 1XPBS on ice until subdissection in 1XPBS and cut along the mesenteric line. Gut muscle 
strips (GMS), also known as laminar muscle preparations, were then subdissected from all gut 
regions.  (Gut muscle strips include the serosa, longitudinal muscle, myenteric plexus, and circular 
muscle layers of the gut.  All other layers were discarded.)  Efforts were made to remove as much 
extraneous tissue (mesentery, blood vessels, etc.) as possible from the GMS.  Subsequent fix 
times and IHC differed depending on the antibodies being used.  Details can be found in 
proceeding sections of this chapter. 
 
IHC for neurons and glia  
Following subdissection, GMS were placed back into NBF with 0.5% TritonX-100 and fixed 
O/N at 4°C.  GMS were then rinsed once in 1XPBS and twice in 1XPBS/0.1% TritonX-100 for a 
minimum of 10 minutes per rinse.  GMS were then placed in filtered NDS block (0.1 g BSA, 0.5 
mL Normal Donkey Serum, 9.5 mL 1XPBS/0.1% Triton X-100) for 1.5 hr at RT.  Next, GMS were 
placed in Human anti-Hu primary antibody to label neurons (Table 8.2) for at least O/N at 4°C.   
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During this time, extra GMS tissue was placed in freshly diluted (1:400) Rabbit anti-FoxD3 
antibody (Table 8.2) in NDS block and placed with other samples at 4°C O/N.  (Use of this “pre-
incubated” anti-FoxD3 dilution significantly reduced background in GMS samples, especially in 
the colon.)  Following the first primary antibody incubation, the GMS were rinsed four times for a 
minimum of 5 minutes in 1XPBS/0.1% TritonX-100.  GMS were then placed in the second primary 
antibody, Rabbit anti-FoxD3 (the same dilution prepared with extra GMS tissue) to label glia for 
at least O/N at 4°C.  The GMS were then rinsed four times for a minimum of 5 minutes in 
1XPBS/0.1% TritonX-100.  Next, GMS were placed in secondary antibody Donkey anti-Human 
DyL649 (Table 8.3) for 1.5 hours at RT followed by four rinses for a minimum of 5 minutes in 
1XPBS/0.1% TritonX 100.  GMS were then placed in secondary antibody Donkey anti-
RabbitAlexa488 (Table 8.3) for 1.5 hours at RT.  GMS were then rinsed for at least 10 minutes in 
1XPBS/0.1% TritonX-100 and twice for at least 10 minutes in 1XPBS.  GMS were then placed in 
fresh 1XPBS and placed at 4°C.  Efforts were made throughout the IHC procedure to guard GMS 
and secondary antibodies from light.  Anti-FoxD3 antibody dilution was only used once and then 
discarded.  Attempts to reuse this antibody produced very weak signals.   
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IHC for Calretinin expressing neurons  
Following subdissection, GMS were immediately rinsed once in 1XPBS and twice in 
1XPBS/0.1% TritonX-100 for a minimum of 10 minutes per rinse.  GMS were then placed in NDS 
block for either one hour at RT or O/N at 4°C.  GMS were then placed in Human anti-Hu primary 
antibody for a minimum of 4 hours at RT or at least O/N at 4°C.  Following the first primary antibody 
incubation, the GMS were rinsed four times for a minimum of 5 minutes in 1XPBS/0.1% TritonX-
100.  GMS were then placed in a second primary antibody, Goat anti-Calretinin (Table 8.2) for a 
minimum of 4 hours at RT or O/N at 4°C.  The GMS were rinsed four times for a minimum of 5 
minutes in 1XPBS/0.1% TritonX-100.  GMS were then placed in secondary antibody Donkey anti-
Human DyL649 (Table 8.3) for 1 hour at RT followed by four rinses for a minimum of 5 minutes 
in 1XPBS/0.1% TritonX-100.  GMS then incubated in secondary antibody Goat anti-Cy2 for 1 hour 
at RT followed by a rinse for at least 10 minutes in 1XPBS/0.1% TritonX-100 and two rinses for 
at least 10 minutes in 1XPBS.  GMS were then placed in fresh 1XPBS and placed at 4°C.  Efforts 
were made throughout the IHC procedure to guard GMS and secondary antibodies from light.  Of 
note, all antibodies were diluted in NDS block and both primary anti-Hu and anti-Calretinin 
antibodies were used multiple times (5+) before replacing.  
 
IHC for nNOS expressing neurons 
Following subdissection, GMS were placed back into NBF with 0.5% TritonX-100 and fixed 
O/N at 4°C.  GMS were then rinsed once in 1XPBS and twice in 1XPBS/0.1% TritonX-100 for a 
minimum of 10 minutes per rinse.  GMS were blocked in NDS block for 1.5 hr at RT.  GMS were 
then placed in Human anti-Hu primary antibody for at least O/N at 4°C.  Following the first primary 
antibody incubation, the GMS were rinsed four times for a minimum of 5 minutes in 1XPBS/0.1% 
TritonX-100.  GMS were then placed in a second primary antibody, Rabbit anti-nNOS (Table 8.2) 
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for at least O/N at 4°C followed by four rinses for a minimum of 5 minutes/rinse in 1XPBS/0.1% 
TritonX-100.  GMS were then placed in secondary antibody Donkey anti-Human DyL649 (Table 
8.3) for 1.5 hour at RT followed by four rinses for a minimum of 5 minutes in 1XPBS/0.1% TritonX 
100.  GMS were then placed in secondary antibody Donkey anti-Rabbit Alexa488 (Table 8.3) for 
1.5 hours at RT.  GMS were then rinsed for at least 10 minutes in 1XPBS/0.1% TritonX-100 and 
twice for at least 10 minutes in 1XPBS.  Following rinses, GMS were placed in fresh 1XPBS and 
stored at 4°C.  Efforts were made throughout the IHC procedure to guard GMS and secondary 
antibodies from light.  Of note, all antibodies were diluted in NDS block and both primary anti-Hu 
and anti-nNOS antibody dilutions were used multiple times (5+) before replacing. 
 
IHC for Interstitial Cells of Cajal 
 Early in my studies, I recognized the possible necessity of analyzing Interstitial Cells of 
Cajal (ICC) number and morphology.  ICC cells are largely responsible for the slow wave 
movement and pace maker activity of the gut (3). Additionally, they are found closely juxtaposed 
to ENS neurons and muscle.  In regard to muscle movement, enteric neurons may signal directly 
onto smooth muscle cells or onto ICC that in turn signal onto smooth muscle cells (3). The role of 
ICC in HSCR is disputed.  Many studies note reductions in ICC in hypoganglionic and/or 
aganglionic portions of human HSCR intestine (4-7). One study has highlighted changes in ICC 
architecture (8) while another study suggested ICC, while possibly reduced in number, were 
regularly distributed and patterned (9).  ICC cells have been evaluated in the aganglionoic region 
of Ednrbls/ls HSCR mice, but not in ganglionated regions (10).  Because I saw the possibility of 
having to analyze ICC in our HSCR mouse samples, I optimized IHC with a cKit (CD 117) antibody 
on gut muscle strips (Figure 8.3) as well as sections. cKit is a tyrosine protein kinase purportedly 
expressed in a subset of ICC  in the myenteric plexus (3).  IHC on GMS for cKit is identical to the  
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protocol outlined above for Calretinin neurons, except for the primary and secondary antibodies 
used (Tables 8.2 & 8.3). 
For cKit IHC on sections, I first dissected whole guts into 1XPBS followed by fix in 
NBF/0.5% Triton X-100 on ice. Fixation was followed by four 5 minute rinses in 1XPBS at RT and 
a one hour rinse in 1XPBS at 4°C.  Guts were then placed in 30% sucrose O/N at 4°C.  Following 
equilibration, sampled were embedded in OCT tissue embedding medium.  After freezing, 
samples were sectioned on a cryostat, allowed to dry on a slide warmer for at least 30 minutes, 
and blocked in 1% donkey serum in 1XPBS/0.1% Triton X-100.  Samples were then incubated in 
cKit antibody (1:500 dilution in block) O/N at 4°C followed by secondary antibody incubation 
(Table 8.3) for 30 minutes at RT.  Slides were then rinsed in 1XPBS.  Importantly, attempts by 
other lab members and labs to use this antibody were not always successful in different tissues 
or slice types.  The Bob Coffey lab had clear staining with this antibody if tissue was fresh frozen 
and sliced followed by fixation in either PFA or acetone (Jumpei Kondo, personal 
communications).  
 
IHC for other cell types (SERT, TH, ChAT, vAChT) 
During my studies, I tested and attempted to optimize numerous antibodies to label 
specific neurons subtypes and other cell types.  Here, I provide details for additional antibodies 
not used ultimately in my analysis of NC derived lineages, but that could potentially be used in 
future studies.  SERT antibody was used to label serotonergic neurons within the myenteric 
plexus.  For IHC with the SERT (serotonin transporter) antibody (Table 8.2), the protocol was 
identical to that of Calretinin IHC except for the type of fix used.  Fixing tissues in NBF/0.5% 
TritonX-100 led to suboptimal staining, but fixing tissues in 4%PFA/3% sucrose led to clearer 
staining.  (With thanks to Mike Gershon and Kara Margolis for this suggestion.)  Ultimately though, 
SERT signal is strong in neuronal processes and does not label cell bodies as clearly as one 
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would like to quantify this cell type.  This same type of issue arose when I attempted IHC with a 
TH (tyrosine hydroxylase) antibody (Table 8.2) to label dopaminergic neurons.  Neuronal 
processes were clearly labeled, but cell bodies only had punctate signal, making quantification 
difficult.  On the other hand ChAT (choline transferase) and vAChtT antibodies (Table 8.2) clearly 
labeled cholinergic neuron cell bodies and processes (Figure 8.4).  The ChAT antibody tended to 
label both neuron cell bodies and processes with high expression in both.  The vAChT antibody 
clearly labeled both, but with less signal emanating from cell bodies.  This outcome was expected 
though as the vAChT antibody specifically labels vesicular acetyl choline transporters, which in 
neurons will be found prominently in neuronal processes as vesicles filled with acetylcholine are 
trafficked to axonal boutons.  The ChAT antibody is less specific, labeling all ChAT (found outside 
and insides vesicles) within the neuron.  The IHC protocol for TH, ChAT, and vAChT is identical 
to the Calretinin protocol above except for the primary and secondary antibodies used.   
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IHC with s100B 
 I initially set out to label and quantify glia in Sox10Dom and Sox10+/+ pups with a well known 
glial maker in the ENS, s100B.  The IHC protocol for the s100B is identical to the Calretinin 
protocol above except for the primary and secondary antibodies used.  Additionally, longer fixation 
times do not seem to impact labeling.  For the most part, I obtained clear labeling of glia within all 
regions of the intestine along with successful labeling of neurons (Hu+) (Figure 8.5).  However, 
while trying to complete this analysis, I noticed some samples did not “label as well” with the 
s100B antibody as other samples (Figure 8.6).  I initially thought this might be an issue with my 
IHC technique, such as gut muscle strips not being completely submerged within antibody 
incubation solutions.  However, once this difference in labeling occurred a few times, despite 
careful attention to IHC technique, I unblinded myself to mouse phenotype and genotype.  
Interestingly, I immediately noticed that my “problem” samples all originated from Sox10Dom/+ pups.  
Thus, the difference in s100B signal intensity in my imaging was probably biologically driven and 
not a result of poor lab technique.  This discovery led me to abandon labeling glia with s100B for 
my studies.  Instead, I utilized a FoxD3 antibody.  FoxD3, unlike s100B, is temporally upstream 
of Sox10, and thus expression is less likely perturbed by the Sox10Dom mutation. 
  
Mounting & Imaging 
Following IHC, GMS were flat-mounted onto slides (Fisherbrand, Cat.No. 12-550-15) with 
Aqua Poly/Mount (Polysciences, Cat. No. 18606-20) and cover slipped (Fisherbrand, Cat.No. 12-
545-F).  Clear nail polish was used to seal the edges of the cover slip and slide in order to prevent 
drying out of the mounting medium and samples.  All samples for NC-lineage analysis were 
imaged on an LSM 510 Meta Inverted Confocal Microscope system at 200X (20X objective; 10X 
eyepiece) with a 1.5 software zoom with LSM software.  For each region of the gut, areas were  
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randomly selected to image and noted during imaging to avoid image redundancy.  Areas were 
randomly selected by visualization of the ROSA26R-tdTomato reporter under the Cy3 filter.  
Random selection via this channel ensured the imager was not biasing imaging based on neural 
crest derivative types (neurons, glia, neuron subtypes) since the only signal visible during 
selection was that generated from tdTomato expression within all neural crest derivatives.  Due 
to fixation issues or unknown reasons, sometimes tdTomato expression was not consistently 
observed in patches of neurons, especially in the ileum and colon.  To avoid this issue, I moved 
my analysis to an earlier developmental time period (P15-17 from P17-P20.)  I also noted that 
expression was better with a longer fixation period.  However, since some antibodies worked 
better with a shorter fix period, the best option was to move the analysis earlier.  Additionally, lack 
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of tdTomato reporter expression appeared to occur primarily along the anti-mesenteric line.  And, 
blood vessels and mesentery made imaging directly next to the mesenteric line difficult. Thus, for 
consistency, images were randomly selected from in between the mesenteric and anti-mesenteric 
lines in the ileum and colon.  For all images, pinhole and laser power were adjusted accordingly 
for optimal signal capture.  (Individual LSM files contain these parameters.  To easily access these 
settings, open an image file in the LSM Image Browser and click on the “info” icon in the lower 
right hand corner of the image viewer window. In general, I aimed for a pinhole setting of near 1.0 
for each laser channel. The 633 nm wavelength laser could typically, but not always, be set at a 
lower power (2-4%) while 488 nm and 543 nm wavelength lasers were typically more mid-range 
(5-14%)). Set parameters included: 4X averaging, 512x512 resolution or higher, “optimal slice 
interval” selection through the LSM software, 20X objective with 1.5X software zoom. 
 
Image processing & counting 
Z-stack images were converted to 3D projections using LSM software.  Separate channel 
images were exported from LSM and adjusted in Adobe PhotoShop for brightness and contrast 
and merged.  Cell types were counted manually in Adobe PhotoShop with a manual cell counter.  
Layer(s) with dots denoting each cell counted were added in Adobe PhotoShop.  Cells were only 
counted if they were in the same layer as myenteric plexus ganglia.  For neuron and glia analysis, 
neurons and glia were only counted if they were contained in ganglia and primary connectives.  
(Initial counting of all glia in all layers in each image introduced large intragroup variance.  Also, 
samples differed in thickness due to fix times as well as phenotype.  For example, Sox10Dom 
mutants have thinner muscle in hypoganglionic and aganglionic regions.  Thus, preliminary tests 
indicated that analysis should be limited to ganglia and primary connectives.) 
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Western Blot  
Although I chose not to use s100B for IHC studies, the biological relevance of reduced 
s100B expression in glia of Sox10Dom pups is intriguing. S100B has been implicated in numerous 
processes that could be relevant to my studies, such as cell migration, proliferation, and 
differentiation (reviewed in (11)).  Interestingly, Sox family genes, although not Sox10, have been 
implicated in downregulating s100B expression (reviewed in (12).  Although differences in IHC 
signaling hinted that s100B expression is perturbed in Sox10Dom/+ mice, measurements of 
fluorescent signaling within IHC images is not easily compared between samples. Variations in 
IHC from experiments on different days typically leads to slightly altered confocal microscope 
specifications for optimal imaging.  And, sheer measuring of fluorescent intensity does not take 
into account the number or size of cells within an image.  Furthermore, because s100B can act 
extracellularly, differences seen in fluorescent signal intensity in glia may not be caused by glia in 
Sox10Dom/+ mice producing less s100B, but rather be caused by glia extruding more s100B into 
the extracellular space.  A more accurate measurement of s100B protein within GI tissue can be 
obtained through Western blotting.  My attempts at Western blotting are most accurately labeled 
as “partially successful.”  In my cleanest attempt, the control protein neuronal β-tubulin bands are 
evident in duodenal samples and very clean and evident in ileal samples.  Additionally, presumed 
s100B dimer bands were visualized for some wild type samples for the duodenum, but not for 
Sox10Dom/+ samples, suggesting a true decrease of this protein in Sox10Dom/+ mice (Figure 8.7).  
However, results were not clean enough to conclusively make this statement.  Here, I include a 
full protocol for Western Blot analysis with the caveat that more stringent denaturing conditions 
might be needed to visualize monomer (non-dimerized) s100B and that modifications/alternatives 
to imaging blots might be needed for publication quality data.  I would be remiss if I did not 
acknowledge Byron Knowles (Jim Goldenring lab) and Eric Armour (Kevin Ess lab) for sharing  
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Western Blot protocols.  All my protocols related to Western Blots are unchanged or modified 
versions of recipes and protocols from these two lab groups. 
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Protein Isolation 
 Sox10Dom/+ or Sox10+/+; Sox10-Cre; R26RtdTom pups (P16-17) were euthanized quickly with 
isoflurane followed immediately by cervical dislocation.  Sections of the duodenum, ileum, and 
colon (identical to those described for IHC protocols) were immediately removed and placed in 
ice cold 1XPBS.  Sox10Dom/+ colons were immediately viewed under a BX41 Olympus fluorescent 
microscope as quickly as possible to assess length of hypoganglionosis and aganglionosis.  
These parameters were measured for two reasons.  First, hypoganglionosis and/or aganglionosis 
in the colon has to be taken into consideration as a sheer decrease in glia number would appear 
as decreased s100B expression on a Western blot when compared to controls.  Second, given 
the correlations I observed between small intestine neuronal subtypes and extent of aganglionosis 
in Sox10Dom/+ animals, I wanted to be able to test for correlations between s100B expression levels 
and aganglionosis should Sox10Dom/+ animals have visible variability in s100B expression in 
different regions of the small intestine.   
 Immediately following dissection and/or measurement of aganglionosis, in cold 1XPBS, 
the entire gut muscle strip was removed from each section of the gut collected.  The gut muscle 
strip was immediately placed in and along the side of a pre-labeled 1.5 mL microtube.  A pipette 
was used to remove as much 1XPBS as possible from the sample and microtube.  Once the 
microtube cap was securely screwed into place, the sample was flash frozen in liquid nitrogen.  
(Do NOT attempt to use 1.7 mL centrifuge (snap cap) tubes for flash freezing and double check 
screw caps to make sure they are closed.  Centrifuge tubes with snap caps tend to not seal as 
well as screw cap tubes.  If the tube is not adequately sealed, liquid nitrogen will enter the tube 
and the tube will explode when removed from the liquid nitrogen.  This inevitably leads to loss of 
your sample and possibly your eye.)  This procedure was repeated for each section of the gut.  
Samples were allowed to stay in liquid nitrogen until all GMS dissections were completed.  Once 
all dissections were complete, samples were moved into a tube rack and stored at -80°C.  
185 
 
Importantly, this whole procedure was done as carefully, but as quickly as possible in order to 
avoid protein degradation.  Also, I chose to use GMS since the only cells that purportedly express 
s100B in these samples would be glia in the myenteric plexus. Whole gut samples would also 
include the submucosal plexus and epithelium which contain glia and other cell types that express 
s100B and other s100 proteins (13-15). 
  To isolate protein from tissues, I first placed my samples from -80°C onto ice. I then added 
to 200 μL of pre-made RIPA buffer (Table 8.4) and 2 μL of Inhibitor Cocktail (Thermoscientific, 
Pierce, Halt Protease Inhibitor Cocktail, Cat. No. 87785) to each sample and placed back on ice 
for 30 minutes. (Note: It is important to mix the inhibitor cocktail and RIPA buffer immediately 
BEFORE placing into sample tubes.  Enzyme activity of inhibitors can be lost if mixed before the 
day of your experiment and protein can be lost if you add inhibitors after you add RIPA buffer to 
your samples.) At the start of this 30 minute interval, I used a filter pipette tip to mechanically 
dissociate the tissue in each tube.  This pulverization was done gently and the RIPA solution was 
relied upon to do most of the cell lysing.  Approximately 15 minutes into the 30 minute interval, 
each sample tube was flicked multiple times.  Tubes were flicked again at the end of 30 minutes 
before centrifugation for 10 minutes at 10,000G at 4°C.  Importantly, the amount of RIPA buffer 
and Inhibitor Cocktail can be adjusted for these steps depending on tissue size.  Additionally, one 
can add a small amount of RIPA buffer and Inhibitor Cocktail initially and pulverize tissue, followed 
by addition of more RIPA buffer.  After centrifugation, I placed supernatant in new, labeled 1.5 mL 
tubes.  To avoid multiple freeze thaws to the protein, I eventually chose to aliquot each sample 
into multiple tubes and to place 5 uL of each sample’s supernatant in a tube for subsequent protein 
quantification.  If I was not using protein immediately, I stored at -80°C.  If protein was to be used 
in the next day or two, I stored it at -20°C.   
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 To quantify protein, I prepared samples with the Biorad DC Protein assay system (Cat. 
No. 500-0113 & 500-0114) and measured protein quantities on a NanoDrop 2000 
(Thermoscientific).  Within the NanoDrop software, I chose the “Protein Bradford” application to 
measure my protein amounts.  In addition to the protein from my samples, I made serial dilutions 
(2, 1, 0.5, 025, 0.125, 0.0625 µg/mL) of BSA protein (Sigma-Aldrich, Cat.No. #A2153) to establish 
a standard curve.  Detailed instructions on how to measure proteins on the NanoDrop 2000 using 
the “Protein Bradford” application are available within the NanoDrop 2000 manual as well as at 
nanodrop.com. 
 
Gels & Transfer 
 On days I was going to perform SDS-PAGE to separate my proteins, I first mixed and 
poured my gels.   I chose to run my samples through a 6% stacking gel and 12% resolving gel 
(Table 8.5). However, percentages and reagents should be adjusted based on the size and 
possible separation/denaturing needed for the protein of interest.  A handy tool for quickly 
calculating gel ingredient amounts at specific percentages can be found at Cytographica.com. 
When pouring gels, I allowed the resolving gel to set slightly before pouring the stacking gel.  I 
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also used a squirt bottle to add 100% EtOH across the top of the resolving gel.  The EtOH 
effectively evens out the top surface of the gel which enables proteins to run more evenly.  After 
pouring the stacking and gel and while my gel was setting, I measured out equal amounts (10 ng) 
of my protein samples (if I had not already). To these samples, I added 5X Laemli Sample Buffer 
(SB).  I added 5X SB up to bring my final sample size to 40 µL.   Once SB was added, samples 
were gently flicked and placed at 70°C for at least 10 minutes in a heat block that had been pre-
heated with tube holes filled with water.  Following this incubation, samples were loaded into gels 
along with a ladder (Biorad, Precision Plus Protein Dual Color Sandards Ladder, Cat. No. 151-
0374).  Samples were run on the gel at 100 volts at RT in 1XTGS.  Due to the high percentage of 
my resolving gel and the small size of my protein of interest, I ran the gel at least 3 hours.  (Usually, 
1hr 30 min to 2 hr is sufficient.)   
 
 While the gel is nearing the end of its run, protein membranes can be prepped if needed.  
I chose to use the Immobilon-P PVDF membrane (0.45 µm pore size, Millipore, Cat. No. 
IPVH00010) which is suggested for small proteins.  Immobilon membranes must be soaked for 
at least 15 seconds in 100% methanol followed by a 2 minute soak in MilliQ water and then at 
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least 5 minutes in transfer buffer.  (I used 1XTGS with 2X methanol for my transfer buffer.)  For 
the transfer step, I first cut off extra gel (stacking gel) from the gel on which I ran my proteins. In 
a large tub with transfer buffer, I stacked the following in this order: 
Back (black) side of transfer cassette  
Sponge 
Absorbent gel blot paper  
Gel 
Immobilon membrane 
Absorbent gel blot paper 
Sponge 
Front (white or red) side of transfer cassette 
Care was taken to try to eliminate bubbles between gel and membrane.  This can be done 
carefully with gloved hands.  After stacking and elimination of bubbles, the cassette was closed 
and inserted into the transfer rig with transfer buffer.  The cassette was moved up and down within 
the rig to try to ensure complete submersion (without bubbles) of the gel and membrane.  The 
transfer was then run at 250 mA for ~1 hr 45 min.  The transfer rig was kept on top of a stir plate 
with a large stir bar stirring inside.  Post transfer, the presence of ladder bands on the membrane 
indicated transfer had successfully taken place.   
 
Blot 
 After transfer, the membrane was rinsed 4 times in 1XTBST for at least 5 minutes/rinse 
with slow horizontal shaking.  After rinsing, the membrane was trimmed and cut into two pieces 
(one with duodenum samples and one with ileum samples.)  These smaller membrane pieces 
enabled conservation of reagents (antibodies) and fit better into crystal plastic boxes used in 
subsequent steps.  Membrane pieces were then blocked for 30 minutes at RT on the horizontal 
shaker in 1XTBST/5% powdered milk (Kroger brand, instant non-fat).    
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 Following block, membranes were subjected to O/N incubation at 4°C on a horizontal 
shaker in 1:5000 control antibody dilution in block.  I chose to use Rabbit anti-neuronal β-tubulin 
(COVANCE #PRB-435P) as a control.  Another lab (Goldenring lab) has had great success with 
this antibody in Western blots.  Additionally, this is a better control than many housekeeping gene 
controls as it is specific to neuronal cell types.  Other control antibodies, such as GADPH or actin, 
are found in many other cell types.  Sox10Dom/+ mice have thicker muscle and different tissue 
consistency in some areas of their intestine, indicating that other tissue types outside the ENS 
may be altered or overgrown, making GADPH and actin poor choices for controls.  Furthermore, 
at 50kDA, the control protein is small and runs near the dimer (~21 kDA) of s100B, permitting me 
to blot less membrane and thus conserve reagents. 
 After incubation, control antibody dilution was sucked off samples and saved for later use 
at 4°C.  Membranes were then rinsed 4 times in 1XTBST for at least 5 minutes/rinse.  Membranes 
were then incubated in 1:5000 s100B antibody (DAKO, Z0311) dilution O/N at 4°C on a horizontal 
shaker.  The next day, membranes were rinsed 4 times in 1XTBST for at least 5 minutes/rinse.  
Next, membranes were placed in a 1:10,000 secondary antibody dilution (Donkey anti-Rabbit-
HRP, Jackson Immuno, Cat.No. #711-035-152) for 1.5 hr at RT (covered).  Following secondary 
antibody application, membranes were rinsed 4 times in 1XTBST for at least 5 minutes/rinse.    
Samples were then subjected to ECL substrate (Biorad, Clarity ECL Substrate system) incubation 
for 5 minutes followed immediately by a quick rinse in 1XTBST.  Membranes were then placed 
between layers of Saran wrap, laid into cassettes (FisherBiotech, Electrophoresis System, 
Autoradiography Cassette, FBAC 810) and film (KODAK,  8 x 10 inch BioMAx MR Film, Cat. No. 
870 1302) was exposed to the membrane in a dark room at roughly 1 sec, 10 sec, 30 sec, etc. 
intervals until optimal film exposure was reached.  For my films, I was looking for evidence of 
bands at 50 kDA (β-tubulin control protein), 21 kDA (s100B dimer) and 10 kDA (s100B monomer).  
In my attempts, most of the control bands were clearly evident and worked well.  I also saw 
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evidence of s100B dimers in my wild type duodenal samples, but not my Sox10Dom/+ samples 
(Figure 8.7). This result was encouraging given that I expected less s100B expression in my 
Sox10Dom/+ samples.  However, I never fully optimized the procedure in order to visualize s100B 
dimer bands from the Sox10Dom/+ or to visualize monomer s100B bands.  More stringent conditions 
during gel running may be required to de-dimerize s100B.  Additionally, alterations in the amount 
of protein loaded, antibody concentrations, rinses post ECL treatment, developing time, or 
imaging methods could lead to clearer s100B signal.   
 
Gastric emptying & small intestine transit assay 
Prior to the experiment, 2% methylcellulose (Sigma Aldrich Cat. No. 274429-5G) was 
dissolved in water at RT.  To ensure full dissolution, the 2% methylcellulose mixture was either 
mixed for 4 or more hours at room temperature and stored at 4°C prior to use or mixed O/N.  
Rhodamine B Dextran (Invitrogen Cat. No. D-1841) was added and mixed into the 2% 
methylcellulose the following day at 2.5 mg/mL.  For each mouse, 4 ml of filtered 0.9% NaCl 
solution (Corning 1L filter system; 0.22 µm; Cat. No. 431098) was placed in eleven 15-mL conical 
tubes (Corning CentriStar, 15-ml polypropylene, Cat. No.05-598-59B).  For each mouse, tubes 
were labeled with an identifier for that mouse as well as the numbers 1-10 to denote small intestine 
segments and 11 to denote the stomach.  Another tube was filled with at least 7 mL of 1XPBS 
and labeled 12 for the cecum and colon.  Additionally, a “cardboard ruler” was prepared in order 
to divide the small intestine into 10 equal segments the day of the experiment.  This cardboard 
ruler included several measurements of equal segments of 10.  For example, one set of lines had 
each segment equaling 2 cm and another set of lines had 1.5 cm segments.  Because the age 
and strain of the mouse significantly affects the length of the intestine, having several sets of 
equal segments allows the experimenter to quickly dissect and divide the intestine without having 
to pull out a ruler and draw new sets of lines in the middle of the experiment.  The cardboard ruler 
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was covered in Saran™ wrap to allow for easy cleaning with 100%EtOH after each mouse 
dissection. 
The day before the experiment, adult mice (4-8 weeks) were fasted overnight in cages 
with CAREfresh® or Purcell bedding and then water deprived for 3 hours prior to the experiment.  
Each mouse was gavaged (BD 1 ml Syringe Ref. No. 309602; Instech Plastic Feeding Needle 
Ref. No. FTP 22-30) with 200 µl of the Rhodamine B Dextran/2% methylcellulose solution and 
allowed to survive for 15 minutes singularly in a cage with CAREfresh® bedding with no food or 
water.  (Gavage needles were replaced between mice if bent or damaged.  Mice that spit up the 
gavage solution or had solution come through their nasal cavity were excluded from the study.)  
At 15 minutes, mice were placed in a chamber and exposed to isoflurane (Piramal Healthcare) 
for 30 seconds and then immediately underwent cervical dislocation.   
Post-sacrifice, the ventral side of the mouse was wetted down and cleaned with 100% 
EtOH.  The abdominal cavity was opened and the esophagogastric junction, pyloric sphincter, 
and ileocecal junction were immediately clipped (Dieffenbach Serrefine Artery Clamps, ordered 
through Amazon.com, Part No. SBD-225) to prevent further movement of gastrointestinal 
contents.  Extraneous tissue (mesentery, blood vessels, pancreas, spleen) was then removed 
with a dissection scissor and forceps.  The cecum and colon were submerged in 1XPBS in a 15 
mL conical tube for later use.  The stomach was removed above the pyloric sphincter clip and 
placed in the tube labeled 11 for the stomach.  The remaining small intestine was divided into ten 
equal segments using the cardboard ruler and placed in tubes labeled 1-10, with 1 denoting the 
most proximal segment and 10 denoting the most distal segment. All segments were emerged in 
the 4 mL of 0.9% NaCl solution as soon as possible and covered with aluminum foil to avoid 
exposure to light.   
Once all segments were collected, each segment was homogenized in the 4 mL 0.9% 
NaCl solution (IKA-WERKE® ULTRA-TURRAX®, T-25 at approximately 19,000 
rotations/minute).  Tissue was homogenized for a minimum of 3 seconds.  Between each 
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segment, the probe was washed with deionized water, 0.9% NaCl, and then again with 0.9% 
NaCl.  Between each mouse, tissue stuck to the probe was removed with forceps and the 
deionized water was replaced.  (Because the stomach usually caused the most tissue to stick to 
the probe, it was homogenized last for each mouse.)  Homogenized tissue was then spun down 
for a minimum of 10 minutes at a minimum of 2000 RPM in a SORVALL RT7 tabletop centrifuge.  
15 μl of supernatant from each tube was placed in a well of a 384-well PCR plate (Phenix, Cat. 
No. MPS-3898BLK).  Additionally, the equivalent of 200µl of rhodamine B dextran/2% 
methylcellulose solution in 4 mL of 0.9% NaCl solution and 0.9% NaCl solution were placed in at 
least three wells to serve as ‘maximum possible fluorescence’ and blank controls respectively. 
Fluorescence intensity was read the day of or plates were covered and placed at 4°C until read.  
(Plates never sat more than two days at 4°C before being read.)  Plates were read on a Molecular 
Devices/LJL Analyst HT (Molecular Devices, Union City, CA, USA).  For the LJL Analyst, Phenix 
plate dimensions were entered and saved.  Settings for readings were as follows: 
 Averaging: 3 reads per well 
 Excitation Filter: 7 TAMRA 
 Emission Filter: 620-635  
 Read location: Top well read 
 Time between readings: 100 ms 
 Motion settling time: 25 ms 
 Shake time: none (0 s) 
 Attenuator mode: high 
 
Data from fluorescence reads was then used to calculate gastric emptying and a small intestine 
motility score.  To calculate gastric emptying, the total fluorescent count (all fluorescence detected 
in the stomach and small intestine) was calculated first: 
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Call= ∑ (Csegment)  
where Call is the total fluorescence count and Csegment is the fluorescence count in each 
segment. 
 
Gastric emptying (the percent of fluorescent signal that has left the stomach) was then calculated: 
 
Gastric emptying = [(Call - Cstomach)/ Call] x 100 
where Cstomach is the fluorescence reading for the stomach 
 
A small intestine motility score was calculated for each mouse based on the geometric center 
(mean) of fluorescence in the small intestine: 
 
Geometric center (mean) = ∑[( Csegment x segment number)/CSI]  
where CSI is the total fluorescence count in the small intestine. 
 
This method to determine gastric emptying and small intestine motility in rats was first described 
in detail by Miller and colleagues (16) and have been used more recently in mouse (17).  I tested 
for differences in gastric emptying rates and small intestine motility scores using a Student’s t-test 
assuming unequal variance (also known as Welch’s t-test) in JMP version 10 (SAS Institute Inc., 
Cary, NC, USA.)     
To generate heat maps used to depict gastric emptying and small intestine motility data, I 
first determined the percent contribution of each intestine segment to the transit score for each 
mouse (ie intestine segments with large amounts of the fluorescent meal contribute greatly to the 
score; while those with little fluorescent meal contribute little.)  I chose “percent contribution” as 
our measurement in generating these maps as fluorescence intensity itself is a relative 
measurement and “percent contribution” normalizes the data.  Once I determined the percent 
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contribution for each intestine segment for each mouse, I averaged the percent contributions 
within each genotype for each intestine segment.  Using MATLAB (Mathworks, Natwick, MA, 
USA) to generate a heat map, we assigned higher average percent contributions the color red 
(representing greater fluorescent reads) and lower average percent contributions no color 
(representing no or little fluorescent reads.)  These colors (averages) were then interpolated 
across segment numbers to generate a heat map.  This type of schematic can be generated using 
the following code (with labels and data included here as an example) within MATLAB: 
close all 
clear all 
 
data= [ 4.0416096 14.28408441 4.295096182 12.09379354 7.553430393 6.350554323 4.700948565 7.68474756 
22.0739831 38.5162063 20.70632278 35.45094993 22.77372882 30.86191969 16.00892165 20.95407008 
24.88038928 26.29393612 29.94567845 36.40508425 25.01027451 32.51049307 16.02055989 18.80964905 
31.21113151 9.992309122 28.44167445 8.089767516 15.53496235 7.549006448 15.71863551 12.81208631 
12.25236999 6.451572256 9.80013087 1.453495287 9.358071659 15.34240155 10.54429915 2.365436026 
1.05727502 0.62966815 0.797701269 0.588716867 6.735494095 3.434370837 0.668142608 0.384875792 
0.676744389 0.7652144 0.649828756 0.570780285 6.947050581 1.052032025 1.054545974 0.55150921 
1.212253706 0.761793527 1.485846914 1.241554973 2.24019892 0.593656462 0.936757664 0.884501296 
1.502352027 1.13635819 2.008245828 2.394361344 1.983012587 1.065398182 0.918010851 1.39678111 
1.091891383 1.168857521 1.869474496 1.711496006 1.863776084 1.240167411 0.962616775 1.628591084 
]; 
 
 
labels=[4 wk male WT' '4 wk male Dom' '4 wk female WT' '4 wk female DOM' '6 wk male WT' '6 wk male Dom' '6 wk 
female WT' '6 wk female DOM]; 
 
custcolor=[1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    1.0000    1.0000 
    1.0000    0.9750    0.9865 
    1.0000    0.9500    0.9730 
    1.0000    0.9250    0.9596 
    1.0000    0.9000    0.9461 
    1.0000    0.8750    0.9326 
    1.0000    0.8500    0.9191 
    1.0000    0.8250    0.9056 
    1.0000    0.8000    0.8922 
    1.0000    0.7750    0.8787 
    1.0000    0.7500    0.8652 
    1.0000    0.7250    0.8517 
    1.0000    0.7000    0.8382 
    1.0000    0.6750    0.8248 
    1.0000    0.6500    0.8113 
    1.0000    0.6250    0.7978 
    1.0000    0.6000    0.7843 
    1.0000    0.5875    0.7603 
    1.0000    0.5750    0.7363 
    1.0000    0.5625    0.7123 
    1.0000    0.5500    0.6882 
    1.0000    0.5375    0.6642 
    1.0000    0.5250    0.6402 
    1.0000    0.5125    0.6162 
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    1.0000    0.5000    0.5922 
    1.0000    0.4875    0.5681 
    1.0000    0.4750    0.5441 
    1.0000    0.4625    0.5201 
    1.0000    0.4500    0.4961 
    1.0000    0.4375    0.4721 
    1.0000    0.4250    0.4480 
    1.0000    0.4125    0.4240 
    1.0000    0.4000    0.4000 
    1.0000    0.3750    0.3750 
    1.0000    0.3500    0.3500 
    1.0000    0.3250    0.3250 
    1.0000    0.3000    0.3000 
    1.0000    0.2750    0.2750 
    1.0000    0.2500    0.2500 
    1.0000    0.2250    0.2250 
    1.0000    0.2000    0.2000 
    1.0000    0.1750    0.1750 
    1.0000    0.1500    0.1500 
    1.0000    0.1250    0.1250 
    1.0000    0.1000    0.1000 
    1.0000    0.0750    0.0750 
    1.0000    0.0500    0.0500 
    1.0000    0.0250    0.0250 
    1.0000         0         0 
    0.9375         0         0 
    0.8750         0         0 
    0.8125         0         0 
    0.7500         0         0 
    0.6875         0         0 
    0.6250         0         0 
    0.5625         0         0 
    0.5000         0         0]; 
 
 
for iii=1:8 
     
     
     
MUTmat=ones(10,100); 
tem=data(:,iii); 
 
for i=1:100 
    for j=1:10 
        columncontmut(j,i)=tem(j)*MUTmat(j,i); 
         
    end 
end 
 
figure(iii) 
 
[hC hC] = contourf(transpose(columncontmut),500); 
set(hC,'LineStyle','none');5 
title(labels(iii)); 
%colormap(custcolor); 
fnam= num2str(cell2mat(labels(iii))); 
 
saveas(hC,fnam,'pdf'); 
 
end 
 
 
Total GI tract transit assay 
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Prior to the experiment, 0.5% methylcellulose (Sigma-Aldrich, Cat. No. 274429-5G) 
solution was made in filtered 0.09% NaCl (saline) solution (Corning 1L Filter System, Cat. No. 
431098) by O/N stirring.  Carmine (Sigma-Aldrich, Cat. No. C1022-5G) was added to make a 6% 
carmine red solution and allowed to either stir O/N the day before the experiment or vortexed 
vigorously the day of the experiment to ensure uniform mixing of the carmine into the solution.  
Solution was either used directly after addition of Carmine or stored at 4°C for future use.  If the 
6% Carmine solution was stored in 4°C for future use, it was allowed to warm to RT before 
beginning the experiment.   
Cages were prepared by removing bedding and cleaning the interior with 100% EtOH.  
Whatman paper (Whatman, Cat.No. 3030-392) was placed in the bottom of the cage to enhance 
visualization of fecal pellets.  A numbered sticky note was placed on each cage to record the 
mouse assigned to that cage, gavage time, and time of appearance of red fecal pellets.  Water 
bottles and low-fat mouse chow were available in the food and water bottle holder so mice could 
eat and drink ad libitum during the experiment.  A 15-mL clear canonical tube filled with tap water 
was numbered corresponding to the cage number and set on top of the food in its corresponding 
cage.  
Day of the experiment, 6 week old mice were brought from the mouse facility in either 
cages or buckets and immediately placed singularly in experimental cages.  Unlike the gastric 
emptying and small intestine transit assay, I did not fast mice O/N prior to testing. (Although, if I 
were testing other mouse disease models, I would consider fasting before and/or during the 
experiment if regular feeding behaviors are known to differ. For example, ob/ob mice overeat due 
to leptin deficiency.  Overeating would cause an increase in total gut transit due to sheer volume 
of food being ingested and not necessarily changes in ENS function.)   Mouse information 
(breeding cage, ear punch, etc.) was added to each sticky note on each cage. I gavaged (BD 1 
ml Syringe Ref. No. 309602; Instech Plastic Feeding Needle Ref. No. FTP 22-30) each mouse 
with 300 µl of 6% Carmine solution and recorded the time at which the gavage was complete on 
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each cage sticky note.  Gavage needles were replaced in between mice if visibly bent or 
damaged.  Any animals that spit up solution or had solution come through their nasal cavity were 
excluded from the study.  For the first one or two experiments for each phenotype tested in these 
studies, stool was checked for and collected starting 1 hour after gavage and then repeated 30 
minutes later.  Then cages were checked every 10 minutes until the first appearance of red fecal 
pellets.  Then cages were checked at least every 10 minutes or more often after that.  These 
checks included visualization of the underside of mouse cages beneath the Whatman paper since 
fecal pellets occasionally were located beneath the paper. Fecal pellets were collected via forceps 
and placed in the 15 ml canonical tubes with tap water for easy visualization of Carmine within 
the pellet.  The time of fecal Carmine visualization was recorded on the sticky note under gavage 
start time.  The total time in minutes from gavage to excretion of red fecal pellets was then 
calculated. All mouse information and recorded times were also written down on lab notebook 
paper during the experiment to ensure no data would be lost.   
Because strain background plays a large role in total transit time, the first check for fecal 
pellets was adjusted accordingly throughout the course of these experiments.  (For example, after 
two experiments, the fastest transit time I recorded for 129SvEdrnb+/+ mice was 2 hours and 56 
minutes.  Thus, the next time I performed this assay on 129SvEdrnb+/+ mice, I did not check for 
fecal pellets after one hour, but started at 1 hour and 45 minutes post-gavage.  Conversely, if you 
predict a fast transit time in your animals, consider checking for fecal pellets prior to the suggested 
1 hour post-gavage.) Additionally, large variation can exist in this experiment and other labs 
suggest repeating in mice 5-6 days following the first gavage if possible.  However, I was limited 
to one test per animal due to IACUC guidelines and mouse facility requirements within my 
institution. 
Transit time between HSCR mutants and WT littermates for each gender were compared 
using a student’s t-test assuming unequal variance (Welch’s t-test) using JMP version 10 and 11 
(SAS Institute Inc., Cary, NC, USA.)     
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Histology 
Intestine “jelly rolls” 
Adult mice (6-8 weeks) were sacrificed with isoflurane.  Two regions of gut—the distal half 
of the small intestine and the large intestine—were immediately dissected out into 1XPBS and 
gently flushed with 1XPBS.  Care was taken to flush gently since forceful flushing can disturb gut 
epithelium.  Guts were then flushed once with 10% NBF to help preserve the integrity of the gut 
epithelium. Flushed gut pieces were cut along the mesenteric line and then laid out flat using 
forceps onto Whatman paper.  Using curved tip forceps, gut pieces were then rolled into “jelly 
rolls” starting from the most distal section and working proximally.  As the gut was rolled, the 
forceps were used to flatten the gut and pull the roll tight.  Care was taken not to roll the gut piece 
too tight as “tenting”—where inner rolls get squeezed out from the entire roll—can occur. Once 
gut pieces were completely rolled, a syringe needle was pushed through the roll and the proximal 
plastic portion of the syringe needle removed.  Pinned, rolled intestines were placed in cassettes 
with the edges of the rolled intestine against the surface of the cassette. Cassettes with samples 
were submerged completely in 10% NBF in plastic containers or glass beakers and placed in 4°C 
O/N.  Whittem and colleagues (2010) provide an excellent video detailing the process of “jelly 
rolling” intestines should future lab members need a visualization of this technique (18). 
Post-fix, samples in cassettes were delivered to the Translational Pathology Shared 
Resource (TPSR) Core facility at Vanderbilt University for processing and embedding.  Initially, 
samples were embedded in paraffin wax, picked up at the TPSR facility, and stored at RT or -
20°C until sectioned.  Samples were sectioned on a microtome at 5-13 µm.  A heated water bath 
was used to mount sections onto slides.  Sections were allowed to dry on a slide warmer for a 
minimum of 1 hour before being stored at RT or undergoing H&E staining. Ultimately, we had the 
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TPSR Core process, embed, section, and stain samples to insure consistency in sectioning and 
staining as well as save time. 
 
Pyloric sphincter collection for H&E 
 Pyloric sphincter samples were typically collected at the same time as intestine “jelly roll” 
samples. For each animal, the gastrointestinal tract was cut at the esophagus and ~1 cm below 
the duodenum and removed from the animal and placed in 1XPBS.  Once in 1XPBS, I cut off the 
proximal 0.5-0.75 of the stomach and gently swished the sample around in 1XPBS to remove 
large food items from the stomach.  After swishing, I used a syringe with 1XPBS to rinse the inside 
of the stomach and gently flushed through the pyloric sphincter.  I also gently flushed 1XPBS in 
the opposite direction through the duodenum to remove as much food stuffs as possible from the 
sample.  Importantly, when I first attempted to collect pyloric sphincter samples, I left the entire 
stomach intact.  I inserted a syringe into the stomach and tried flush the entire stomach with 
1XPBS to remove food stuffs.  Interestingly, in my first attempt with a Sox10+/+ mouse sample, 
the pyloric sphincter snapped shut and the stomach became engorged with liquid.  The next 
sample I attempted was from a Sox10Dom/+ mouse.  Here, I once again attempted to clear the 
stomach totally intact; however, in this mouse, the liquid immediately went through the pyloric 
sphincter.  In an attempt later with another Sox10Dom/+ mouse sample, liquid was able to make it 
through the pyloric sphincter again, but in very quick spurts as the pyloric sphincter visibly 
contracted and relaxed multiple times.  This observation, in combination with the increased gastric 
emptying observed in 6-week+ male Sox10Dom/+ mice (Chapter 2), led us to pursue further studies 
in pyloric sphincter dynamics (Chapter 4). In regard to experiment design for pyloric sphincter 
collection, leaving the entire stomach intact not only led to difficulties in cleaning out food material 
from the stomach, but also led to difficulties in sectioning (as wax had issues permeating into the 
lumen of the stomach.)  These technical issues, as well as the fact the proximal stomach was not 
needed for evaluation, led me to alter the protocol to remove the majority of the stomach from the 
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sample before flushing.  After samples were thoroughly (but gently) flushed, they were laid in 
cassettes on their sides.  Cassettes with samples were submerged completely in 10% NBF in 
plastic containers or glass beakers, placed at 4°C O/N, and then delivered to the TPSR facility for 
processing, embedding, sectioning, and H&E staining.  Attempts were made by myself and by 
the TPSR core staff to section samples so that the lumen of the GI tract was visible and continuous 
throughout the distal stomach, pyloric sphincter, and duodenum for the section.  This quality 
control, in theory, would reduce variability in measurements (muscle thickness, antral opening, 
etc.) due to samples being cut at different angles. 
 
Hematoxylin & Eosin staining 
Throughout the H&E procedure, I used slide carriers and solution basins from the Tissue-
Tek® Manual Slide Staining Set.  Slides were deparrafinized by placing slides into xylenes 
(Fisher, Cat. No. X3P1Gal) for 2 minutes and then repeating this step in a new xylene bath.   
Gentle swishing for a few seconds immediately upon submersion and immediately before removal 
helped to insure complete removal of all paraffin wax. This step was performed in the chemical 
hood, and xylenes were reused several times for this step.  However, when it was noted that the 
reused xylenes were not removing wax very efficiently, reused xylenes were properly disposed of 
and fresh xylenes were used. Sections were rehydrated in a series of ethanol dilutions (100%, 
90%, 70%, 50%) and then placed in deionized water.  Slides were in each ethanol and water bath 
for 2 minutes.  
Next, sections were stained with filtered Harris hematoxylin (VWR Scientific, Cat. No. 
84000090) for 3 minutes.  Following hematoxylin staining, slides were immediately immersed in 
a slide basin with tap water and then brought over to the sink.  In the sink, tap water was allowed 
to wash over the slides for 10 minutes.  Care was taken to avoid direct contact of sections with 
the faucet water stream as this can cause sections to fall off slides.  However, attempts were 
made to keep the water pressure coming from the faucet high so that water was constantly 
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circulating throughout the entire basin.  Next, slides were dipped 4 times in 1% acid alcohol (1mL 
12N HCl in 99 mL 70% EtOH) followed by a 45 second rinse in 0.1% Na bicarbonate.  Then, as 
previously described, slides were washed with running tap water for 10 minutes.  Slides were then 
immersed in 80% ethanol for 2 minutes followed by eosin (1% alcoholic, HARLECO®, VWR 
Scientific, Cat. No. 15204-132) stain for 2 minutes.  Finally, slides were dehydrated in a series of 
ethanol dilutions (90%, 95%, 100%) and two basins of xylenes.  Slides were in each dilution for 2 
minutes.  Slides were then laid out on paper towels to dry in the chemical hood for at least 1 hour 
or O/N.  Coverslips were mounted onto sections in the chemical hood with Permount mounting 
medium (Fisher, Cat. No. SP15-100).  Importantly, the protocol above was derived from a series 
of H&E optimization attempts by myself and another graduate student, Elaine Ritter, in lab. H&E 
staining improved drastically over these series of optimizations.  However, although this H&E 
staining was a simple procedure, it was time intensive, my H&E staining had not reached “text 
book” or “publication quality”, and the TPSR Core at Vanderbilt offers H&E staining services at 
very reasonable prices.  We ultimately decided to have the TPSR Core at Vanderbilt section and 
H&E stain samples when it came to samples for analysis and publications.  A comparison of H&E 
staining from our protocol compared to that of the TPSR Core is provided in Figure 8.8. 
 
HSCR Surgical Resections 
Sample acquisition 
Following surgery and pathology evaluation, full length surgical resections from colons of 
Hirschsprung patients were collected from the Pediatric Pathology Suite of the Monroe Carell Jr. 
Children’s Hospital at Vanderbilt.  Samples were either collected and placed on ice immediately 
after pathologist evaluation or were placed into a 4°C fridge and acquired at the earliest 
convenience of the investigator.  (Longest time to collection was after a weekend (~2.3 days) due 
to a long surgical procedure followed by confusion over storage location.) The vast majority of 
samples were acquired the same day as surgery; however, a few samples were collected up to 2  
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days post-surgery.  Collection time did not seem to affect subsequent NADPH-β staining.  
These results are in line with a study by Wester and colleagues wherein pediatric autopsy colonic 
tissue collected several hours after time of death still successfully stained with NADPH-β staining 
(19).  The maximum length of time from surgery to sample collection and fix to still achieve 
successful acetylcholinesterase (AChE) stain or immunohistochemistry is unknown.  Samples I 
performed successful AChE stain or IHC on were collected and fixed day of surgery.  Obstacles 
with AChE staining and IHC led me to abandon these techniques early in the study, leaving 
samples collected and fixed at later times (1-2 days post-surgery) untested with these techniques.   
Control (autopsy) samples were collected during autopsy from the Autopsy Suites at 
Vanderbilt University Hospital or after autopsy from a 4°C fridge in the Pediatric Pathology Suite 
of the Monroe Carell Jr Children’s Hospital at Vanderbilt.  Samples were collected as close to 
‘time of death’ as possible, usually the morning or afternoon following death when autopsies are 
routinely performed.   
 
Sample fixation and dissection 
All samples were transported on ice to the laboratory, immediately rinsed at least once in 
1XPBS, and then fixed in 4% PFA.  (1XPBS rinses prior to fixation can be increased if samples 
contain a lot of fecal material or blood. Although fecal material and blood do not seem to affect 
fixation or future staining, tissue is much more pleasant to manipulate if relatively clean.) Initially, 
samples acquired early in the study were fixed 15-30 minutes in 4% PFA, partially dissected 
(serosa, mucosa and some muscle fibers removed), and then fixed an additional 30 min – 1.5 
hours in 4% PFA at RT.  Although this fix time was adequate for successful IHC, AChE stain, and 
NADPH-β stain, it was not adequate for long term storage of tissue.  Typically, tissue not fixed 
overnight started to disintegrate and grow mold.  Once I dropped AChE staining and IHC from the 
study and also discovered O/N fixing of samples in 4% PFA did not affect the NADPH-β stain, all 
collected samples from that point on were fixed at least O/N in 4% PFA at 4°C.  Fixation of tissue 
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was followed by at least three rinses in 1XPBS for samples or sample pieces undergoing IHC or 
NADPH-β stain.  Samples or sample pieces undergoing AChE staining were additionally rinsed 
in tap H20 or dH20 and then stored in saturated sodium sulfate solution at 4°C as per standard 
procedures (20, 21).  Most samples were sub-dissected several times to aid in exposing the 
myenteric plexus to stain or IHC reagents.  Typically, post 15-45 minutes fix, pieces of the serosa, 
mucosa and some muscle fibers were removed.  Following O/N fix and/or immediately prior to 
staining, additional muscle fibers were removed (from the circular and/or longitudinal muscle layer 
depending on the thickness of the sample.)  Finally, for NADPH-β stain, samples were sub-
dissected during the stain. (See NADPH-β stain section below for more details.) 
 
IHC on human intestine samples 
Colonic tissue samples subjected to IHC were rinsed with 1XPBS, blocked in NDS block 
for 1 hour at RT or O/N at 4°C, and then incubated in primary antibody O/N at 4°C.  Primary 
antibodies tested on human tissues include: Rabbit anti-Phox2b, Human anti-HuC/D, and Rabbit 
anti-s100 (Table 8.2). Primary antibody incubation was followed by rinses in 1XPBS/0.1% TX-100 
(x4), incubation in secondary antibody, one rinse in 1XPBS/0.1% TX-100 and two rinses in 
1XPBS.  Tissues were stored in fresh 1XPBS at 4°C until imaging.  Successful IHC was only 
attained with the Rabbit anti-Phox2b antibody (Figure 8.9C’&C’’).  Several factors may have 
influenced my results with the other antibodies.  To my knowledge, none of antibodies had ever 
been tested on human tissue and thus the binding dynamics of the antibody to the protein of 
interest, concentration of antibody needed, and optimal fix time for tissue before IHC was 
attempted were unknown.  All samples that I performed IHC on were fixed under two hours. 
Longer fix times in the future could influence results.  Additionally, the thickness of the human 
tissue could make it difficult for primary and secondary antibodies to permeate the tissue and 
come in contact with the myenteric plexus (MP).  Although efforts were made to remove muscle 
fibers and expose parts of the MP, the inability to see the MP while dissecting often times led to 
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too much muscle still covering the MP or disruption and destruction of the MP if too much muscle 
was removed.  Besides appropriately dissecting off muscle fibers, longer incubation times in 
primary and secondary antibodies and/or stronger detergents to break up tissue could potentially 
resolve some of the permeation issues. 
 
AChE staining on human intestine samples 
Following storage in saturated Sodium Sulfate solution at 4°C, samples were rinsed in 
MilliQ filtered H20 and then incubated in incubation buffer for 2.5 – 3 hours at 50-60 rpm on a 
horizontal shaker.  (Incubation buffer: 0.886% Sodium Acetate Trihydrate, 0.075% Glycine, 0.05% 
Cupric Sulfate, 0.1156% Acetylthiocholine iodide, 0.0072% Ethopropazine in MilliQH20, pH 5.5. 
pH adjusted with 1.7 N Acetic Acid.)  Following incubation, in a chemical hood, samples were 
rinsed in MilliQ H20, immersed 1 – 3 minutes in freshly made 1.25% Sodium Sulfide solution, pH 
6.0, and rinsed six times in MilliQ H20.  Samples were then stored in scintillation vials in autoclaved 
50% glycerol solution at 4°C until they were imaged.  AChE staining was successfully performed 
on samples where the muscle layers were very easily separated without disturbing the MP, such 
as premature fetal autopsy samples, or in older patient samples where some muscle fibers were 
removed to successfully uncover part of the MP so that it was easily exposed to AChE staining 
reagents (Figure 8.9A).  Unfortunately, because removal of muscle fibers was very difficult to 
complete without disturbing the MP and extremely time intensive, AChE staining on human 
tissues was dropped midway through the study. 
 
NADPH-β stain on human intestine samples 
Following fixation and rinses in 1XPBS (see “Sample fixation and dissection” section for 
details), samples subjected to NAPDH-β were rinsed in fresh 1XPBS day of NAPDH-β staining 
and then placed in 10 mL of NAPDH-β incubation buffer at RT on a nutator (Table 8.6).  During 
incubation, samples were checked multiple times for appearance of stain in the MP on the edges  
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of the sample between the longitudinal and circular muscle layers (Figure 8.10A).  Once the MP 
was visible, muscle fibers from the longitudinal and/or circular muscle layers were removed from 
the sample under a dissection microscope to help expose more of the internal MP to incubation 
buffer.  (MP stain visibility varied with samples, but stain will probably not appear for at least 15 
minutes and usually took longer.  Additionally, in my experience, it is best to allow the stain 
reaction at least 45 minutes – 1 hour to start.  If no MP is visible by that time, chances are the 
tissue will fail to stain at all.)   The stained MP on the edges of the sample was used as a guide 
for the dissection to avoid accidentally dissecting off or tearing the MP in the sample (Figure 
8.10B).  Additionally, samples were kept in incubation buffer during dissection, allowing for MP to 
continue to stain and further aid in dissection.  Samples were periodically returned to the nutator 
after dissection and allowed to stain more undisturbed. This process of alternating between 
dissecting and undisturbed staining was repeated multiple times until the majority of MP on a 
sample was visible and stained (Figure 8.10C&D).  Typically, stain times ran over 200 minutes.  
To quench the staining process, samples were rinsed three times in 1XPBS, fixed 1.5 – 2 hour fix 
in 4% PFA, rinsed three times in 1XPBS, and then placed in fresh 1XPBS and stored at 4°C until 
clearing.  For clearing samples, samples were placed in the following glycerol solution gradient: 
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15% glycerol in 1XPBS, 25% glycerol in 1XPBS, 50% glycerol in H20, and 70% glycerol in H20.  
For each glycerol solution, samples were allowed to equilibrate at 4°C on a nutator O/N.  
 
NADPH-β stain sample imaging 
Following NADPH-β staining and clearing, samples were mounted between two large 
glass slides (Ted Pella, Inc., 152 x 114 mm, No. 260233).  Samples were kept moist while 
mounted on slides with 70% glycerol solution or 1XPBS.  Samples images were captured on a 
Nikon AZ 100 M wide field microscope (Vanderbilt CISR) with a Nikon DS-Ri1 color camera using 
NIS-Elements software.   
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